Panel Update 5 PDF

Adult Therapy
Guide Legend
Panel Update 5
International
9020-7493 Rev. B
SMN 10714735
Adult Therapy Guide Legend

No part of this work covered by the copyrights herein may be reproduced or copied in any form or by any meansgraphic, electronic, or mechanical; including photocopying, recording, typing, or information storage and retrieval
systems without written permission of the publisher.
MicroScan , MICroSTREP plus , Synergies plus and WalkAway systems are trademarks of Siemens Healthcare
Diagnostics.
9020-7493, Rev. B
May 2013
Siemens Healthcare Diagnostics Inc.

1584 Enterprise Blvd.
West Sacramento, CA 95691 USA
www.siemens.com/diagnosics
(916) 372-1900
(800) 677-7226
2013 Siemens Healthcare Diagnostics Inc.
All rights reserved.
Spec: 9900-3651
9020-7493B
Page 2 of 158
Table of Contents
Revision Record ........................................................................................................................................................ 5
General Notes for Reporting Results: ..................................................................................................................... 6
DEFINITIONS: ............................................................................................................................................................. 6
INTERPRETIVE GUIDELINES ......................................................................................................................................... 6
SYNERGIES PLUS GRAM NEGATIVE PANELS: .............................................................................................................. 6
SYNERGIES PLUS GRAM POSITIVE PANELS: ............................................................................................................... 6

REFERENCED FROM THE CLSI M100-S22: ................................................................................................................. 6
MISCELLANEOUS NOTES: ........................................................................................................................................... 7
URINE/SYSTEMIC THERAPY INTERPRETATION RULES:.................................................................................................. 7
ADDITIONAL RULES:................................................................................................................................................... 7
Warning From the CLSI M100-S22: ......................................................................................................................... 7
Extreme Caution from the CLSI M100-S22: ........................................................................................................... 8
Use of Inducible Beta-Lactamase Flag:................................................................................................................... 8
Cefoxitin Screen: ....................................................................................................................................................... 9
Inducible Clindamycin: ............................................................................................................................................. 9
Streptococci Reporting (Viridans, Beta-hemolytic and S. pneumoniae): .......................................................... 10
Streptococci Limitations: ....................................................................................................................................... 10
Miscellaneous Fastidious Organism Limitation: .................................................................................................. 10
Miscellaneous Organism Recommendation: ........................................................................................................ 10
Synergies Screen Reporting: ................................................................................................................................. 10
Predicted Susceptibility Rules for Synergies plus Pos Panels: ......................................................................... 11
Extended Spectrum Beta-Lactamase (ESBL) Interpretations: ........................................................................... 12
ANTIMICROBIAL AGENT THERAPY GUIDE TABLES .......................................................................................... 15
DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS ............................................. 15
DRIED OVERNIGHT GRAM-POSITIVE PANELS ........................................................................... 64
SYNERGIES PLUS GRAM-NEGATIVE PANELS .............................................................................................. 112
SYNERGIES PLUS GRAM-POSITIVE PANELS ................................................................................................ 126

FASTIDIOUS PANELS - STREPTOCOCCI ......................................................................................................... 130
FASTIDIOUS PANELS - HAEMOPHILUS ........................................................................................................... 145
Species Classifications for Organism Groups ................................................................................................... 153
ACINETOBACTER GROUP ................................................................................................................................ 153
ENTEROBACTER GROUP ................................................................................................................................. 153
CITROBACTER GROUP ..................................................................................................................................... 153
CITROBACTER FREUNDII GROUP ................................................................................................................... 153
ESBL GROUP- SCREENING .............................................................................................................................. 153
ESBL GROUP- CONFIRMATION ........................................................................................................................ 153
CITROBACTER AMALONATICUS/KOSERI GROUP ......................................................................................... 153
PROTEUS/PROVIDENCIA GROUP .................................................................................................................... 153
KLEBSIELLA GROUP .......................................................................................................................................... 153
PROVIDENCIA GROUP ...................................................................................................................................... 154
SALMONELLA/SHIGELLA GROUP .................................................................................................................... 154
SERRATIA GROUP ............................................................................................................................................. 154
9020-7493B
Page 3 of 158
SHIGELLA GROUP.............................................................................................................................................. 154

VIBRIO SPP other than V. cholerae ..................................................................................................................... 154
MISCELLANEOUS FASTIDIOUS GROUP-NEG ................................................................................................. 154
MISCELLANEOUS FASTIDIOUS GROUP-POS ................................................................................................. 154
PROTEUS GROUP .............................................................................................................................................. 154
AEROMONAS SPP. GROUP .. .... 154
OTHER SPECIES GROUP .................................................................................................................................. 155
VIRIDANS STREPTOCOCCI GROUP................................................................................................................. 156
MISCELLANEOUS STREPTOCOCCI GROUP ................................................................................................... 156
BETA-HEMOLYTIC STREPTOCOCCUS GROUP .............................................................................................. 156
GROUP A STREPTOCOCCUS GROUP ............................................................................................................. 156
ENTEROCOCCUS GROUP (for DRIED-OVERNIGHT GRAM-POSITIVE PANELS) ......................................... 156
ENTEROCOCCUS GROUP (for SYNERGIES PLUS GRAM-POSITIVE PANELS)........................................... 156

COAGULASE NEGATIVE STAPHYLOCOCCI GROUP ..................................................................................... 157
Specific Classifications for Panel Groups .......................................................................................................... 158
9020-7493B
Page 4 of 158
Rev.
Date
Affected Sections
March
2013
May
2013
Initial revision.
9020-7493B
Revision Record
Add NC54 panel to Note 2 of Fosfomycin Table with 16, 32 and 64 dilutions in the Dried Overnight and
Rapid (Fluorogenic) Gram-Negative Panels section
Page 5 of 158
General Notes for Reporting Results:

Definitions:
Minimum inhibitory concentration (MIC) dilutions are a sequence of 3 or more dilutions.
Breakpoint dilutions are a 1 or 2 dilution sequence.
For therapy reporting, Enterobacteriaceae includes all fermenters (except V. cholerae and Y. pestis) in the
LabPro Information Manager database unless otherwise noted.
For therapy reporting, Non-Enterobacteriaceae includes all non-fermenters unless otherwise noted.
For therapy reporting, EUCAST and CLSI reports for Haemophilus influenzae and Haemophilus
parainfluenzae.
INTERPRETIVE GUIDELINES
The Interpretive Guidelines were based on the following references, unless otherwise noted.
Reference
EUCAST Clinical Breakpoint Tables
CLSI M45-A2; Methods for Antimicrobial

Dilution and Disk Susceptibility Testing of
Infrequently Isolated or Fastidious Bacteria,
nd
2 edition
CLSI M100-S9, S14, S17, S19, S21 and S22;
Performance Standards for Antimicrobial
Susceptibility Testing; Informational
Supplements
ANVISA Guidelines
SFM
MENSURA
Revision
2013-02-11 (Version 3.1)
2013-01-01 (Version 3.0)
2012-01-01 (Version 2.0)
January 2011 (version 1.3)
December 2009 (Version 1.0)
August 2010
January 1999, 2004, 2007, 2009,

2011 and 2012
Nota Technica No. 1/2010 (2010-1025)
January 2008, 2009 and 2012
An Clin 2001; 26 (4) 109-126
Synergies plus Gram Negative panels:
The Synergies plus Gram Negative panels contain antimicrobial agents that will report-when-ready together
with dried overnight antimicrobial agents.
The report-when-ready antimicrobial agents may report rapid results (4.5 - 12 hrs) or overnight results (16 - 20
hrs) and the dried overnight antimicrobial agents will report overnight results (16 - 20 hrs).
The report-when-ready antimicrobial agents can only be read rapidly (4.5 - 12 hrs) by the WalkAway SI or
WalkAway plus System. Manual reading of all antimicrobial agents must be performed at 16 20 hrs.
Synergies plus Gram Positive panels:
The Synergies plus Gram Positive panels contain antimicrobial agents that will report-when-ready.
The report-when-ready antimicrobial agents may report rapid results (4.5 - 12 hrs) or overnight results (16 - 18 hrs).
The report-when-ready antimicrobial agents can only be read rapidly (4.5 - 12 hrs) by the WalkAway SI or
WalkAway plus System. Manual reading of all antimicrobial agents must be performed at 16 - 20 hrs.
For all Beta-lactam antimicrobial agents, the predicted interpretation for staphylococci will be based on the
penicillin and/or Oxacillin MICs.
MICs will only be reported for staphylococci and/or enterococci. MICs will not be reported for streptococci.
Referenced from the CLSI M100-S22
For some organism groups excluded from Tables 2A through 2J, the CLSI guideline M45 Methods for
Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria provides
suggestions for standardized methods for susceptibility testing, including information about drug selection,
interpretation and QC. The organism groups covered in that document are Abiotrophia and Granulicatella spp.
(formerly known as nutritionally deficient or nutritionally variant streptococci); Aeromonas spp.; Bacillus spp.
(not B. anthracis), Campylobacter jejuni/coli, Corynebacterium spp. (including C. diptheriae); Erysipelothrix
rhusiopathiae, the HACEK group: Aggregatibacter spp. (formerly Haemophilus aphrophilus, H. paraphrophilus,
9020-7493B
Page 6 of 158
H. segnis and Actinobacillus actinomycetemcomitans), Cardiobacterium spp., Eikenella corrodens, and

Kingella spp.; Helicobacter pylori; Lactobacillus spp.; Leuconostoc spp.; Listeria monocytogenes; Moraxella
catarrhalis; Pasteurella spp.; Pediococcus spp.; potential agents of bioterrorism; and Vibrio spp., including V.
cholerae.
For organisms other than those in the groups mentioned above, studies are not yet adequate to develop
reproducible, definitive standards to interpret results. These organisms may require different media or different
atmospheres of incubation, or they may show marked strain-to-strain variation in growth rate. For these
microorganisms, consultation with an infectious disease specialist is recommended for guidance in determining
the need for susceptibility testing and in the interpretation of results. Published reports in the medical literature
and current consensus recommendations for therapy of uncommon microorganisms may obviate the need for
testing. If necessary, a dilution method usually is the most appropriate testing method, and this may require
submitting the organism to a reference laboratory. Physicians should be informed of the limitations of results
and advised to interpret results with caution.
Miscellaneous Notes:
S = Susceptible
I = Intermediate
R = Resistant
R* = Extrapolated Resistance
S* = Extrapolated susceptible result
Blac = Beta-lactamase positive

TFG = Thymidine dependent strain
Blank = Data not available, or drug not advisable or tested
N/R = Not reported
NS = Nonsusceptible
MIC values are reported in g/ml or mg/l.

If the MIC was not reported, N/R will be printed in the MIC area.
If a column under an organism group is blank, interpretations are not available.
The following antimicrobial agents can be reported for V. cholerae with CLSI interpretations: Ampicillin,
Chloramphenicol, Tetracycline and Trimethoprim/Sulfamethoxazole.
Urine/Systemic Therapy Interpretation Rules:

1. For all panels (dried overnight, rapid fluorogenic; Gram-positive or Gram-negative) therapy interpretation will be
driven by source of specimen.
2. In the LabPro System, if the specimen source is systemic (non-urine), only the systemic therapy will be reported,
when available.
3. In the LabPro System, if the specimen source is urine, only urine therapies will be reported, when available.
Additional Rules:
1. If a Haemophilus or Neisseria from the HNID database is stored as the organism for a non-HNID panel, the
therapies will not be printed.
2. If a panel has not been tested, or the panel has not been interpreted, the phrase results to follow will be
printed in the therapy area.
3. Additional antimicrobial agent MIC results will print after the panel MIC results.
4. Therapy results for one isolate may require two or more successive pages.
5. Only results of testing with penicillin, vancomycin, cefotaxime, ceftriaxone or meropenem should be reported
routinely for CSF isolates of S. pneumoniae.
6. For Y. pestis, studies have demonstrated that although beta-lactam antimicrobial agents may appear active in
vitro they lack efficacy in animal models of infection. These antimicrobial agents should not be reported as
susceptible.
Warning from the CLSI M100-S22:
The following antimicrobial agents should not be routinely reported for bacteria isolated from the CSF that are
included in this document. These antimicrobial agents are not the drugs of choice and may not be effective for
treating CSF infections caused by these organisms (ie, the bacteria included in Tables 2A through 2J):
agents administered by oral route only
st
nd
1 - and 2 -generation cephalosporins (except cefuroxime parenteral)
and cephamycins
clindamycin
macrolides
tetracyclines
fluoroquinolones
9020-7493B
Page 7 of 158
Extreme Caution from the CLSI M45-A2:

Public health officials should be notified about all isolates presumptively identified as B. anthracis, Brucella spp., Y.
pestis, B. mallei, B. pseudomallei or F. tularensis. Confirmation of isolates of these bacteria may require
specialized testing only available in reference or public health laboratories.
Use of Inducible Beta-Lactamase Flag:
There is an option to utilize a flag to note possible inducible beta-lactamase isolates on the Long Format Patient
Report. If customization is to be used, the therapies for the organisms and antimicrobial agents listed below will
NOT utilize the attached pages of this document. The flag will perform as follows:
Possible inducible beta-lactamase producing organisms:
Aeromonas caviae
Citrobacter braakii/freundii/sedlakii
Aeromonas hydrophila
Citrobacter werkmanii/youngae
Enterobacter aerogenes
Aeromonas hydrophila group
Aeromonas hydrophila/trota/veronii
Enterobacter cloacae
Aeromonas jandaei
Hafnia alvei
Aeromonas schubertii
Morganella morganii
Providencia alcalifaciens
Aeromonas species
Aeromonas sobria
Providencia alcalifaciens/rustigianii
Aeromonas trota
Providencia rettgeri
Aeromonas veronii
Providencia rustigianii
Citrobacter braakii
Providencia stuartii
Pseudomonas aeruginosa
Citrobacter freundii complex
Citrobacter sedlakii
Serratia liquefaciens
Citrobacter werkmanii
Serratia marcescens
Citrobacter youngae
Beta-lactam antimicrobial agents for inducible beta-lactamase flag:
Amoxicillin
Cefotetan
Amoxicillin/K Clavulanate
Cefoxitin
Ampicillin
Cefpodoxime
Ampicillin/Sulbactam
Cefsulodin
Azlocillin
Ceftazidime
Aztreonam
Ceftizoxime
Carbenicillin
Ceftriaxone
Cefaclor
Cefuroxime
Cefamandole
Cephalothin
Cefazolin
Loracarbef
Cefdinir
Mecillinam
Cefixime
Mezlocillin
Cefmetazole
Piperacillin
Cefonicid
Piperacillin/Tazobactam
Cefoperazone
Ticarcillin
Cefoperazone/Sulbactam
Ticarcillin/K Clavulanate
Cefotaxime
If the inducible beta-lactamase flag is customized, an IB flag will appear on the Long Format Patient Report
for all the above listed organism-drug combinations in place of the Susceptible (S) therapy result.
9020-7493B
Page 8 of 158
Cefoxitin Screen
The Dried Cefoxitin Screen is intended to determine the susceptibility of staphylococci to the penicillinasestable beta-lactams, using the Cefoxitin Screen Well (CfxS) and the Oxacillin MIC result at 16/18 hours. The
CfxS result and Oxacillin MIC are read independently at 16/18 hours and then processed through the LabPro
software or interpreted manually to determine the final interpretation to the penicillinase-stable beta-lactams
(i.e., Oxacillin). The interpretation rules are shown in the following table:
CfxS
Oxacillin MIC
0.25
0.5
Oxacillin Interpretation
S. aureus or S. lugdunensis
Other CNS
S
S
S
S*
4 Neg
R Check mecA
1 or 2
S
(see comment)
>2
R
R
0.25
R*
R*
0.5
R*
R
> 4 Pos
1 or 2
R*
R
>2
R
R
Comment: CNS with CfxS 4 and Oxacillin MICs of 1 or 2 give variable mecA results. Perform mecA testing
if beta-lactam therapy is critical for patient care.
Interpretations of S* or R* are used by the LabPro software when the Cefoxitin Screen result changes the
interpretation of the Oxacillin MIC result. The LabPro software will flag CNS isolates when CfxS is negative
and Oxacillin MICs are 1 or 2 g/ml. The default interpretation will be R, however, mecA status is variable and
must be checked before these isolates are reported as Oxacillin susceptible (mecA negative only). These
criteria should also be followed when interpreting the results manually; however, the asterisk is not required.
For panels containing Oxacillin only: Staphylococci should be reported as resistant to Ampicillin, Amoxicillin/K
Clavulanate, Ampicillin/Sulbactam, Ertapenem, Imipenem, Meropenem, Penicillin, Piperacillin/Tazobactam,
Ticarcillin/K Clavulanate and the Cephalosporin antimicrobics (regardless of the MIC) when Oxacillin MICs are
>2 g/ml for S. aureus and S. lugdunensis and 0.5 g/ml for coagulase negative staphylococci other than S.
lugdunensis.
For panels containing both Oxacillin and the Cefoxitin Screen Well (CfxS): Staphylococci should be reported as
resistant to Ampicillin, Amoxicillin/K Clavulanate, Ampicillin/Sulbactam, Ertapenem, Imipenem, Meropenem,
Penicillin, Piperacillin/Tazobactam, Ticarcillin/K Clavulanate and the Cephalosporin antimicrobics (regardless of
the MIC) when CfxS is > 4 g/ml for all staphylococci or Oxacillin MICs are >2 g/ml for S. aureus and S.
lugdunensis or > 0.5 g/ml for other coagulase negative staphylococci. Based on MicroScan clinical studies, for
coagulase negative staphylococci other than S. lugdunensis when CfxS is 4 g/ml and Oxacillin MIC is 0.5,
the mecA status has been shown to be negative and the Oxacillin interpretation will be reported as S*. For
coagulase negative staphylococci other than S. lugdunensis when CfxS is 4 g/ml and Oxacillin MIC is 1 or 2,
mecA status is variable and must be checked before reporting these antimicrobial agents as susceptible.
Inducible Clindamycin
The Inducible Clindamycin test (ICd) is intended to detect inducible clindamycin resistance in staphylococci
intermediate or resistant to erythromycin and susceptible or intermediate to clindamycin. Expression of
resistance due to the erm gene may require induction by erythromycin. Results of ICd are equivalent to the Dzone disk approximation test. Reported for systemic sources only.
Tests
Negative
Positive
Inducible Clindamycin Test
4/0.5
> 4/0.5
- Staphylococci
When ICd is reported as Positive (>4/0.5) the clindamycin result will be reported as resistant (R*)
regardless of the MIC.
9020-7493B
Page 9 of 158
Streptococci Reporting (Viridans, Beta-hemolytic and S. pneumoniae):
1. MICroSTREP plus panels can report antimicrobial agent results for all streptococci: S. pneumoniae, betahemolytic streptococci, viridans streptococci and viridans streptococci (S. bovis group).
2. The Dried Overnight Gram-Positive panels can report antimicrobial agent results for beta-hemolytic
streptococci (S. agalactiae) and viridans streptococci (S. bovis) only.
3. Antimicrobial agent results for viridans streptococci (S. bovis) will be reported using viridans streptococci
breakpoints (CLSI and EUCAST).
4. Antimicrobial agent results for beta-hemolytic streptococci (S. agalactiae) will be reported using beta-hemolytic
streptococci breakpoints (CLSI) or Streptococcus groups A, B, C and G breakpoints (EUCAST).
5. Antimicrobial agent results for viridans streptococci (S. bovis) and beta-hemolytic streptococci (S.
agalactiae) will be reported using other streptococci breakpoints when using SFM interpretive guidelines.
Streptococci Limitations:
1. S. pneumoniae is contraindicated for use on the Antimicrobial Susceptibility Test (AST) portion of MicroScan
Dried Overnight Gram positive panels.
2. All streptococci, except beta-hemolytic streptococci (S. agalactiae) and viridans streptococci (S. bovis) are
contraindicated on MicroScan Dried Overnight Gram positive panels.
3. All streptococci are contraindicated on Synergies plus Positive panels.

Miscellaneous Fastidious Organism Limitation:
1. MICs for Actinobacillus actinomycetemcomitans, Bordetella pertussis, Bordetella parapertussis, CDC groups
EO-2, HB-5, EF-4A and EF-4B, Eikenella corrodens, Kingella species, Moraxella atlantae, Moraxella lacunata,
Moraxella non-liquifaciens, Moraxella osloensis, Moraxella species/Psychrobacter species, Psychrobacter (M.)
phenylpyruvicus, Oligella urethralis, Oligella ureolytica, Pasteurella species, Mannheimia (P.) haemolytica,
Myroides species, Roseomonas species, Neisseria elongata and Neisseria weaveri are contraindicated for use
and should not be reported on MicroScan Dried Overnight panels, and Rapid (fluorogenic)/Synergies plus
panels. An ID may be obtained on the Rapid (fluorogenic) panel. An ID may be obtained on the rapid
(fluorogenic)/Synergies plus panels with the exception of Bordetella pertussis and Bordetella parapertussis.
Refer to back of therapy guide (Miscellaneous Fastidious Organism Group).
2. MICs for Abiotrophia/Granulicatella species, Aerococcus urinae, Aerococcus viridans, Erysipelothrix species,
Gemella haemolysans, Gemella morbillorum, Gemella species, Kytococcus sedentarius, Leuconostoc
species, Listeria innocua/seeligeri, Pediococcus species, Rhodococcus equi, Rothia dentocariosa, Rothia
mucilaginosa, and Rothia species are contraindicated for use and should not be reported on MicroScan Dried
Overnight Gram positive panels, and Synergies plus Positive panels. An ID may be obtained on the Synergies
plus Positive panels. Refer to the back of this therapy guide (Miscellaneous Fastidious Organism Group-Pos).
Miscellaneous Organism Recommendation:
For the Synergies plus Gram-Negative Panels, sufficient strains of Vibrio cholerae were not tested to establish
efficacy with Ampicillin, Chloramphenicol, Tetracycline and Trimethoprim/Sulfamethoxazole. Interpretive
breakpoints should not be reported.
Synergy Screen Reporting
Gentamicin Synergy Screen
1
(GmS) Reporting
Enterococci
500 = S, >500 = R
Streptococci
Do not report, drug, therapy
(S. agalactiae and
or MIC.
S. bovis group)
1
Based on CLSI M100-S22.
2
Based on French Market Center request in 1995.
9020-7493B
Streptomycin Synergy
Screen
(StS)
1
Reporting
1000 = S, >1000 = R
Do not report, drug, therapy
or MIC.
Kanamycin Synergy
Screen
(KSS )
2
Reporting
1000 = S, >1000 = R
1000 = S, >1000 = R
Page 10 of 158
Predicted Susceptibility Rules for Synergies plus Pos Panels

The predicted susceptibility results for staphylococci are based on the interpretive results for penicillin and/or
Oxacillin.
The following antimicrobial agents may have a predicted susceptibility result for the Synergies plus Pos panels.
Antimicrobial
Class
Penicillins
Antimicrobial
Subclass
Amoxicillin
Ampicillin
Ureidopenicillin
Piperacillin
Carboxypenicillin Ticarcillin
-lactam/ Amoxicillin-clavulanate
lactamase
(Aug)
inhibitor
Ampicillin-sulbactam
combinations
Piperacillin-tazobactam
Ticarcillin-clavulanate
(Tim)
Cephems
Cefaclor
Cefazolin
Cefdinir
Cefepime
Cefotaxime
Cefpodoxime
Ceftriaxone
Cefuroxime
Cephalothin
Carbapenems
Ertapenem
Imipenem
Meropenem
An asterisk (*) will appear beside every predicted interpretation
9020-7493B
Aminopenicillin
Antimicrobial Agent
If
PenicillinS &
Oxacillin-S
S*
S*
S*
S*
S*
If
Penicillin-R &
Oxacillin-S
R*
R*
R*
R*
S*
If Penicillin-S or R
& Oxacillin-R
S*
S*
S*
S*
S*
S*
R*
R*
R*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
S*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
R*
Page 11 of 158
Extended Spectrum Beta-Lactamase (ESBL) Interpretations:

The software has two different sets of rules for Screen and confirmation testing for ESBL-producing organisms on
Dried Overnight Gram-Negative Panels and Synergies plus Gram-Negative Panels. The SCREEN for suspected
ESBL-producing organisms is for Escherichia coli, K. oxytoca, and K. pneumoniae only and utilizes cefpodoxime (1
or 4 g/ml, depending on panel type), aztreonam, cefotaxime, ceftazidime, ceftriaxone, ESBL-a (cefpodoxime at 1
or 4 g/ml depending on panel type) and ESBL-b (ceftazidime, 1 g/ml) as Screening agents. P. mirabilis utilizes
cefotaxime, ceftazidime and cefpodoxime (1 g/ml) as screening agents. Some antimicrobials used as screening
agents on the Dried Gram-Negative Panels are also present on the Synergies plus panels; however, only ESBL-a
and ESBL-b are used as screening agents for Synergies plus panels.
ESBL CONFIRMATION testing utilizes a comparison of MIC values obtained with ceftazidime to ceftazidime/ K.
clavulanate (4 g/ml), or cefotaxime to cefotaxime/ K. clavulanate (4 g/ml). Some older panels compare
ceftazidime to the BSE well (ceftazidime/ K. clavulanate (2 g/ml)). The MIC to the single antimicrobial must be 3
doubling dilutions greater than the MIC to the combination antimicrobial. If either comparison meets the criteria for
a positive result, the confirmation test will be positive. ESBL confirmation rules take precedence over ESBL
Screening rules in the software.
ESBL confirmation rules apply to the following members of the
Enterobacteriaceae: Citrobacter amalonaticus, C. koseri (diversus), C. farmeri, C. freundii complex, Citrobacter
species, Enterobacter aerogenes, E. cloacae, Escherichia coli, K. oxytoca, K. pneumoniae, Morganella morganii,
Proteus mirabilis, P. vulgaris, P. rettgeri, Salmonella species, and Serratia marcescens. The ESBL confirmation
test is being applied to more organisms than are included in the CLSI ESBL confirmation test and should not be
construed as being CLSI approved.
If the ESBL Screen is activated, the report generated for a suspected ESBL-producing strain of E. coli, K.
pneumoniae, K. oxytoca or P. mirabilis will report MIC values with normal SIR interpretations for all antimicrobial
agents tested. However, if elevated MIC values are obtained for one or more of the screening antimicrobial
agents, those agents giving the elevated MIC values will carry the interpretation EBL?
The report generated for a CONFIRMED ESBL-producing strain will still report MIC values for all antimicrobial
agents tested; however, the single or screening antimicrobial agents, including ESBL-a or ESBL-b, giving elevated
MIC values will carry the interpretation ESBL, while all other cephalosporins, penicillins and aztreonam will have
MIC values but will be given the interpretation R*.
The footnotes on the patient report corresponding to these interpretations are as follows:
EBL? indicates that a particular strain is a suspected ESBL. Confirmatory tests are needed to differentiate
ESBLs from other beta-lactamases.
ESBL indicates that a particular strain is a confirmed ESBL.
R* indicates resistance to cephalosporins, penicillins and aztreonam is due to confirmed extended-spectrum
beta-lactamases (ESBL).
These special interpretations will not appear if the laboratory chooses no when a suspected or confirmed ESBLproducer is flagged; normal SIR interpretative categories will be reported.
9020-7493B
Page 12 of 158
Interpretations Reported as ESBL? or ESBL for the following ESBL Screening Antimicrobial Agents:
Drug
Panel Dilution Ranges
MIC
Cefpodoxime
CPD1,3
0.5-1
1
1-4
1-4, 32
1-16
1, 4-8
1, 4-16
1, 8-16
1,8
2-16
4-16
4-32
8-16
0.5-2,16
1-16
1-32
1-64
1-2, 16
1-2, 8-16
1-2, 8-32
2-32
2-8, 32
2, 8-32
2, 16
4-32
4-8, 32
8-32
8,32
0.5-8
1-8
1-16
1-32
1, 4-8
1, 4-16
1, 8-16
1, 8
1-128
2-16
4-32
8-16
0.5-2
1-8
1-2, 8, 32
2-32
4-32
4-8, 32
8-32
8,32
4
>1
>1
>4
>2
>2
>4
>4
>8
>8
>4
>8
>8
>16
>2
>2
>2
>2
>2
>2
>2
>4
>4
8
>16
>8
>8
>16
>32
>2
>2
>2
>2
>4
>4
>8
>8
>2
>4
>8
>16
>2
>2
>2
>4
>8
8
>16
>32
>4
>1
Aztreonam
AZT
Cefotaxime
CFT
Ceftazidime
CAZ
Ceftriaxone
CAX
ESBL-a1,3
(Cefpodoxime)
ESBL-b,3
(Ceftazidime)
1. Panels containing a dilution of 4 g/ml Cefpodoxime will follow ESBL rules based on current CLSI
documents. Panels with dilutions of 1 g/ml or 1-2 g/ml Cefpodoxime will follow CLSI/NCCLS M100-S9.
2. Rapid results (<16 hrs) are not provided for ESBL-a and ESBL-b on Synergies plus Gram-Negative
panels. Results are available at 16-20 hours.
3. P. mirabilis utilizes Cefotaxime, Cefpodoxime at > 1 g/ml and Ceftazidime as screening agents.
9020-7493B
Page 13 of 158
Interpretations Reported as R* for the following Antimicrobial Agents:

When a confirmed ESBL is selected, the MIC interpretations for all other cephalosporins and penicillins report
as R* - Predicted resistance due to extended-spectrum beta-lactamase (ESBL).
Cephalosporins
Cefazolin
Cefepime
Cefoperazone
Cefaclor
Cefdinir
Cefixime
CFZ
CPE
CFP
CFR
CDN
CFE
Cefuroxime
Cephalothin
Ceftizoxime
Ceftriaxone
CRM
CF
CZ
CAX
Penicillins
Amoxicillin
Ampicillin
Mecillinam
Mezlocillin
Piperacillin
Ticarcillin
AMX
AM
MEC
MZ
PI
TI
Interpretations Reported as S, I or R for the following Antimicrobial Agents:

When a confirmed ESBL is selected, MIC interpretations for the following antimicrobial agents report as S, I or
R. The normal rules for interpreting the MICs for these antimicrobial agents do not change.
Beta-Lactam/
Beta-Lactamase Inhibitors
Amoxicillin-K Clavulanate
Ampicillin-Sulbactam
Cefoperazone-Sulbactam
Piperacillin-Tazobactam
Ticarcillin-K. Clavulanate
9020-7493B
AUG
A/S
C/S
P/T
TIM
Carbapenems
Imipenem
Meropenem
Ertapenem
Doripenem
IMP
MER
ETP
DOR
Cephamycins
Cefotetan
Cefoxitin
CTN
CFX
Page 14 of 158
ANTIMICROBIAL AGENT THERAPY GUIDE TABLES

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS
Amikacin
(Ak)
NOTE: 1.
2.
3.
4.
5.
Amikacin
(Ak)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
4.
NONENTEROBACTERIACEAE
PSEUDOMONAS
SPP.
ACINETOBACTER SPP.
>
R
R
R
R
32
R
I
R
R
16
I
S
I
I
8
S
S
S
S
4
S
S
S
S
2
S
S
S
S
Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp. therapies based on EUCAST V3.1.
Non-Enterobacteriaceae (except for Acinetobacter spp. and Pseudomonas spp.) therapy based on CLSI
M100-S22.
Use for EUCAST Blended panel class, except for NBC45, NBC46, NBC49E, NM40, NUC56 and NUC69E
panels.
For Dried Overnight panels, do not report therapy for Salmonella/Shigella group because dangerously
misleading results can occur.
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Y. pestis.
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS
SPP.
ACINETOBACTER SPP.
>
R
R
R
R
16
I
S
I
I
8
S
S
S
S
Non-Enterobacteriaceae (except for Acinetobacter spp. and Pseudomonas spp.) therapy based on
CLSI M100-S22.
Use for NBC45, NBC46, NM40, NUC56 and NUC69E panels.
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Y. pestis.
Based on CLSI M100-S22 interpretive guidelines for Non-Enterobacteriaceae, all MICs of >16 will report
as R, since these dilutions do not differentiate between I and R (S16, I=32, R64).
Amikacin (Ak)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
R
32
R
R
R
16
I
I
I
8
S
S
S
4
S
S
S
2
S
S
S
Therapy based on EUCAST V3.1.
Use for EUCAST panel class.
Do not report therapy for Y. pestis.
9020-7493B
Page 15 of 158

Amikacin (Ak)
MIC
ENTEROBACTERIACEAE
NON-ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
32
I
I
I
16
S
S
S
8
S
S
S
4
S
S
S
2
S
S
S
NOTE: 1. Therapy based on CLSI M100-S22.
2. For Dried Overnight panels, do not report therapy for Salmonella/Shigella group because dangerously
3. Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Y. pestis.
Amikacin (Ak)
NOTE: 1.
2.
3.
4.
5.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
>
R
8
S
4
S
2
S
1
S
Do not report therapy for Y. pestis because dangerously misleading results can occur.
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides and Vibrio spp.
Amoxicillin /
K Clavulanate (Aug)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
R
16
S
S
S
8
S
S
S
Therapy based on CLSI M100-S22.
Use for NUC69C panel
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Y. pestis. .
Based on CLSI M100-S22 interpretive guidelines for Enterobacteriaceae, Non-Enterobacteriaceae and
P. aeruginosa, all MICs of >16 will report as R, since these dilutions do not differentiate between I and R
(S16, I=32, R64).
Amoxicillin (Amx)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
16/8
R
8/4
S
4/2
S
2/1
S
Use for EUCAST Blended and EUCAST panel classes.
Do not report drug, therapy or MIC for B. pseudomallei.
9020-7493B
Page 16 of 158

Amoxicillin /
K Clavulanate (Aug)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16/8
I
8/4
S
4/2
S
2/1
S
2. Do not report therapy for Y. pestis because dangerously misleading results can occur.
3. Do not report drug, therapy or MIC for B. pseudomallei.
Ampicillin (Am)
NOTE: 1.
2.
3.
4.
5.
2.
3.
4.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
8
S
4
S
2
S
1
S
0.5
S
Enterobacteriaceae therapy based on EUCAST V3.1.
V. cholerae therapy based on CLSI M45-A2.
Use for NBC46, NM40 and NUC56 panels
Based on CLSI interpretive guidelines for V. cholerae, all MICs of >8 will report
as N/R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
Ampicillin (Am)
NOTE: 1.
ENTEROBACTERIACEAE
>
R
16
R
8
S
V. cholerae therapy based on CLSI M45-A2.
Use for EUCAST Blended panel class except NBC46, NM40 and NUC56 panels.
Ampicillin (Am)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
V. CHOLERAE
R
I
S
V. CHOLERAE
N/R
S
S
S
S
S
V. CHOLERAE
>
R
R
16
I
I
8
S
S
4
S
S
2
S
S
Enterobacteriaceae therapy based on CLSI M100-S22 and V. cholerae therapy based on CLSI M45A2.
For Rapid fluorogenic panel MIC format, do not report drug, therapy or MIC for C. braakii/C. freundii/C.
sedlakii, C. werkmanii/C. youngae, C. amalonaticus/koseri group, Citrobacter species, Proteus/Providencia
group (except P. mirabilis) or Other Species group. See back of therapy guide for species names.
Do not report therapy for Aeromonas spp. and Plesiomonas shigelloides.
9020-7493B
Page 17 of 158

Ampicillin (Am)
NOTE: 1.
2.
3.
4.
5.
5.
5.
6.
P. AERUGINOSA
V. CHOLERAE
MIC
ENTEROBACTERIACEAE
(Acinetobacter spp. only).
PSEUDOMONAS SPP.
>
R
R
16/8
R
I
8/4
S
S
4/2
S
S
Non-Enterobacteriaceae (Acinetobacter spp. only) therapy based on CLSI M100-S22.
Use for EUCAST Blended therapy panel class, except for NM40 panel.
Do not report drug, therapy or MIC for C. freundii group (See back of therapy guide for species names),
E. aerogenes, and E. cloacae.
(A/S)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
16
I
I
8
S
S
Enterobacteriaceae therapy based on CLSI M100-S22 and V. cholerae therapy based on CLSI M45-A2.
Use for panels with breakpoint format.
For Rapid fluorogenic panel breakpoint format, do not report drug, therapy or MIC for C. braakii/C.
freundii/C. sedlakii, C. werkmanii/C. youngae, C. amalonaticus/koseri group, Citrobacter species, P.
mirabilis or M. morganii. See back of therapy guide for species names.
(A/S)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
(Acinetobacter spp. only).
PSEUDOMONAS SPP.
>
R
R
8/4
S
S
4/2
S
S
2/1
S
S
1/0.5
S
S
Non-Enterobacteriaceae (Acinetobacter spp. only) therapy based on CLSI M100-S22.
Use for NM40 panel.
Do not report drug, therapy or MIC for C. freundii group (See back of therapy guide for species names),
E. aerogenes, and E. cloacae.
Based on CLSI M100-S22 interpretive guidelines for Non-Enterobacteriaceae, all MICs of >8/4 will
report as R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
(A/S)
MIC
ENTEROBACTERIACEAE
(Acinetobacter spp. only)
P. AERUGINOSA
R
>
R
I
16/8
I
S
8/4
S
S
4/2
S
S
2/1
S
2. Report CLSI therapy for Enterobacteriaceae and Acinetobacter spp. See back of therapy guide for
species names.
9020-7493B
Page 18 of 158

Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
5.
6.
5.
6.
7.
5.
6.
7.
8.
9.
NON-ENTEROBACTERIACEAE.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
NON-ENTEROBACTERIACEAE.
PSEUDOMONAS SPP.
>
R
R
R
16
R
I
I
8
R
S
I
1
S
S
S
Enterobacteriaceae and Pseudomonas spp. therapies based on EUCAST V3.1.
Non-Enterobacteriaceae (except Pseudomonas spp.) therapy based on CLSI M100-S22.
Use for NC53, NM40 and NUC56 panels.
Aztreonam is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
panels with E. coli, K. pneumoniae, and K. oxytoca. See ESBL information in front of guide.
Do not report therapy for Acinetobacter spp., B. cepacia, B. pseudomallei, S. maltophilia and Vibrio spp.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs of >1 will report as R, since
these dilutions do not differentiate between I and R (S1, I=2-4, R>4).
Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
R
16
R
I
I
8
R
S
I
4
I
S
I
2
I
S
I
1
S
S
S
Use for EUCAST Blended panel class, except for NBC45, NC53, NM40 and NUC56 panels.
Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
8
R
S
I
1
S
S
S
Use for NBC45 panel.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs >1 will report as R, since
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae (except Pseudomonas spp.), all MICs of
>8 will report as R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
Based on EUCAST interpretive guidelines for Pseudomonas spp., all MICs of >8 will report
as R, since these dilutions do not differentiate between I and R (S1, I=2-16, R>16).
9020-7493B
Page 19 of 158

Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
5.
4.
5.
6.
5.
6.
7.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
16
R
I
8
R
I
1
S
S
Use for NUC57 panel.
Do not report therapy for Vibrio spp.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs >1 will report as R, since
Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
32
R
R
16
R
I
8
R
I
4
I
I
2
I
I
1
S
S
Use for EUCAST panel class, except for NUC57 panel.
Aztreonam (Azt)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
R
S
S
4
I
S
S
1
S
S
S
Enterobacteriaceae therapy based on ANVISA.
Non-Enterobacteriaceae and P. aeruginosa therapy based on CLSI M100-S22.
Use for NC66 panel.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and P. aeruginosa, all MICs of >8 will
9020-7493B
Page 20 of 158

Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
3.
4.
5.
5.
6.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
R
I
I
8
N/R
S
S
Aztreonam is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried
Overnight panels with E. coli, K. pneumoniae, and K. oxytoca. See ESBL information in front of guide.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of 8 will report as N/R, since these
dilutions do not differentiate between S and I (S4, I=8, R16).
Aztreonam (Azt)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
R
32
R
R
R
16
R
I
I
8
I
S
S
4
S
S
S
2
S
S
S
1
S
S
S
Aztreonam is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried
Overnight panels with E. coli, K. pneumoniae, and K. oxytoca. See ESBL information in front of guide.
Aztreonam (Azt)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
I
I
I
8
S
S
S
Use for RNBC3 and RNUC1 panels.
For Rapid fluorogenic panel breakpoint format, do not report drug, therapy or MIC for P. aeruginosa.
Aztreonam is a screening antimicrobial agent for extended-spectrum beta-lactamases (ESBL). For Dried
Overnight panels and E. coli, K. oxytoca and K. pneumoniae see ESBL information in front of guide.
Cefazolin (Cfz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
4
S
2
S
2. For Rapid fluorogenic panel MIC and breakpoint format, do not report drug, therapy or MIC for C.
braakii/C. freundii/C. sedlakii, C. werkmanii/C. youngae, Citrobacter species, Proteus/Providencia
group (except P. mirabilis) or Other Species group. See back of therapy guide for species names.
3. Do not report therapy for Salmonella/Shigella group or Y. pestis because dangerously misleading
results can occur.
9020-7493B
Page 21 of 158

Cefazolin (Cfz)
NOTE: 1.
2.
3.
4.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
16
R
I
R
8
R
S
S
4
I
S
S
2
I
S
S
1
S
S
S
Use for NC58, NC70E, NC71E and NM44E panels.
Do not report therapy for B. cepacia, B. pseudomallei and S. maltophilia.
Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
5.
6.
ENTEROBACTERIACEAE
>
N/R
4
S
2
S
Use for NC63, NC68 and NC72 panels.
Do not report therapy for Salmonella/Shigella group or Y. pestis because dangerously misleading
results can occur.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs >4 will report as N/R, since these
dilutions do not differentiate between S, I and R (S8, I=16, R32).
Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
8
R
S
S
4
I
S
S
2
I
S
S
1
S
S
S
0.5
S
S
S
Use for NBC46 NM40, NUC56 panels.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs >8 will report as R, since these
dilutions do not differentiate between I and R (S8, I=16, R32).
Cefepime (Cpe)
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
16
R
I
R
8
R
S
S
1
S
S
S
NOTE: 1. Enterobacteriaceae and Pseudomonas spp. therapies based on EUCAST V3.1.
2. Non-Enterobacteriaceae (except Pseudomonas spp.) therapy based on CLSI M100-S22.
3. Use for NC53 and NUC59 panels.
5. Do not report therapy for B. cepacia, B. pseudomallei and S. maltophilia.
6. Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs of >1 will report as R, since
9020-7493B
Page 22 of 158

Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
5.
6.
7.
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
8
R
S
S
1
S
S
S
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs >8 will report as R, since
these dilutions do not differentiate between I and R (S8, I=16, R32).
Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
32
R
R
8
R
S
4
I
S
2
N/R
S
Use for NC48 panel.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs of 2 will report as N/R,
since these dilutions do not differentiate between S and I (S1, I=2-4, R>4).
Cefepime (Cpe)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
8
R
S
4
I
S
2
I
S
1
S
S
0.5
S
S
NOTE: 1. Therapy based on EUCAST V3.1.
2. Use for NM39 panel.
Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
8
R
S
1
S
S
9020-7493B
Page 23 of 158

Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
R
S
S
4
I
S
S
1
S
S
S
Non-Enterobacteriaceae and P. aeruginosa therapies based on CLSI M100-S22.
Use for NC66 panel.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and P. aeruginosa, all MICs of >8 will
Cefepime (Cpe)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
32
R
R
R
16
I
I
I
8
S
S
S
4
S
S
S
2
S
S
S
1
S
S
S
0.5
S
S
S
Cefixime (Cfe)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
2
R
1
S
Cefixime (Cfe)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
2
I
1
S
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides and Vibrio spp.
9020-7493B
Page 24 of 158

Cefoperazone/Sulbactam
(C/S)
NOTE: 1.
2.
3.
4.
3.
4.
5.
6.
7.
8.
3.
4.
5.
6.
7.
8.
9.
ACINETOBACTER SPP.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
>
R
R
32
R
I
16
R
I
8
R
S
4
R
S
2
I
S
1
S
S
Non-Enterobacteriaceae (including Acinetobacter spp. and Pseudomonas spp.) therapy based on CLSI
M100-S22.
Use for EUCAST Blended panel class, except for NBC46, NC70E, NC71E, NM40, NUC56 and
NUC69E panels.
Do not report drug, therapy or MIC for M. morganii and Serratia spp.
Cefotaxime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
panels with E. coli, K. pneumoniae, K. oxytoca and P. mirabilis. See ESBL information in front of guide.
Do not report therapy for B. cepacia, B. pseudomallei, and S. maltophilia.
Based on CLSI M100-S22, do not report therapy for P. aeruginosa.
Cefotaxime (Cft)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
R
32
I
I
I
16
S
S
S
Therapy based on Manufacturers Breakpoints.
For Dried Overnight panels, do not report drug, therapy or MIC for S. maltophilia.
For Dried Overnight panels, do not report therapy for Aeromonas spp, Plesiomonas shigelloides,
Vibrio spp. and Non-Enterobacteriaceae (except Acinetobacter spp. and P. aeruginosa).
Cefotaxime (Cft)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
>
R
N/R
16
R
I
8
R
S
4
R
S
2
I
S
1
S
S
0.5
S
S
Non-Enterobacteriaceae (including Acinetobacter spp. and Pseudomonas spp.) therapy based on CLSI
M100-S22.
Use for NBC46, NC70E, NM40, NUC56 and NUC69E panels.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs of >16 will report as N/R,
since these dilutions do not completely differentiate between I and R (S8, I=16-32, R64).
9020-7493B
Page 25 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
5.
6.
3.
4.
5.
6.
7.
8.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
32
R
8
R
4
R
2
N/R
Use for NC48 panel.
Based on EUCAST interpretive criteria for Enterobacteriaceae, all MICs of 2 will report as N/R, since
these dilutions do not differentiate between S and I (S1, I=2, R>2).
Cefotaxime (Cft)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
16
R
2
I
1
S
0.5
S
Use for EUCAST panel class, except for NC48 panel.
Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
16
R
I
8
N/R
S
Use for NC71C and NC71E panels.
Based on CLSI interpretive breakpoints for Enterobacteriaceae, all MICs of 8 will report as N/R, since
these dilutions do not differentiate between S, I and R (S1, I=2, R4).
9020-7493B
Page 26 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
6.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
N/R
16
R
I
8
R
S
4
R
S
2
I
S
1
S
S
Use for NC66, NC70C and NUC69C panels
Do not report therapy for B. cepacia, B. pseudomallei, P. aeruginosa and S. maltophilia.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs of >16 will report as N/R, since
these dilutions do not completely differentiate between I and R (S8, I=16-32, R64).
NOTE: 1.
2.
3.
4.
5.
6.
7.
Cefotaxime (Cft)
3.
4.
5.
6.
ENTEROBACTERIACEAE
>
R
R
64
R
R
32
R
I
16
R
I
8
R
S
4
R
S
2
I
S
1
S
S
Cefotaxime (Cft)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
16
R
I
8
R
S
4
R
S
2
N/R
S
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of 2, will report as N/R, since these
9020-7493B
Page 27 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
6.
3.
4.
5.
6.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
8
N/R
S
Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
ENTEROBACTERIACEAE
>
R
R
32
R
I
16
R
I
8
R
S
4
N/R
S
Cefotaxime (Cft)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
16
I
I
8
S
S
4
S
S
Cefotaxime (Cft)
NOTE: 1.
9020-7493B
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
16
2
Page 28 of 158

Cefotaxime-K
Clavulanate (Cft/CA)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
16/4
8/4
4/4
2/4
1/4
0.5/4
0.25/4
NOTE: 1. Cefotaxime/4 K Clavulanate is a confirmation antimicrobial for extended-spectrum betalactamases (ESBL) on Dried Overnight panels. See ESBL information in front of guide.
Cefotetan (Ctn)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
32
I
16
S
8
S
4
S
2. Do not report therapy for Salmonella/Shigella group or Y. pestis because dangerously misleading results can
occur.
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides and Vibrio spp.
Cefoxitin (Cfx)
MIC
ENTEROBACTERIACEAE
>
32
8
4
2
NOTE: 1. Therapy based on SFM 2012.
2. Use for EUCAST panel class.
Cefoxitin (Cfx)
MIC
P. AERUGINOSA
P. AERUGINOSA
R
I
S
S
S
ENTEROBACTERIACEAE
>
R
32
R
16
I
8
S
4
S
2
S
2. Do not report therapy for Salmonella/Shigella group or Y. pestis because dangerously misleading results can
occur.
9020-7493B
Page 29 of 158

Cefoxitin (Cfx)
NOTE: 1.
2.
3.
4.
5.
6.
3.
4.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
1
S
0.5
S
Use for EUCAST Blended panel class, except for NBC46 panel.
Do not report drug, therapy or MIC for S. marcescens.
Cefpodoxime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
panels with E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis. See ESBL information in front of guide.
Cefpodoxime (Cpd)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
8
S
Use for NBC49C, NBC49E, NBC42, NBC46 and NUC56 panels.
Do not report therapy for Salmonella/Shigella group or Y. pestis because dangerously misleading results can
occur.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of >8 will report as R, since these
Cefpodoxime (Cpd)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
4
I
2
S
1
S
Cefpodoxime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
Cefpodoxime (Cpd)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
1
NOTE: 1. Cefpodoxime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
panels with E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis . See ESBL information in front of guide.
2. Use for NBC46 panel.
Cefsulodin (Cfs)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
32
8
9020-7493B
Page 30 of 158

Ceftazidime (Caz)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
6.
7.
3.
4.
5.
6.
B. PSEUDOMALLEI
NONPSEUDOMONAS SPP.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
NON-ENTEROBACTERIACEAE PSEUDOMONAS SPP.
B. PSEUDOMALLEI
>
R
R
R
N/R
8
R
S
S
S
4
I
S
S
S
2
I
S
S
S
1
S
S
S
S
0.5
S
S
S
S
Non-Enterobacteriaceae (except Pseudomonas spp. and B. pseudomallei) including Acinetobacter spp.
therapy based on CLSI M100-S22 and B. pseudomallei therapy based on CLSI M45-A2.
Use for NBC46, NC70E, NM40 and NUC56 panels.
Ceftazidime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae all MICs >8 will report as R, since these
dilutions do not differentiate between I and R (S8, I=16, R>32).
Based on CLSI interpretive guidelines for B. pseudomallei, all MICs >8 will report as N/R, since these dilutions
do not differentiate between I and R (S8, I=16, R32).
Ceftazidime (Caz)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
R
R
32
R
R
R
R
16
R
I
R
I
8
R
S
S
S
4
I
S
S
S
2
I
S
S
S
1
S
S
S
S
Use for EUCAST Blended panel class, except for NBC45, NBC46, NC70E, NM40 and NUC56 panels.
panels with E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis. See ESBL information in front of therapy guide.
Ceftazidime (Caz)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
NON-ENTEROBACTERIACEAE PSEUDOMONAS SPP.
B. PSEUDOMALLEI
>
N/R
R
R
R
16
N/R
I
R
I
8
N/R
S
S
S
1
S
S
S
S
panels with E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis. See ESBL information in front of therapy guide.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs >1 will report as N/R, since
9020-7493B
Page 31 of 158

Ceftazidime (Caz)
NOTE: 1.
2.
3.
4.
3.
4.
5.
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
32
R
R
16
R
R
8
R
S
4
I
S
2
I
S
1
S
S
0.5
S
S
Ceftazidime (Caz)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
P. AERUGINOSA
B.PSEUDOMALLE
I
>
R
R
R
R
16
R
I
I
I
8
R
S
S
S
4
I
S
S
S
1
S
S
S
S
Non-Enterobacteriaceae and P. aeruginosa therapies based on CLSI M100-S22 and B. pseudomallei
therapy based on CLSI M45-A2.
Use for NC66 panel.
Ceftazidime (Caz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
128
R
R
R
R
64
R
R
R
R
32
R
R
R
R
16
R
I
I
I
8
I
S
S
S
4
S
S
S
S
2
S
S
S
S
1
S
S
S
S
NOTE: 1. Therapy based on CLSI M100-S22 and B. pseudomallei therapy based on CLSI M45-A2.
2. Ceftazidime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
9020-7493B
Page 32 of 158

Ceftazidime (Caz)
NOTE: 1.
2.
3.
4.
5.
6.
3.
4.
4.
NON-ENTEROBACTERIACEAE P. AERUGINOSA
B. PSEUDOMALLEI
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
16
R
I
I
I
8
N/R
S
S
S
Therapy based on CLSI M100-S22 and B. pseudomallei therapy based on CLSI M45-A2.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of 8 will report as N/R, since
these dilutions do not differentiate between S and I (S4, I=8, R16).
Ceftazidime (Caz)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
>
R
R
R
N/R
8
I
S
S
S
4
S
S
S
S
2
S
S
S
S
1
S
S
S
S
Use for NC70C panel.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and P. aeruginosa, all MICs of >8
will report as R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
Based on CLSI interpretive guidelines for B. pseudomallei, all MICs of >8 will report as N/R, since these
Ceftazidime (Caz)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
16
I
I
I
I
8
S
S
S
S
4
S
S
S
S
2
S
S
S
S
Use for RNUC1 panel.
For Rapid fluorogenic panel MIC format, do not report drug, therapy or MIC for P. mirabilis and M.
morganii.
Ceftazidime (Caz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
16
I
I
I
8
S
S
S
NOTE: 1. Therapy based on CLSI M100-S19 and B. pseudomallei therapy based on CLSI M45-A2.
2. Use for RNBP3 panels.
9020-7493B
R
I
S
Page 33 of 158

Ceftazidime (Caz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
8
1
NOTE: 1. Ceftazidime is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
2. Use for NC67 panel.
Ceftazidime-K
Clavulanate (Caz/CA)
MIC
Ceftizoxime (Cz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
32/4
16/4
8/4
4/4
2/4
1/4
0.5/4
0.25/4
NOTE: 1. Ceftazidime/4 g/ml K Clavulanate is a confirmation antimicrobial for extended-spectrum betalactamases (ESBL) on Dried Overnight panels. See ESBL information in front of therapy guide.
NOTE: 1.
2.
3.
4.
5.
6.
7.
P. AERUGINOSA
>
R
R
32
I
I
8
S
S
Do not report therapy for Acinetobacter spp., Aeromonas spp., B. cepacia, B. pseudomallei,
Plesiomonas shigelloides, S. maltophilia and Vibrio spp.
Do not report therapy for P. aeruginosa.
Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS
SPP.
>
R
N/R
2
I
S
1
S
S
0.5
S
S
Non-Enterobacteriaceae therapy based on CLSI M100-S22.
Use for EUCAST Blended panel class.
Ceftriaxone is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried
Overnight panels with E. coli, K. oxytoca and K. pneumoniae. See ESBL information in front of therapy guide.
Do not report therapy for B. cepacia, B. pseudomallei, P. aeruginosa, S. maltophilia, and Vibrio spp.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs >2 will report as N/R since
these dilutions do not differentiate between S, I and R (S8, I=16-32, R64).
9020-7493B
Page 34 of 158

Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
3.
4.
5.
6.
3.
4.
5.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
N/R
8
R
S
4
R
S
2
I
S
1
S
S
Ceftriaxone is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight
panels with E. coli, K. oxytoca and K. pneumoniae. See ESBL information in front of therapy guide.
Use for NC67 panel.
since these dilutions do not differentiate between I and R (S8, I=16-32, R64).
Ceftriaxone (Cax)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
32
R
I
8
R
S
2
I
S
1
S
S
Ceftriaxone (Cax)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
16
R
I
8
R
S
4
R
S
2
N/R
S
9020-7493B
Page 35 of 158

Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
16
R
I
8
R
S
4
N/R
S
Ceftriaxone (Cax)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
R
I
16
R
I
8
N/R
S
Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
5.
9020-7493B
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
16
I
I
8
S
S
4
S
S
Use for RNUC1 panel.
For Rapid fluorogenic panel MIC format, do not report drug, therapy or MIC for P. aeruginosa.
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia, and Vibrio spp.
Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
8
S
S
Use for RNBP3 panel.
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia, and Vibrio spp.
Page 36 of 158

Cefuroxime (Crm)
NOTE: 1.
2.
3.
4.
3.
4.
4.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
4
S
2
S
1
S
For Rapid fluorogenic panel MIC format, do not report drug, therapy or MIC for Proteus/Providencia group
(except P. mirabilis) or Other Species groups. See back of therapy guide for species names.
Do not report therapy for Salmonella/Shigella group and Y. pestis because dangerously misleading results
can occur.
The CLSI breakpoints for Cefuroxime axetil (oral) are S4, I=8-16, R32.
Cefuroxime sodium (Crm)

(parenteral)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
>
R
16
R
8
S
4
S
2
S
1
S
Report therapy for E. coli, P. mirabilis, and Klebsiella spp. only.
Do not report therapy for Salmonella/Shigella group and Y. pestis because dangerously misleading
results can occur.

(parenteral)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
Use for NC66, NC70C and NUC69C panels.
Do not report therapy for Salmonella/Shigella group and Y. pestis because dangerously misleading results can
occur.
The CLSI breakpoints for Cefuroxime axetil (oral) and Enterobacteriaceae are S4, I=8-16, R32;
based on these breakpoints, panel dilutions do not differentiate between S and I.
Cephalothin (Cf)
MIC
ENTEROBACTERIACEAE
>
32
16
8
9020-7493B
P. AERUGINOSA
R
I
I
S
Page 37 of 158

Cephalothin (Cf)
NOTE: 1.
2.
3.
4.
MIC
5.
6.
3.
4.
5.
6.
3.
4.
5.
6.
7.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P.
AERUGINOSA
V. CHOLERAE
Y. PESTIS
>
R
R
R
16
R
I
I
8
S
S
S
Enterobacteriaceae (except Y. pestis) therapy based on EUCAST V3.1.
Non-Enterobacteriaceae therapy based on CLSI M100-S22 and V. cholerae and Y. pestis therapies
based on CLSI M45-A2.
Use for NM44E panel.
Only systemic therapy will be reported.
Do not report drug, therapy or MIC for E. cloacae, M. morganii, P. mirabilis and S. marcescens.
Do not report therapy for Acinetobacter spp. and B. pseudomallei.
ChloramphenicoI (C)
NOTE: 1.
2.
P. AERUGINOSA
>
N/R
8
S
Report for urine sources only.
results can occur.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of >8 will report as N/R, since
Chloramphenicol (C)
NOTE: 1.
2.
>
R
16
I
8
S
4
S
2
S
Report for urine sources only.
results can occur.
Cephalothin (Cf)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
P.
AERUGINOSA
V.
CHOLERAE
R
I
S
Y. PESTIS
>
R
N/R
N/R
N/R
8
S
S
S
S
Enterobacteriaceae (except Y. pestis) therapy based on EUCAST V3.1.
Non-Enterobacteriaceae therapy based on CLSI M100-S22 and V. cholerae and Y. pestis therapies
based on CLSI M45-A2.
Use for NBC46 and NM40 panels.
Do not report drug, therapy or MIC for E. cloacae, M. morganii, P. mirabilis and S. marcescens.
Do not report therapy for Acinetobacter spp. and B. pseudomallei.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, V. cholerae and Y. pestis, all MICs
of >8 will report as N/R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
9020-7493B
Page 38 of 158

ChloramphenicoI (C)
MIC
ENTEROBACTERIACEAE
P.
AERUGINOSA
V. CHOLERAE
Y. PESTIS
>
R
R
R
R
16
I
I
I
I
8
S
S
S
S
4
S
S
S
S
NOTE: 1. Enterobacteriaceae (except V. cholerae and Y. pestis) and Non-Enterobacteriaceae therapies based on CLSI
M100-S22 and V. cholerae and Y. pestis therapies based on CLSI M145-A2.
2. Only systemic therapy will be reported.
3. Do not report therapy for Acinetobacter spp., B. pseudomallei and Vibrio spp.
Cinoxacin (Cn)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
3.
4.
5.
6.
P. AERUGINOSA
Y. PESTIS
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS
SPP.
Y. PESTIS
>
R
R
R
2
R
I
R
1
I
S
I
0.5
S
S
S
Enterobacteriaceae (except Y. pestis) and Pseudomonas spp. therapies based on EUCAST V3.1.
Non-Enterobacteriaceae (except Pseudomonas spp.) including Acintobacter spp. therapy based on
CLSI M100-S22 and Y. pestis therapy based on CLSI M100-S17.
Use for EUCAST Blended panel class, except for NBC45, NBC46, NBC49E (use CLSI M100-S21
breakpoints), NM40 and NUC56 panels.
Panel dilutions do not allow reporting of EUCAST breakpoints for Salmonella spp.
Ciprofloxacin (Cp)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
N/R
16
S
Use for RNB3 panel.
Only urine therapy will be reported.
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp. and Y. pestis.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of >16 will report as N/R, since
Ciprofloxacin (Cp)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS
SPP.
R
I
S
S
Y. PESTIS
>
R
N/R
R
N/R
1
I
S
I
S
0.5
S
S
S
S
Enterobacteriaceae (except Y. pestis) and Pseudomonas spp. therapies based on EUCAST V3.1.
Non-Enterobacteriaceae (except Pseudomonas spp.) therapy including Acintobacter spp. based on
CLSI M100-S22 and Y. pestis therapy based on CLSI M100-S17.
Use for NBC45, NBC46, NM40 and NUC56 panels.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and Y. pestis, all MICs of >1 will
report as N/R, since these dilutions do not differentiate between I and R (S1, I=2, R4).
9020-7493B
Page 39 of 158

Ciprofloxacin (Cp)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
>
R
2
R
1
I
0.5
S
0.25
S
Do not report drug, therapy or MIC for Acinetobacter spp.
Ciprofloxacin (Cp)
MIC
ENTEROBACTERIACEAE
>
R
R
4
R
R
2
I
I
1
S
S
0.5
S
S
0.12
S
S
2. Therapy for Y. pestis based on CLSI M100-S17.
3. Do not report therapy for B. cepacia, B. pseudomallei, and S. maltophilia.
Colistin (Cl)
NOTE: 1.
2.
3.
4.
MIC
5.
ENTEROBACTERIACEAE
R
R
I
S
S
P. AERUGINOSA
R
R
I
S
S
S
Y. PESTIS
R
R
I
S
S
S
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
4
R
S
2
S
S
Use for EUCAST Blended panel class, except for NM40 panel.
Do not report drug, therapy or MIC for Salmonella species, E. cloacae, Acinetobacter species or Other
Non-Enterobacteriaceae (except Pseudomonas spp).
Colistin (Cl)
NOTE: 1.
2.
3.
4.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
2
S
S
Use for NM40 panel.
Based on EUCAST interpretive guidelines for Pseudomonas spp., all MICs >2 will report as R, since
these dilutions do not differentiate between S and R (S4, R>4).
Non-Enterobacteriaceae (except Pseudomonas spp).
9020-7493B
Page 40 of 158

Colistin (Cl)
NOTE: 1.
2.
3.
4.
MIC ENTEROBACTERIACEAE
5.
MIC
MIC
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
P. AERUGINOSA
>
R
R
4
R
I
2
S
S
P. aeruginosa therapy based on CLSI M100-S22.
Use for NC66 panel.
Do not report therapy for B. cepacia, S. maltophilia and Y. pestis.
Non-Enterobacteriaceae.
Colistin (Cl)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
P. AERUGINOSA
>
4
2
Do not report therapy for B. cepacia, S. maltophilia and Y. pestis.
Do not report drug, therapy or MIC for Acinetobacter species or Other Non-Enterobacteriaceae.
NOTE: 1.
2.
3.
Doripenem (Dor)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
2
S
S
Use for NM39 panel.
Based on EUCAST interpretive guidelines for Pseudomonas spp., all MICs of >2 will report as R, since
Do not report drug, therapy or MIC for Salmonella species, E. cloacae or Acinetobacter species.
Colistin (Cl)
NOTE: 1.
2.
3.
4.
5.
PSEUDOMONAS SPP.
>
R
R
4
R
S
2
S
S
Use for EUCAST panel class, except for NM39 panel.
Colistin (Cl)
NOTE: 1.
2.
3.
4.
ACINETOBACTER SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
R
I
S
PSEUDOMONAS SPP.
>
R
R
R
4
I
I
I
2
I
I
I
1
S
S
S
Do not report drug, therapy, or MIC for Aeromonas spp., Plesiomonas shigelloides, and Vibrio spp.
(including V. cholerae).
9020-7493B
Page 41 of 158

Doripenem (Dor)
NOTE: 1.
2.
3.
4.
4.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
4
R
2
R
1
I
0.5
S
Ertapenem (Etp)
NOTE: 1.
2.
3.
4.
>
R
R
2
I
S
1
S
S
0.5
S
S
Based on CLSI interpretive guidelines for P. aeruginosa, all MICs of >2 will report as R, since these
dilutions do not differentiate between I and R (S2, I=4, R 8).
Ertapenem (Etp)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
4
R
I
2
I
S
1
S
S
Use for NM44C and NC71C panels.
Doripenem (Dor)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
1
I
0.5
S
Therapy based on ANVISA.
Use for NC66 panel.
9020-7493B
Page 42 of 158

Ertapenem (Etp)
Ertapenem (Etp)
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
4
R
2
R
1
N/R
Use for NBC43, NBC44, NBC47, NM38, NUC55, NUC60, NUC61 and NUC62 panels.
Enterobacteriaceae that are resistant to extended spectrum cephalosporins (3rd generation) and have
Ertapenem MICs of >1 may produce KPC-type or other carbapenemases. The isolate should be saved
and results verified by repeat testing unless patient had isolate previously. Follow current CLSI or
public health guidelines. Infectious Disease Consult suggested.
these dilutions do not differentiate between S and I (S0.5, I=1, R2).
NOTE: 1.
2.
3.
4.
5.
6.
Ertapenem (Etp)
6.
ENTEROBACTERIACEAE
>
R
4
R
2
R
1
I
0.5
S
NOTE: 1.
2.
3.
4.
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
4
R
2
N/R
Use for NBC33, NBC34, NBC39, NBC41, NBC42, NC39, NC50, NUC45 and NUC51 panels.
these dilutions do not differentiate between S and I (S0.5, I=1, R2).
9020-7493B
Page 43 of 158

Ertapenem (Etp)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
1
2. Use for NUC52 panel.
3. Per CLSI, Enterobacteriaceae that are resistant to extended spectrum cephalosporins (3rd generation)
and have Ertapenem MICs of >1 may produce KPC-type or other carbapenemases. The isolate should
be saved and results verified by repeat testing unless patient had isolate previously. Follow current
CLSI or public health guidelines. Infectious Disease Consult suggested.
ESBL-a (ESa)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
4
NOTE: 1. ESBL-a is Cefpodoxime.
2. ESBL-a is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight panels
with E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis. See ESBL information in front of the guide.
ESBL-b (ESb)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
1
NOTE: 1. ESBL-b is Ceftazidime.
2. ESBL-b is a screening antimicrobial for extended-spectrum beta-lactamases (ESBL) on Dried Overnight panels
with E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis. See ESBL information in front of the guide.
Fosfomycin (Fos)
NOTE: 1.
2.
3.
4.
4.
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
64
R
32
S
16
S
Use for EUCAST blended, EUCAST panel classes and NBC42, NBC43, NC54 and NM37 panels.
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp., and Y. pestis.
Anecdotal evidence suggests that infections caused by wild type isolates of Pseudomonas spp. (ECOFF:
WT128mg/L) may be treated with combination of fosfomycin and other agents.
Fosfomycin (Fos)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
64
N/R
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp., and Y. pestis.
Anecdotal evidence suggests that infections caused by wild type isolates of Pseudomonas spp. (ECOFF:
WT128mg/L) may be treated with combination of fosfomycin and other agents.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs of 64 will report as N/R, since
9020-7493B
Page 44 of 158

Gatifloxacin (Gat)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
4
I
2
S
NOTE: 1. Therapy based on FDA approved breakpoints.
2. For Dried Overnight panels, do not report drug, therapy or MIC for Non-Enterobacteriaceae and P.
aeruginosa.
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp., and Y. pestis.
Gemifloxacin (Gem)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
0.5
I
0.25
S
2. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp., and Y. pestis.
Gentamicin
(Gm)
NOTE: 1.
2.
3.
4.
5.
2.
3.
4.
5.
6.
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
PSEUDOMONAS
SPP.
Y. PESTIS
>
R
R
R
R
R
8
R
I
R
R
I
4
I
S
S
S
S
2
S
S
S
S
S
1
S
S
S
S
S
Enterobacteriaceae (except Y. pestis), Acinetobacter spp. and Pseudomonas spp. therapies based on
EUCAST.
Non-Enterobacteriaceae (except Pseudomonas spp. and Acinetobacter spp.) therapy based on CLSI
M100-S22 and Y. pestis therapy based on M45-A2.
Do not report therapy for Salmonella/Shigella group because dangerously misleading results can occur.
Gentamicin
(Gm)
NOTE: 1.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
PSEUDOMONAS
SPP.
Y. PESTIS
>
R
R
R
R
R
4
I
S
S
S
S
2
S
S
S
S
S
Enterobacteriaceae (except Y. pestis), Acinetobacter spp. and Pseudomonas spp. therapies based on
EUCAST V3.1.
Non-Enterobacteriaceae (except Pseudomonas spp. and Acinetobacter spp.) therapy based on CLSI
M100-S22 and Y. pestis therapy based on M45-A2.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and Y. pestis, all MICs of >4 will
report as R, since these dilutions do not differentiate between S and I (S4, I=8, R16).
9020-7493B
Page 45 of 158

Gentamicin (Gm)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
R
8
R
R
R
4
I
S
S
2
S
S
S
1
S
S
S
3. Do not report therapy for Salmonella/Shigella group because dangerously misleading results can occur.
Gentamicin (Gm)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
Y. PESTIS
>
R
R
R
R
8
I
I
I
I
4
S
S
S
S
2
S
S
S
S
1
S
S
S
S
Imipenem
(Imp)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
ACINETOBACTER
SPP.
PSEUDOMONAS
SPP.
B. PSEUDOMALLEI
>
R
R
R
R
R
8
I
I
I
I
4
I
S
S
S
2
S
S
S
S
1
S
S
S
S
Non-Enterobacteriaceae (except Acinetobacter spp and Pseudomonas spp.) therapy based on CLSI
M100-S22 and B. pseudomallei therapy based on CLSI M45-A2.
For Acinetobacter spp., susceptible and intermediate results will not be reported.
For Dried Overnight panels, do not report therapy for B. cepacia and S. maltophilia.
Imipenem (Imp)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
R
8
I
I
4
I
S
2
S
S
1
S
S
0.5
S
S
9020-7493B
Page 46 of 158

Imipenem (Imp)
NOTE: 1.
2.
3.
4.
5.
6.
4.
5.
4.
5.
6.
P.
AERUGINOSA
B. PSEUDOMALLEI
MIC
ENTEROBACTERIACEAE
P.
AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
8
R
I
R
I
4
R
S
I
S
2
I
S
S
S
1
S
S
S
S
For Rapid fluorogenic panels, do not report drug, therapy or MIC for all gram-negative organisms.
For Dried Overnight panels, do not report therapy for Y. pestis because dangerously misleading results can
occur.
For Dried Overnight panels, do not report therapy for B. cepacia, S. maltophilia, Aeromonas spp.,
Plesiomonas shigelloides and Vibrio spp.
Imipenem (Imp)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
>
R
R
R
R
8
R
I
R
I
4
R
S
I
S
2
I
S
S
S
1
S
S
S
S
Non-Enterobacteriaceae and P. aeruginosa therapies based on CLSI M100-S22 and B. pseudomallei
therapy based on CLSI M45-A2.
Use for NC66 panel.
Do not report therapy for B. cepacia and S. maltophilia, Aeromonas spp., Plesiomonas shigelloides and
Vibrio spp.
Imipenem (Imp)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P.
AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
8
R
I
R
I
4
R
S
I
S
2
N/R
S
S
S
occur.
9020-7493B
Page 47 of 158

Imipenem (Imp)
NOTE: 1.
2.
3.
4.
5.
6.
7.
3.
4.
3.
4.
5.
P.
AERUGINOSA
B. PSEUDOMALLEI
MIC
ENTEROBACTERIACEAE NON-ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
R
R
4
R
I
R
R
2
I
S
I
I
1
S
S
S
S
Non-Enterobacteriaceae (except Acinetobacter spp. and Pseudomonas spp.) therapy based on CLSI
M100-S22.
Use for EUCAST Blended panel class, except for NBC45, NBC46, NBC49E, NM40 and NUC56
panels.
Do not report therapy for B. pseudomallei and Y. pestis.
Levofloxacin (Lvx)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
R
R
8
R
I
R
I
4
N/R
S
N/R
S
occur.
Based on CLSI interpretive guidelines for P. aeruginosa, all MICs of 4 will report as N/R, since these
Levofloxacin (Lvx)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE NON-ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
R
R
2
I
S
I
I
1
S
S
S
S
M100-S22.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs of >2 will report as R,
since these dilutions do not differentiate between S, I and R (S2, I=4, R8).
Levofloxacin (Lvx)
NOTE: 1.
2.
9020-7493B
MIC
ENTEROBACTERIACEAE
>
R
4
I
2
S
1
S
0.5
S
R
I
S
S
S
P. AERUGINOSA
R
I
S
S
S
Page 48 of 158

Mecillinam (Mec)
NOTE: 1.
2.
3.
4.
5.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
8
S
Use for EUCAST blended and EUCAST panel classes.
For Dried Overnight panels, do not report drug, therapy or MIC for Klebsiella spp.
Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
PSEUDOMONAS
SPP.
>
R
R
R
R
8
I
I
I
I
4
I
S
I
I
2
S
S
S
S
1
S
S
S
S
0.5
S
S
S
S
M100-S22.
Do not report therapy for B. pseudomallei and S. maltophilia.
Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
R
I
R
4
R
S
I
2
I
S
S
1
S
S
S
Non-Enterobacteriaceae and P aeruginosa therapies based on CLSI M100-S22.
Use for NC66 panel.
Meropenem (Mer)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
R
I
R
4
R
S
I
2
I
S
S
1
S
S
S
3. Do not report therapy for Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides, S. maltophilia,
and Vibrio spp.
9020-7493B
Page 49 of 158

Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
4.
4.
5.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
R
R
R
8
R
I
R
4
R
S
I
2
N/R
S
S
Do not report therapy for Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides, S. maltophilia,
and Vibrio spp.
Meropenem (Mer)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
>
R
R
R
8
R
I
R
4
R
S
I
1
S
S
S
Use for NBC42 and NBC43 panels.
and Vibrio spp.
Based on CLSI interpretive guidelines for Enterobacteriaceae, all MICs of >1 will report as R, since
Meropenem (Mer)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
R
I
R
4
N/R
S
N/R
and Vibrio spp.
Based on CLSI interpretive guidelines for P. aeruginosa, all MICs of 4 will report as N/R, since these
9020-7493B
Page 50 of 158

Mezlocillin (Mz)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
32
I
I
S
16
S
S
S
8
S
S
S
For Rapid fluorogenic panel MIC format, do not report drug, therapy or MIC for Serratia group. See back of
therapy guide for species names.
For Rapid fluorogenic panels, do not report therapy for S. maltophilia.
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides and Vibrio
spp.
Minocycline (Min)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
8
I
I
4
S
S
2
S
S
1
S
S
2. Do not report therapy Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides, Vibrio spp, and Y.
pestis.
Moxifloxacin (Mxf)
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
R
>
2
R
1
I
0.5
S
Use for the EUCAST Blended panel class and NBC42, NBC49C and NM37 panels.
Do not report drug, therapy or MIC for P. aeruginosa.
Do not report therapy for Aeromonas spp, Plesiomonas shigelloides, Vibrio spp. and Y. pestis.
NOTE: 1.
2.
3.
4.
5.
Moxifloxacin (Mxf)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
R
>
4
I
2
S
Therapy based on FDA approved breakpoints.
Do not report drug, therapy or MIC for P. aeruginosa.
9020-7493B
Page 51 of 158

Nalidixic Acid (NA)
NOTE: 1.
2.
3.
4.
5.
6.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
4
S
Therapy based on SFM 2012.
For Dried Overnight panels, do not report drug, therapy or MIC for E. cloacae and K. pneumoniae.
Do not report therapy for Salmonella because the ability of the dried gram negative panels to detect
Nalidixic Acid resistance in Salmonella strains is unknown, resistant strains were not available at the
time of comparative testing. An alternate method should be used.
Nalidixic Acid (NA)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
S
For Dried Overnight panels, do not report drug, therapy or MIC for E. cloacae and K. pneumoniae.
Do not report therapy for Salmonella because the ability of the dried gram negative panels to detect
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, and Vibrio spp.
Netilmicin (Nt)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
I
I
I
8
S
S
S
4
S
S
S
2
S
S
S
3. Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides, S.
maltophilia, Vibrio spp. and Y. pestis.
Nitrofurantoin (Fd)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
64
S
32
S
9020-7493B
Page 52 of 158

Nitrofurantoin (Fd)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
64
I
32
S
2. Only urine therapy will be reported.
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp. and Y. pestis.
Norfloxacin (Nxn)
NOTE: 1.
2.
3.
4.
5.
6.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
1
I
S
S
0.5
S
S
S
Plesiomonas shigelloides, S. maltophilia, Vibrio spp. and Y. pestis.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and P. aeruginosa, all MICs of >1
will report as R, since these dilutions do not differentiate between S, I and R (S4, I=8, R16).
Norfloxacin (Nxn)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
1
I
0.5
S
Norfloxacin (Nxn)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
I
I
I
4
S
S
S
1
S
S
S
0.5
S
S
S
3. Do not report therapy for Acinetobacter spp., Aeromonas spp., B. cepacia, B. pseudomallei,
9020-7493B
Page 53 of 158

Ofloxacin Ofl)
NOTE: 1.
2.
3.
4.
5.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
1
I
S
S
0.5
S
S
S
Plesiomonas shigelloides, S. maltophilia and Y. pestis.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae and P. aeruginosa , all MICs of
>1 will report as R, since these dilutions do not differentiate between S, I and R (S2, I=4, R8).
Ofloxacin (Ofl)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
4
R
2
R
1
I
0.5
S
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides and Y. pestis.
Ofloxacin (Ofl)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
4
I
I
I
2
S
S
S
1
S
S
S
0.5
S
S
S
2. Do not report therapy for Acinetobacter spp., Aeromonas spp., B. cepacia, B. pseudomallei,
Plesiomonas shigelloides, S. maltophilia and Y. pestis.
Ofloxacin (Ofl)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
4
I
I
I
2
S
S
S
For Rapid fluorogenic panel breakpoint format, do not report drug, therapy or MIC for A. baumannii, A.
haemolyticus, A. baumannii/haemolyticus, Acinetobacter spp. or P. aeruginosa. See back of therapy
guide for species names.
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides, S.
maltophilia and Y. pestis.
For Dried Overnight panels, do not report therapy for Acinetobacter spp.
9020-7493B
Page 54 of 158

Piperacillin (Pi)
NOTE: 1.
2.
3.
4.
5.
6.
4.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
64
R
R
16
I
S
8
S
S
Do not report drug, therapy or MIC for C. koseri and S. maltophilia.
Piperacillin (Pi)
NOTE: 1.
2.
3.
>
R
N/R
R
16
I
S
S
8
S
S
S
4
S
S
S
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, and Plesiomonas shigelloides.
Piperacillin (Pi)
NOTE: 1.
2.
3.
4.
5.
ENTEROBACTERIACEAE
>
R
R
R
64
R
I
R
16
I
S
S
8
S
S
S
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, and Plesiomonas shigelloides.
Piperacillin (Pi)
NOTE: 1.
2.
3.
4.
5.
6.
7.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
128
R
R
R
64
I
I
I
32
I
I
I
16
S
S
S
8
S
S
S
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, and Plesiomonas
shigelloides.
Do not report drug, therapy or MIC for S. maltophilia.
9020-7493B
Page 55 of 158

Piperacillin (Pi)
NOTE: 1.
2.
3.
4.
4.
5.
6.
5.
6.
7.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
64
R
I
R
32
R
I
R
16
I
S
S
8
S
S
S
Do not report drug, therapy or MIC for S. maltophilia and Acinetobacter species. See back of therapy
Do not report therapy for B. cepacia and B. pseudomallei.
(P/T)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
R
64
I
I
S
16
S
S
S
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides and S.
maltophilia.
(P/T)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
R
R
16
I
S
S
8
S
S
S
4
S
S
S
Do not report drug, therapy or MIC for S. maltophilia and Acinetobacter species. See back of therapy
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs of >16 will report as R,
(P/T)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
64
R
R
16
I
S
8
S
S
4
S
S
3. Do not report drug, therapy or MIC for S. maltophilia and Acinetobacter species. See back of therapy
9020-7493B
Page 56 of 158

(P/T)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
I
32
I
I
I
16
S
S
S
8
S
S
S
For Dried Overnight panels, do not report drug, therapy or MIC for S. maltophilia and Acinetobacter
species. See back of therapy guide for species names.
Tetracycline (Te)
MIC
ENTEROBACTERIACEAE
>
R
8
I
4
S
2. Use for EUCAST blended and EUCAST panel classes.
Tetracycline (Te)
P. AERUGINOSA
R
I
S
MIC
ENTEROBACTERIACEAE
>
8
4
2
R
I
S
S
R
I
S
S
MIC
B. PSEUDOMALLEI
Y. PESTIS
P. AERUGINOSA
V. CHOLERAE
R
I
S
S
>
R
R
8
I
I
4
S
S
2
S
S
NOTE: 1. Enterobacteriaceae (except V. cholerae and Y. pestis) and Non-Enterobacteriaceae (except B.
pseudomallei) therapies based on CLSI M100-S22. V. cholerae, Y. pestis and B. pseudomallei
therapies based on CLSI M45-A2.
2. Do not report therapy for B. cepacia and S. maltophilia.
Ticarcillin (Ti)
NOTE: 1.
2.
3.
4.
5.
6.
7.
MIC
ENTEROBACTERIACEAE
PSEUDOMONAS SPP.
>
R
N/R
R
32
R
I
R
16
I
S
S
8
S
S
S
Use for EUCAST Blended panel class, except for NC71E (use CLSI M100-S21 breakpoints) panel.
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides and
Vibrio spp.
9020-7493B
Page 57 of 158

Ticarcillin (Ti)
NOTE: 1.
2.
3.
4.
5.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
32
I
I
S
16
S
S
S
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides and
Vibrio spp.
Ticarcillin (Ti)
NOTE: 1.
2.
3.
4.
ACINETOBACTER SPP.
>
R
R
64
R
R
16
N/R
S
Use for NC48 panel.
since these dilutions do not differentiate between S and I (S8, I=16, R>16).
Ticarcillin (Ti)
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
>
R
R
64
R
R
32
R
R
16
I
S
8
S
S
Ticarcillin (Ti)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
16
S
S
S
Therapy based on CLSI M100- S21.
maltophilia and Vibrio spp.
9020-7493B
Page 58 of 158

TicarcillinK Clavulanate (Tim)
NOTE: 1.
2.
3.
4.
5.
PSEUDOMONAS
SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
64
R
R
32
R
R
16
I
S
8
S
S
NOTE: 1.
2.
3.
4.
5.
ENTEROBACTERIACEAE
>
R
R
16
I
S
8
S
S
Do not report therapy for Aeromonas spp, Plesiomonas shigelloides and Vibrio spp.
Do not report drug, therapy or MIC for Non-Enterobacteriacea (other than Pseudomonas species).
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
64
R
R
16
N/R
S
Use for NC48 panel.
NOTE: 1.
2.
3.
4.
9020-7493B
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
64
I
I
32
I
I
16
S
S
8
S
S
Do not report drug, MIC or therapy for P. aeruginosa.
Do not report therapy for Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides and Vibrio spp.
Page 59 of 158

NOTE: 1.
2.
3.
4.
5.
3.
4.
4.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
4
R
2
I
1
S
0.5
S
0.25
S
Use for EUCAST Blended, EUCAST panel classes, and NBC42, NBC43, NBC49C, NC54, NC70C,
NC71C, NM44C panels.
Do not report drug, therapy or MIC for Acinetobacter spp., P. mirabilis, Non-Enterobacteriaceae and P.
aeruginosa.
Tigecycline (Tgc)
NOTE: 1.
2.
3.
ENTEROBACTERIACEAE
>
R
R
64
I
I
16
S
S
Use for RNBC3 panel.
For Rapid fluorogenic panel breakpoint format, do not report drug, therapy or MIC for P. aeruginosa, E. coli or
Klebsiella spp. See back of therapy guide for species names.
Do not report therapy for Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides, and Vibrio spp.
Tigecycline (Tgc)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
2
I
1
S
Use for NC66 panel.
Do not report drug, therapy or MIC for Acinetobacter spp., P. mirabilis, Non-Enterobacteriaceae and P.
aeruginosa.
Tigecycline (Tgc)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
4
I
2
S
1
S
2. Do not report drug, therapy or MIC for Acinetobacter spp., P. mirabilis, Non-Enterobacteriaceae and P.
aeruginosa.
3. Do not report therapy for Y. pestis.
9020-7493B
Page 60 of 158

Tobramycin (To)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
6.
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
R
R
8
R
I
R
R
4
I
S
S
S
2
S
S
S
S
M100-S22.
Do not report therapy for Salmonella/Shigella group because dangerously misleading results can
occur.
Tobramycin (To)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS
SPP.
>
R
R
R
R
4
I
S
S
S
2
S
S
S
S
Non-Enterobacteriaceae (except Acinetobacter spp. and Pseudomonas spp.) therapies based on CLSI
M100-S22.
Based on CLSI interpretive guidelines for Non-Enterobacteriaceae, all MICs of >4 will report as R, since
Tobramycin (To)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
R
8
R
R
R
4
I
S
S
2
S
S
S
1
S
S
S
Tobramycin (To)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
R
R
R
8
I
I
I
4
S
S
S
2
S
S
S
1
S
S
S
3. Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides,
S. maltophilia, Vibrio spp. and Y. pestis.
9020-7493B
Page 61 of 158

Trimethoprim (T)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
8
S
For Rapid fluorogenic panel breakpoint format, do not report drug, therapy or MIC for A. baumannii, A.
haemolyticus, A. baumannii/haemolyticus and Acinetobacter spp. See back of therapy guide for
species names.
TrimethoprimSulfamethoxazole
(T/S)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
>
R
I
S
R
R
S
R
I
S
4/76
2/38
MIC
B. PSEUDOMALLEI
V. CHOLERAE
S. MALTOPHILIA
P. AERUGINOSA
Y. PESTIS
>
R
R
R
R
R
R
S
R
S
S
S
S
Enterobacteriaceae (except Y. pestis), Acinetobacter spp. and S. maltophilia therapies based on
EUCAST.
Non-Enterobacteriaceae (including Pseudomonas spp. other than P. aeruginosa) therapy based on
CLSI M100-S22 and B. pseudomallei, V. cholerae, and Y. pestis therapies based on CLSI M45-A2.
Use for EUCAST blended panel class, except for NC53 and NC58 panels.
4/76
2/38
NOTE: 1.
2.
3.
4.
TrimethoprimSulfamethoxazole
(T/S)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER
SPP.
2/38
>
R
S
R
S
R
S
MIC
B. PSEUDOMALLEI
V. CHOLERAE
Y. PESTIS
P. AERUGINOSA S. MALTOPHILIA
R
S
>
NOTE: 1.
2.
3.
4.
5.
R
R
R
2/38
S
S
S
Enterobacteriaceae (except Y. pestis), Acinetobacter spp. and S. maltophilia therapies based on
EUCAST V3.1.
Non-Enterobacteriaceae (including Pseudomonas spp. other than P. aeruginosa) therapy based on
CLSI M100-S22 and B. pseudomallei, V. cholerae, and Y. pestis therapy based on CLSI M45-A2.
Use for NC53 and NC58 panels.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, Acinetobacter spp., and S. maltophilia
all MICs of >2/38 will report as R, since these dilutions do not differentiate between I and R with
Enterobacteriaceae and Acinetobacter spp. (S2/38, I=4/76, R>4/76), and S and R with S. maltophilia
(S4/76, R>4/76).
9020-7493B
Page 62 of 158

TrimethoprimSulfamethoxazole (T/S)
MIC
MIC
ENTEROBACTERIACEAE
>
R
4/76
I
2/38
S
2. Use for NM39 and NUC57panels.
3. Do not report therapy for P. aeruginosa.
NOTE: 1.
2.
3.
4.
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP. S. MALTOPHILIA
R
I
S
R
S
S
ACINETOBACTER SPP.
PSEUDOMONAS SPP. S. MALTOPHILIA
>
R
R
R
8/152
R
R
R
2/38
S
S
S
Therapies for y based on EUCAST V3.1.
Use for NC48 panel.
Based on EUCAST interpretive guidelines for Enterobacteriaceae and Acinetobacter spp., all MICs of
> 2/38 will report as R, since these dilutions do not differentiate between I and R (S2/38, I=4/76,
R>4/76).
MIC
ENTEROBACTERIACEAE
4/76
2/38
1/19
0.5/9.5
>
R
R
S
S
S
MIC
B. PSEUDOMALLEI
V. CHOLERAE
R
R
S
S
S
R
R
S
S
S
Y. PESTIS
>
R
R
4/76
R
R
2/38
S
S
1/19
S
S
0.5/9.5
S
S
NOTE: 1. Enterobacteriaceae (except V. cholerae and Y. pestis) and Non-Enteroacteriaceae (except B.
pseudomallei) therapies based on CLSI M100-S22. B. pseudomallei, V. cholerae, and Y. pestis
2. Do not report therapy for P. aeruginosa.
MIC
ENTEROBACTERIACEAE
2/38
0.5/9.5
>
R
S
S
MIC
B. PSEUDOMALLEI
V. CHOLERAE
R
S
S
R
S
S
Y. PESTIS
>
R
R
2/38
S
S
0.5/9.5
S
S
pseudomallei) therapies based on CLSI M100-S22. B. pseudomallei, V. cholerae and Y. pestis
2. Use for RNBC3 and RNUC1 panels.
3. Do not report drug, therapy or MIC for P. aeruginosa.
9020-7493B
Page 63 of 158
DRIED OVERNIGHT GRAM-POSITIVE PANELS

Amikacin (Ak)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
32
R
16
I
8
S
Do not report drug, therapy or MIC for beta-hemolytic streptococci (S. agalactiae).
Do not report therapy for enterococci because dangerously misleading results can occur.
Amikacin (Ak)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
32
I
16
S
8
S
2. Do not report drug, therapy or MIC for beta-hemolytic streptococci (S. agalactiae).
3. Do not report therapy for enterococci because dangerously misleading results can occur.
AmoxicillinK Clavulanate (Aug)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8/4
R
4/2
S
2/1
S
1/0.5
S
0.5/0.25
S
Enterococci and streptococci therapy based on EUCAST V3.1, see notes 7 and 8.
Staphylococci therapy based on CLSI M100-S22.
For S. aureus and S. lugdunensis, if Oxacillin is >2 or Cefoxitin Screen (CfxS) is >4, report Amoxicillin-K
Clavulanate as resistant regardless of MIC.
For panels containing only Oxacillin with coagulase-negative staphylococci (CNS) other than S.
lugdunensis, if Oxacillin MIC is 0.5, report Amoxicillin-K Clavulanate as resistant regardless of MIC.
For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS)
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Amoxicillin-K Clavulanate as
resistant regardless of MIC. For additional information refer to Cefoxitin Screen section in the front of
the guide.
Do not report therapy for enterococci, refer to Ampicillin result.
For streptococci, refer to Penicillin result.
9020-7493B
Page 64 of 158

NOTE: 1.
2.
3.
4.
5.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
16/8
R
8/4
R
4/2
S
2/1
S
For S. aureus and S. lugdunensis, if Oxacillin is >2 or Cefoxitin Screen (CfxS) is >4, report Amoxicillin-K
Clavulanate as resistant regardless of MIC.
For panels containing only Oxacillin with coagulase-negative staphylococci (CNS) other than S.
lugdunensis, if Oxacillin MIC is 0.5, report Amoxicillin-K Clavulanate as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Amoxicillin-K Clavulanate as
the guide.
For streptococci and beta-lactamase negative enterococci, refer to Penicillin result.
Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
I
R
4
R
S
I
0.25
S
S
S
S
S
NOTE: 1. Enterococci therapy based on EUCAST V3.1.
2. Staphylococci, beta-hemolytic streptococci and viridans streptococci therapies based on CLSI M100S22. L. monocytogenes therapies based on CLSI M45-A2.
3. Use for PC42E and PM33E panels.
4. Do not report drug, therapy or MIC for all streptococci except for beta-hemolytic streptococci (S.
agalactiae) and viridans streptococci (S. bovis group).
5. For staphylococci, if Penicillin MIC is >0.12, report Ampicillin as resistant regardless of MIC.
6. For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Ampicillin as
resistant regardless of MIC.
7. For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ampicillin as resistant regardless of MIC.
8. For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS)
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ampicillin as resistant
regardless of MIC. For additional information refer to Cefoxitin Screen section in the front of the
therapy guide.
9. The CLSI interpretative guideline for Ampicillin with beta-hemolytic streptococci is 0.25 for susceptible.
Because intermediate and resistant interpretations have not been defined for beta-hemolytic
streptococci, no interpretations will be provided if the result is >0.25.
10. The CLSI interpretative guideline for Ampicillin with L. monocytogenes is 2 for susceptible. Because
intermediate and resistant interpretations have not been defined for L. monocytogenes, no interpretations
will be provided if the result is >0.25.
9020-7493B
Page 65 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
8
R
I
N/R
R
4
R
S
N/R
I
2
R
S
N/R
I
S
1
R
S
N/R
I
S
0.5
N/R
S
N/R
N/R
S
3. Use for PM32 panel.
therapy guide.
streptococci, all MICs of 0.5 will report as N/R, since these dilutions do not differentiate between S and
NS.
will be provided if the result is >2.
11. Based on CLSI interpretive guidelines for staphylococci, all MICs of 0.5 will report as N/R, since
these dilutions do not differentiate between S and R (S0.25, R0.5).
12. Based on CLSI interpretive guidelines for viridans streptococci, all MICs of 0.5 will report as N/R, since
these dilutions do not differentiate between S and I (S0.25, I=0.5-4, R8).
9020-7493B
Page 66 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
8
R
I
N/R
R
4
R
S
N/R
I
2
R
S
N/R
I
S
1
N/R
S
N/R
N/R
S
3. Use for PC35 and PC38 panels.
therapy guide.
streptococci, all MICs of 1 will report as N/R, since these dilutions do not differentiate between S and
NS.
intermediate and resistant interpretations have not been defined for L. monocytogenes, no
interpretations will be provided if the result is >2.
11. Based on CLSI interpretive guidelines for staphylococci, all MICs of 1 will report as N/R, since these
dilutions do not differentiate between S and R (S0.25, R0.5).
12. Based on CLSI interpretive guidelines for viridans streptococci, all MICs of 1 will report as N/R, since
9020-7493B
Page 67 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
8
R
I
N/R
R
4
R
S
N/R
I
2
N/R
S
N/R
N/R
S
3. Use for PBC33 panel.
therapy guide.
NS.
9020-7493B
Page 68 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
N/R
8
R
I
N/R
R
N/R
4
N/R
S
N/R
N/R
N/R
3. Use for PBC32 panel.
8. For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS) other
than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ampicillin as resistant regardless of
MIC. For additional information refer to Cefoxitin Screen section in the front of the guide.
NS.
intermediate and resistant interpretations have not been defined for L. monocytogenes, all MICs of 4
will report as N/R, since these dilutions do not differentiate between S and NS.
Ampicillin
(Am)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
8
I
4
S
2
S
1
S
0.5
S
0.25
S
0.12
S
Do not report therapy for L. monocytogenes.
Do not report drug, therapy or MIC for all streptococci (including viridans streptococci (S. bovis group))
except for beta-hemolytic streptococci (S. agalactiae).
For staphylococci, if Penicillin MIC is >0.12, report Ampicillin as resistant regardless of MIC.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Ampicillin as
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ampicillin as resistant regardless of MIC.
guide.
For staphylococci, refer to the Cefoxitin Screen and/or Oxacillin result.
9020-7493B
Page 69 of 158

Ampicillin
(Am)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
MIC
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
S
R
4
R
S
I
2
R
S
I
S
1
R
S
I
S
0.5
R
S
I
S
0.25
S
S
S
S
S
Staphylococci, Enterococci beta-hemolytic streptococci and viridans streptococci therapies based on
CLSI M100-S22. L. monocytogenes therapies based on CLSI M45-A2.
Do not report drug, therapy or MIC for all streptococci, except for beta-hemolytic streptococci (S.
For streptococci refer to Penicillin result.
For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS) other
If beta-lactamase positive for staphylococci or enterococci, report Ampicillin as Blac regardless of MIC.
The CLSI interpretative guideline for Ampicillin with beta-hemolytic streptococci is 0.25 for susceptible.
Because intermediate and resistant interpretations have not been defined for beta-hemolytic streptococci, no
interpretations will be provided if the result is >0.25.
The CLSI interpretative guideline for Ampicillin with L. monocytogenes is 2 for susceptible. Because
Ampicillin
(Am)
NOTE: 1.
STAPHYLOCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
N/R
8
R
S
N/R
0.25
S
S
S
S
S
Staphylococci, Enterococci beta-hemolytic streptococci and viridans streptococci therapies based on
For streptococci refer to Penicillin result.
If beta-lactamase positive for staphylococci or enterococci, report Ampicillin as Blac regardless of MIC.
interpretations will be provided if the result is >0.25
The CLSI interpretative guideline for Ampicillin with L. monocytogenes is 2 for susceptible. Because
will be provided if the result is >0.25.
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of >0.25 will report as N/R,
since these dilutions do not differentiate between I and R (S0.25, I=0.5-4, R8).
9020-7493B
Page 70 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
8
R
S
N/R
R
4
R
S
N/R
I
2
N/R
S
N/R
N/R
S
NOTE: 1. Staphylococci, Enterococci beta-hemolytic streptococci and viridans streptococci therapies based on
2. Use for PC29, PC33, PC34, PC40, PC41, PM26 and PM29 panels.
5. Do not report drug, therapy or MIC for all streptococci, except for beta-hemolytic streptococci (S.
6. For streptococci refer to Penicillin result.
guide.
8. If beta-lactamase positive for staphylococci or enterococci, report Ampicillin as Blac regardless of MIC.
NS.
dilutions do not differentiate between S and R (S 0.25, R0.5).
13. Based on CLSI interpretive guidelines for viridans streptococci, all MICs of 2, will report as N/R, since
9020-7493B
Page 71 of 158

Ampicillin
(Am)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
R
8
R
S
N/R
R
4
R
S
N/R
I
2
R
S
N/R
I
S
1
N/R
S
N/R
N/R
S
NOTE: 1. Staphylococci, Enterococci beta-hemolytic streptococci and viridans streptococci therapies based on
CLSI M100-S22. L. monocytogenes therapy based on CLSI M45-A2.
2. Use for PC32 panel.
5. Do not report drug, therapy or MIC for all streptococci, except for beta-hemolytic streptococci (S.
6. For streptococci refer to Penicillin result.
guide.
8. If beta-lactamase positive for staphylococci or enterococci, report Ampicillin as Blac regardless of MIC.
NS.
12. Based on CLSI interpretive guidelines for staphylococci, all MICs of 1, will report as N/R, since these
dilutions do not differentiate between S and R (S 0.25, R0.5).
13. Based on CLSI interpretive guidelines for viridans streptococci, all MICs of 1, will report as N/R, since
Amp-Sulbactam (A/S)
NOTE: 1.
2.
3.
4.
5.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
16/8
I
8/4
S
For S. aureus and S. lugdunensis, if oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report
Ampicillin-Sulbactam as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ampicillin-Sulbactam as resistant
regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ampicillin-Sulbactam as
the guide.
For streptococci and beta-lactamase negative enterococci, refer to Penicillin result.
9020-7493B
Page 72 of 158

Arbekacin (Abk)
MIC
STAPHYLOCOCCI
(S. aureus)
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
>
R
8
I
4
S
NOTE: 1. Therapy based on guidelines other than CLSI and EUCAST.
2. Do not report drug, therapy or MIC for enterococci, streptococci and L. monocytogenes.
Azithromycin (Azi)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
>
R
2
I
1
S
Do not report drug, therapy or MIC for enterococci, streptococci or L. monocytogenes.
Azithromycin (Azi)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
>
R
4
I
2
S
1
S
0.5
S
3. Do not report drug, therapy or MIC for enterococci, streptococci or L. monocytogenes.
Cefazolin (Cfz)
NOTE: 1.
2.
3.
4.
5.
6.
9020-7493B
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
>
R
16
I
8
S
4
S
2
S
Do not report therapy for enterococci and L. monocytogenes because dangerously misleading results
can occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report
Cefazolin as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin is 0.5, report Cefazolin as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefazolin as resistant
guide.
Page 73 of 158

Cefdinir (Cdn)
3.
4.
5.
Cefepime (Cpe)
3.
4.
5.
6.
7.
8.
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
>
R
2
I
1
S
can occur.
Cefdinir as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefdinir as resistant regardless of
MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefdinir as resistant
therapy guide.
NOTE: 1.
2.
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
R
16
I
N/R
R
8
S
N/R
R
4
S
N/R
N/R
can occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Cefepime
as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefepime as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefepime as resistant
guide.
The CLSI interpretative guideline for Cefepime with beta-hemolytic streptococci is 0.5 for susceptible.
NS.
Based on CLSI interpretive guidelines for viridans streptococci, all MICs 4 will report as N/R, since these
dilutions do not differentiate between S, I and R (S 1, I=2, R4).
9020-7493B
Page 74 of 158

Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
5.
6.
7.
8.
9.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
N/R
N/R
R
8
S
N/R
R
4
S
N/R
N/R
can occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Cefepime
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefepime as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefepime as resistant
guide.
Based on CLSI interpretive guidelines for staphylococci, all MICs >8 will report as N/R, since these dilutions
do not differentiate between I and R (S 8, I=16, R32).
NS.
Based on CLSI interpretive guidelines for viridans streptococci, all MICs 4 will report as N/R, since these
dilutions do not differentiate between S, I and R (S 1, I=2, R4).
Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
N/R
N/R
R
2
S
N/R
I
1
S
N/R
S
Enterococci therapy based on EUCAST V3.1.
Staphylococci and beta-hemolytic and viridans streptococci therapies based on CLSI M100-S22.
Use for PM32 panel.
can occur.
Cefotaxime as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefotaxime as resistant
regardless of MIC.
than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefotaxime as resistant regardless of
Based on CLSI interpretive guidelines for staphylococci, all MICs of >2 will report as N/R, since these
dilutions do not differentiate between S, I and R (S 8, I=16-32, R 64).
The CLSI interpretative guideline for Cefotaxime with beta-hemolytic streptococci is 0.5 for susceptible.
NS.
9020-7493B
Page 75 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
3.
4.
5.
6.
7.
8.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
16
0.5
can occur.
For staphylococci, refer to Cefoxitin Screen and/or Oxacillin result.
Cefotaxime as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefotaxime as resistant
regardless of MIC.
Do not report drug, therapy or MIC for all streptococci (including viridans streptococci (S. bovis group))
except for beta-hemolytic streptococci (S. agalactiae).
For beta-hemolytic streptococci (S. agalactiae), refer to Penicillin result.
Cefotaxime (Cft)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
32
I
N/R
16
I
N/R
8
S
N/R
1
S
S
0.5
S
S
S
Do not report therapy for enterococci and L. monocytogenes because dangerously misleading results can
occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Cefotaxime as
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefotaxime as resistant regardless of MIC.
For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS) other than
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefotaxime as resistant regardless of MIC. For
additional information refer to Cefoxitin Screen section in the front of therapy guide.
Do not report drug, therapy or MIC for all streptococci except for beta-hemolytic streptococci (S. agalactiae)
and viridans streptococci (S. bovis group).
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of >1 will report as N/R, since these
dilutions do not differentiate between S, I and R (S 1, I=2, R 4).
9020-7493B
Page 76 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
R
32
I
N/R
R
8
S
N/R
N/R
Use for panels with breakpoint format.
occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Cefotaxime
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefotaxime as resistant regardless of
MIC.
NS.
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of 8 will report as N/R, since
these dilutions do not differentiate between S, I and R (S 1, I=2, R 4).
Ceftaroline (Cpt)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
(S. aureus)
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
1
S
0.5
S
Do not report drug, MIC or therapy for enterococci, L. monocytogenes and streptococci.
Do not report therapy for coagulase negative staphylococci.
9020-7493B
Page 77 of 158

Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
3.
4.
5.
6.
7.
8.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
R
32
I
N/R
R
16
I
N/R
R
8
S
N/R
R
4
S
N/R
N/R
can occur.
Ceftriaxone as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ceftriaxone as resistant regardless of
MIC.
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ceftriaxone as resistant regardless of MIC.
For additional information refer to Cefoxitin Screen section in the front of the guide.
The CLSI interpretative guideline for Ceftriaxone with beta-hemolytic streptococci is 0.5 for
susceptible. Because intermediate and resistant interpretations have not been defined for betahemolytic streptococci, all MICs of 4 will report as N/R, since these dilutions do not differentiate
between S and NS.
Based on CLSI interpretive guidelines for viridans streptococci, MICs of 4 will report as N/R, since these
dilutions do not differentiate between I and R (S 1, I =2, R4).
Ceftriaxone (Cax)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
R
32
I
N/R
R
16
I
N/R
R
8
S
N/R
N/R
can occur.
Ceftriaxone as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ceftriaxone as resistant regardless of
MIC.
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ceftriaxone as resistant regardless of MIC. For
additional information refer to Cefoxitin Screen section in the front of the guide.
The CLSI interpretative guideline for Ceftriaxone with beta-hemolytic streptococci is 0.5 for
susceptible. Because intermediate and resistant interpretations have not been defined for betahemolytic streptococci, all MICs of 8 will report as N/R, since these dilutions do not differentiate
between S and NS.
Based on CLSI interpretive guidelines for viridans streptococci, MICs of 8 will report as N/R, since these
9020-7493B
Page 78 of 158

(parenteral)
NOTE: 1.
2.
3.
4.
5.
6.
7.
4.
5.
6.
7.
8.
9.
3.
4.
5.
6.
ENTEROCOCCI
STREPTOCOCCI
L. monocytogenes
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
N/R
8
S
4
S
Use for PM32 panel.
can occur.
Cefuroxime sodium as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefuroxime sodium as resistant
regardless of MIC.
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefuroxime sodium as resistant regardless of MIC.
Based on CLSI interpretive guidelines for staphylococci, all MICs of >8 will report as N/R, since these
Cephalothin (Cf)
NOTE: 1.
2.
STAPHYLOCOCCI
>
R
16
I
8
S
4
S
can occur.
Cefuroxime sodium as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cefuroxime sodium as resistant
regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cefuroxime sodium as
the guide.

(parenteral)
NOTE: 1.
2.
3.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
16
I
8
S
occur.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Cephalothin as
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Cephalothin as resistant regardless of MIC.
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Cephalothin as resistant regardless of MIC. For
additional information refer to Cefoxitin Screen section in the front of the therapy guide.
9020-7493B
Page 79 of 158

Chloramphenicol (C)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
16
I
I
R
8
S
S
I
4
S
S
S
3. Do not report drug, therapy or MIC for all streptococci except for beta-hemolytic streptococci (S. agalactiae)
ChIoramphenicol (C)
NOTE: 1.
2.
3.
4.
5.
6.
7.
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
16
I
I
R
8
S
S
N/R
Based on CLSI interpretive guidelines for streptococci, all MICs of 8 will report as N/R, since these
Chloramphenicol (C)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
N/R
R
8
S
N/R
Use for PBC33 and PM32 panels.
Do not report drug, therapy or MIC for staphylococci.
Based on CLSI interpretive guidelines for enterococci, all MICs of >8 will report as N/R, since these
Based on CLSI interpretive guidelines for streptococci, all MICs of 8 will report as N/R, since these
Ciprofloxacin (Cp)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
2
R
I
1
S
S
0.5
S
S
NOTE: 1. Staphylococci therapy based on EUCAST V3.1.
2. Enterococci therapy based on CLSI M100-S22.
3. Use for EUCAST Blended panel class, except for PBC33 and PM32 panels.
9020-7493B
Page 80 of 158

Ciprofloxacin (Cp)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
STREPTOCOCCI
>
R
R
1
S
S
0.5
S
S
Staphylococci therapy based on EUCAST V3.1.
Enterococci therapy based on CLSI M100-S22.
Based on CLSI interpretive guidelines for enterococci, all MICs of >1 will report as R, since these
Ciprofloxacin (Cp)
MIC
STAPHYLOCOCCI
>
R
2
I
1
S
0.5
S
Clarithromycin (Cla)
NOTE: 1.
2.
3.
4.
ENTEROCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
I
S
S
ENTEROCOCCI
STREPTOCOCCI
>
R
2
I
1
S
Do not report drug, therapy or MIC for enterococci, L. monocytogenes or streptococci.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
4
I
2
S
3. Do not report drug, therapy or MIC for enterococci, streptococci or L. monocytogenes.
Clindamycin (Cd)
NOTE: 1.
2.
3.
4.
5.
6.
7.
9020-7493B
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
2
R
R
1
R
R
0.5
I
I
0.25
S
S
Streptococci therapy based on CLSI M100-S22.
For staphylococci, if Inducible Clindamycin (ICd) test is positive (>4/0.5) report Clindamycin as
Page 81 of 158

Clindamycin (Cd)
NOTE: 1.
2.
3.
4.
5.
6.
5.
5.
ENTEROCOCCI
STREPTOCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
4
R
R
2
I
R
1
I
R
0.5
S
I
0.25
S
S
Do not report drug, therapy or MIC for all streptococci except for beta-hemolytic streptococci (S.
Clindamycin (Cd)
NOTE: 1.
2.
3.
4.
STAPHYLOCOCCI
>
R
2
R
1
R
0.5
I
0.25
S
Do not report drug, therapy or MIC for all streptococci, including beta-hemolytic streptococci (S.
Clindamycin (Cd)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
4
R
R
2
I
R
1
I
R
0.5
S
N/R
Based on CLSI interpretive guidelines for streptococci, all MICs of 0.5 will report as N/R, since these
dilutions do not differentiate between S and I (S0.25, I=0.5, R1).
9020-7493B
Page 82 of 158

Daptomycin (Dap)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
4
R
S
R
2
R
S
R
1
S
S
S
S
0.5
S
S
S
S
0.25
S
S
S
S
Staphylococci and beta-hemolytic streptococci therapies based on EUCAST V3.1.
Enterococci and viridans streptococci therapies based on CLSI M100-S22.
agalactiae) and S. bovis group (Group D).
The CLSI interpretative guideline for Daptomycin with enterococci is 4 for susceptible. Because intermediate
and resistant interpretations have not been defined for enterococci, no interpretations will be provided if the
result is >4.
The CLSI interpretative guideline for Daptomycin with viridans streptococci is 1 for susceptible. Because
intermediate and resistant interpretations have not been defined for viridans streptococci, no interpretations will
be provided if the result is >1.
Daptomycin (Dap)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
4
R
R
2
R
R
1
S
S
Daptomycin (Dap)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
4
S
2
S
1
S
S
S
0.5
S
S
S
0.25
S
S
S
The CLSI interpretative guideline for Daptomycin with staphylococci and streptococci is 1 for
susceptible. Because intermediate and resistant interpretations have not been defined for
staphylococci and streptococci, no interpretations will be provided if the result is >1.
The CLSI interpretative guideline for Daptomycin with enterococci is 4 for susceptible. Because
intermediate and resistant interpretations have not been defined for enterococci, no interpretations will
9020-7493B
Page 83 of 158

Ertapenem (Etp)
5.
6.
7.
8.
9.
Ertapenem (Etp)
3.
4.
5.
6.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
1
S
S
0.5
S
S
Enterococci therapy based on EUCAST V3.1.
Staphylococci and beta-hemolytic streptococci therapies based on CLSI M100-S22.
Do not report drug, therapy or MIC for Listeria monocytogenes and all Coagulase-Negative
Staphylococci (CNS) with MIC >0.5 for Ox or CfxS >4, including S. lugdunensis with an MIC >2 for
Oxacillin.
For S. aureus, if Oxacillin MIC is >2 and\or CfxS is >4, report Ertapenem as resistant regardless of
MIC.
Do not report therapy for viridans streptococci (S. bovis group).
The CLSI interpretative guideline for Ertapenem with beta-hemolytic streptococci is 1 for susceptible.
streptococci, no interpretations will be provided if the result is >1.
Based on CLSI interpretive guidelines for staphylococci, all MICs of >1 will report as R, since these
NOTE: 1.
2.
3.
4.
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
4
I
2
S
1
S
S
0.5
S
S
Oxacillin.
For S. aureus, if Oxacillin MIC is >2 and\or CfxS is >4, report Ertapenem as resistant regardless of MIC.
streptococci, no interpretations will be provided if the result is >1.
9020-7493B
Page 84 of 158

Ertapenem (Etp)
NOTE: 1.
2.
3.
4.
5.
6.
7.
4.
5.
6.
7.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
N/R
4
I
N/R
2
S
N/R
Oxacillin.
For S. aureus, if Oxacillin MIC is >2 and\or CfxS is >4, report Ertapenem as resistant regardless of MIC.
streptococci, all MICs of 2will report as N/R, since these dilutions do not differentiate between S and
NS.
Erythromycin (E)
NOTE: 1.
2.
3.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
4
R
I
R
2
I
I
R
1
S
I
R
0.5
S
S
I
0.25
S
S
S
Use for EUCAST Blended panel class, except for PBC32, PBC33, PC35, PC37, PC42E, PM32 and
PM33E panels.
Do not report drug, therapy or MIC for L. monocytogenes.
Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9020-7493B
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
4
R
I
R
2
I
I
R
1
S
I
R
0.5
S
S
N/R
Use for PC37, PC42E and PM33E panels.
Based on EUCAST interpretive guidelines for beta-hemolytic streptococci, all MICs of 0.5 will report
as N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5, R>0.5).
Page 85 of 158

Erythromycin (E)
7.
8.
9.
Erythromycin (E)
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
2
I
I
R
1
S
N/R
N/R
Enterococci therapy based on CLSI M100-S22
Use for PBC32, PBC33 and PM32 panels.
Based on CLSI interpretive guidelines for enterococci, all MICs of 1 will report as N/R, since these
dilutions do not differentiate between S, I and R (S0.5, I=1-4, R8).
Based on EUCAST interpretive guidelines for beta-hemolytic streptococci, all MICs of 1 will report as
N/R, since these dilutions do not differentiate between S, I and R (S0.25, I=0.5, R>0.5).
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
Erythromycin (E)
6.
STAPHYLOCOCCI
>
R
R
R
2
I
I
R
1
S
I
R
0.5
S
S
N/R
Use for PC35 panel.
dilutions do not differentiate between I and R (S0.5, I=1-4, R8).
Based on EUCAST interpretive guidelines for beta-hemolytic streptococci, all MICs of 0.5 will report
as N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5, R>0.5).
NOTE: 1.
2.
3.
4.
5.
6.
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
4
R
R
2
I
R
1
S
R
0.5
S
I
0.25
S
S
Use for PC36 and PM31 panels.
Only systemic therapy will be reported
9020-7493B
Page 86 of 158

Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
6.
7.
6.
4.
5.
6.
7.
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
4
I
I
R
2
I
I
R
1
I
I
R
0.5
S
S
I
0.25
S
S
S
Use for PBC27, PC32, PM21, PM26 and PM29 panels.
Erythromycin (E)
NOTE: 1.
2.
3.
STAPHYLOCOCCI
>
R
R
8
R
R
4
R
R
2
I
R
1
S
N/R
Use for PC30 panel.
Based on EUCAST interpretive guidelines for beta-hemolytic streptococci, all MICs of 1 will report as
N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5, R>0.5).
Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
R
4
I
I
R
2
I
I
R
1
I
I
R
0.5
S
S
N/R
Use for PBC28, PC20, PC21, PC29, PC31, PC33, PC34, PC39, PC40, PC41, PC42C, PM28 and
PM33C panels.
Based on CLSI interpretive guidelines for beta-hemolytic streptococci, all MICs of 0.5 will report as
N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5, R1).
9020-7493B
Page 87 of 158

Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
6.
6.
7.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
4
I
I
R
0.5
S
S
I
0.25
S
S
S
Therapy based on CLSI M100-S22
Use for PC1A panel.
Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
R
4
I
I
R
0.5
S
S
N/R
Use for PBC20, PBC23 and PBC29 panels.
Based on CLSI interpretive guidelines for beta-hemolytic streptococci, all MICs of 0.5 will report as
N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5, R1).
Fosfomycin (Fos)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
64
R
32
S
Fusidic Acid (FA)
MIC
STAPHYLOCOCCI
>
16
2
Fusidic Acid (FA)
MIC
ENTEROCOCCI
STREPTOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
I
S
STAPHYLOCOCCI
N/R
>
2
S
2. Use for PBC33, PM31, PM32, PM33C and PM33E panel.
3. Based on SFM 2008 interpretive guidelines for staphylococci, all MICs of >2 will report as N/R, since
these dilutions do not differentiate between S, I and R (S2, I=4-16, R>16).
9020-7493B
Page 88 of 158

Gatifloxacin (Gat)
MIC
Gentamicin (Gm)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
>
4
I
2
S
1
S
0.5
S
NOTE: 1.
2.
3.
4.
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
R
4
R
2
R
1
S
Do not report drug, therapy or MIC for all streptococci
Gentamicin (Gm)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
I
4
S
2
S
1
S
3. Do not report drug, therapy or MIC for for all streptococci.
Imipenem (Imp)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
8
I
I
4
S
S
2
S
S
NOTE: 1. Enterococci and beta-hemolytic streptococci therapies based on EUCAST V3.1.
2. Staphylococci therapy based on CLSI M100-S22.
3. Use for EUCAST Blended panel class.
4. For S. aureus and S. lugdunensis if Oxacillin MIC is >2 and/or Cefoxitin Screen >4, report Imipenem as
5. For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Imipenem as resistant regardless of MIC.
6. For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS) other than
S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Imipenem as resistant regardless of MIC. For
7. Do not report drug, therapy or MIC for E. faecium and E. faecium group.
9. Do not report therapy for viridans streptococci (S. bovis group).
10. For beta-hemolytic streptococci, refer to Penicillin result.
9020-7493B
Page 89 of 158

Imipenem (Imp)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
3.
4.
5.
6.
7.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
N/R
2
S
1
S
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Imipenem
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Imipenem as resistant regardless of MIC.
For panels containing Cefoxitin Screen and Oxacillin with coagulase-negative staphylococci (CNS) other than S.
lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Imipenem as resistant regardless of MIC. For
Do not report drug, therapy or MIC for E. faecium and E. faecium group.
For staphylococci, refer to Cefoxitin Screen and/or the Oxacillin result.
For beta-hemolytic streptococci, refer to Penicillin result.
Based on EUCAST interpretive guidelines for enterococci, all MICs of >2 will report as N/R, since
these dilutions do not differentiate between S, I and R (S4, I=8, R>8).
Imipenem (Imp)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
I
4
S
2
S
1
S
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report Imipenem
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Imipenem as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Imipenem as resistant
guide.
Do not report drug, therapy or MIC for E. faecium and E. faecium group.
Kanamycin (K)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
16
I
8
S
4
S
2
S
2. Do not report drug, therapy or MIC for all streptococci (including beta-hemolytic streptococci (S.
agalactiae)), except viridans streptococci (S. bovis group).
9020-7493B
Page 90 of 158

Levofloxacin (Lvx)
NOTE: 1.
2.
3.
4.
5.
6.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
R
4
R
I
R
I
2
I
S
I
S
1
S
S
S
S
Use for EUCAST Blended panel class, except for PBC33 and PM32 panels.
Levofloxacin (Lvx)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
N/R
2
I
S
I
S
1
S
S
S
S
Based on CLSI interpretive guidelines for enterococci all MICs of >2 will report as R, since these
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of >2 will report as N/R, since
Levofloxacin (Lvx)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
4
R
R
2
I
I
1
S
S
0.5
S
S
2. Use for the EUCAST panel class.
Levofloxacin (Lvx)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
4
R
I
I
2
I
S
S
1
S
S
S
0.5
S
S
S
NOTE: 1. Therapy based CLSI M100-S22.
9020-7493B
Page 91 of 158

Levofloxacin (Lvx)
MIC
Lincomycin (Lin)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
4
R
I
I
2
N/R
S
S
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
8
I
I
I
4
I
I
I
2
S
S
S
1
S
S
S
Linezolid (Lzd)
NOTE: 1.
2.
3.
4.
5.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
R
R
R
>
4
S
S
I
2
S
S
S
S
1
S
S
S
S
0.5
S
S
S
S
Staphylococci, enterococci and beta-hemolytic streptococci therapies based on EUCAST V3.1.
Viridans streptococci therapy based on CLSI M100-S22.
The CLSI interpretative guideline for Linezolid with viridans streptococci is 2 for susceptible. Because
intermediate and resistant interpretations have not been defined for viridans streptococci, no
Linezolid (Lzd)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
R
R
R
>
4
S
S
I
2
S
S
S
1
S
S
S
0.5
S
S
S
9020-7493B
Page 92 of 158

Linezolid (Lzd)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
R
>
4
S
I
2
S
S
S
1
S
S
S
0.5
S
S
S
3. The CLSI interpretative guidelines for Linezolid with streptococci is 2 for susceptible. Because
intermediate and resistant interpretations have not been defined for streptococci, no interpretations will
Meropenem (Mer)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
N/R
8
I
N/R
4
S
N/R
2
S
N/R
2. Staphylococci and streptococci therapies based on CLSI M100-S22.
3. Use for EUCAST Blended panel class
5. For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 or Cefoxitin Screen (CfxS) is >4, report
Meropenem as resistant regardless of MIC.
6. For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Meropenem as resistant regardless of
MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Meropenem as resistant
guide.
8. Do not report drug, therapy or MIC for L. monocytogenes, all streptococci, except beta-hemolytic
streptococci (S. agalactiae) and viridans streptococci (S. bovis group).
9. For streptococci, refer to Penicillin result.
10. The CLSI interpretative guideline for Meropenem with beta-hemolytic and viridans streptococci is 0.5
for susceptible. Because intermediate and resistant interpretations have not been defined for
NS.
9020-7493B
Page 93 of 158

Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
4.
5.
4.
ENTEROCOCCI
STREPTOCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
R
>
1
N/R
Use for PM31 panel.
Do not report therapy for beta-hemolytic streptococci (S. agalactiae)
Based on EUCAST interpretive guidelines for staphylococci, all MICs of 1 will report as N/R since
these dilutions do not differentiate between S and I (S0.5, I=1, R>1).
Minocycline (Min)
NOTE: 1.
2.
3.
STAPHYLOCOCCI
>
R
N/R
8
I
N/R
4
S
N/R
2
S
N/R
1
S
N/R
Meropenem as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Meropenem as resistant regardless of MIC.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Meropenem as resistant
guide.
Do not report drug, therapy or MIC for L. monocytogenes
The CLSI interpretative guideline for Meropenem with beta-hemolytic and viridans streptococci is 0.5
for susceptible. Because intermediate and resistant interpretations have not been defined for
NS.
Minocycline (Min)
NOTE: 1.
2.
3.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
R
R
>
8
I
I
4
S
S
2
S
S
1
S
S
Use for PM33C and PM33E.
Do not report therapy for beta-hemolytic streptococci (S. agalactiae).
9020-7493B
Page 94 of 158

Moxifloxacin (Mxf)
NOTE: 1.
2.
3.
4.
5.
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
>
4
I
2
S
1
S
0.5
S
Use for PBC20, PBC23, PC29, PC33, PC34, PM26 and PM29 panels.
Moxifloxacin (Mxf)
NOTE:
STAPHYLOCOCCI
R
>
2
R
1
I
0.5
S
Use for EUCAST Blended and EUCAST panel classes and PBC27, PBC28, PBC29, PM28, and PM33C
panels.
Do not report therapy for beta-hemolytic streptococci (S. agalactiae).
Moxifloxacin (Mxf)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
R
>
2
I
1
I
0.5
I
0.12
S
1. Therapy based on MENSURA.
3. Use for PM21 panel.
Mupirocin (Mup)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
I
I
S
S
ENTEROCOCCI
STREPTOCOCCI
R
>
256
8
4
S
NOTE: 1. Therapy based on manufacturers guidelines.
2. Breakpoints for skin infection isolates are 4, susceptible; 8, resistant. Breakpoints for nasal colonizing
isolates are 256 susceptible, 512 resistant. The Mupirocin category interpretations differ if the MIC is 8 or
256 and an alert will trigger.
3. Do not report drug, therapy or MIC for S. saprophyticus.
9020-7493B
Page 95 of 158

Mupirocin (Mup)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
>
256
S
Therapy based on manufacturers guidelines for nasal colonization isolates.
Use for PC42C, PC42E, PM33C and PM33E panels.
Based on manufacturers guidelines with susceptible 4 and resistant 8, panel dilutions do not allow
reporting for skin infection isolates.
Do not report drug, therapy or MIC for S. saprophyticus.
Netilmicin (Nt)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
N/R
4
S
2
S
NOTE: 1. Enterococci and streptococci therapies based on EUCAST V3.1.
2. Staphylococci therapy based on CLSI M100-S22.
3. Use for EUCAST Blended panel class.
4. Do not report therapy for enterococci and L. monocytogenes because dangerously misleading results can
occur.
5. Based on CLSI interpretive guidelines for staphylococci, all MICs of >4 will report as N/R, since these
Netilmicin (Nt)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
16
I
8
S
4
S
2. Do not report therapy for enterococci and L. monocytogenes because dangerously misleading results can
occur.
Nitrofurantoin (Fd)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
64
S
S
32
S
S
Do not report drug, therapy or MIC for all streptococci, including beta-hemolytic streptococci (S.
Nitrofurantoin (Fd)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
64
I
I
32
S
S
3. Do not report drug, therapy or MIC for all streptococci, including beta-hemolytic streptococci (S.
9020-7493B
Page 96 of 158

Norfloxacin (Nxn)
MIC
STAPHYLOCOCCI
>
R
8
I
4
S
Ofloxacin (Ofl)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
I
S
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
4
R
2
R
1
S
0.5
S
Ofloxacin (Ofl)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
4
I
I
2
S
S
NOTE: 1. Therapy based on CLSI (NCCLS) M100-S14.
Oxacillin (Ox)
NOTE: 1.
2.
3.
4.
5.
MIC
S. AUREUS &
S. LUGDUNENSIS
OTHER
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
2
S
R
1
S
R
0.5
S
R/S*
0.25
S
S
For panels containing the Cefoxitin Screen, all staphylococci report Oxacillin as resistant if the
Cefoxitin Screen is >4. See Cefoxitin Screen information in the front of the therapy guide.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Oxacillin as resistant
therapy guide.
other than S. lugdunensis, if CfxS is <4 and Oxacillin MIC is 0.5, report Oxacillin as susceptible (S*).
For additional information refer to Cefoxitin Screen section in the front of the therapy guide.
9020-7493B
Page 97 of 158

Oxacillin (Ox)
NOTE: 1.
2.
3.
4.
3.
4.
5.
6.
7.
8.
S. AUREUS &
S. LUGDUNENSIS
OTHER
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
4
R
R
2
S
R
1
S
R
0.5
S
R/ S*
0.25
S
S
For panels containing the Cefoxitin Screen, all staphylococci report Oxacillin as resistant if the
Cefoxitin Screen is >4. See Cefoxitin Screen information in the front of the guide.
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Oxacillin as resistant
therapy guide.
other than S. lugdunensis, if CfxS is <4 and Oxacillin MIC is 0.5, report Oxacillin as susceptible (S*).
Penicillin (P)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
S
R
2
R
S
I
S
0.25
R
S
I
S
0.12
S
S
S
S
S
0.03
S
S
S
S
S
Enterococci, beta-hemolytic streptococci and viridans streptococci therapies based on CLSI M100-S22.
L. monocytogenes therapies based on CLSI M45-A2
Use for PC38 panel.
Penicillin as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is >0.25 and/or Cefoxitin Screen >4, report
The CLSI interpretative guideline for Penicillin with beta-hemolytic streptococci is 0.12 for susceptible.
The CLSI interpretative guideline for Penicillin with L. monocytogenes is 2 for susceptible. Because
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of >2 will report as R, since
these dilutions do not differentiate between I and R (S0.12, I=0.25-2, R4).
9020-7493B
Page 98 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
3.
4.
5.
6.
7.
8.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
2
R
S
I
S
0.25
R
S
I
S
0.12
S
S
S
S
S
0.06
S
S
S
S
S
0.03
S
S
S
S
S
Enterococci, bta-hemolytic streptococci and viridans streptococci therapies based on CLSI M100-S22.
L. monocytogenes therapies based on CLSI M45-A2
Use for PBC33, PC35 and PM32 panels.
dilutions do not differentiate between S and R (S8, R16).
Penicillin (P)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
N/R
8
R
S
N/R
0.12
S
S
S
S
S
0.06
S
S
S
S
S
0.03
S
S
S
S
S
L. monocytogenes therapies based on CLSI M45-A2.
Use for PBC32 panel.
9020-7493B
Page 99 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
3.
4.
5.
6.
7.
8.
9.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
S
R
0.25
R
S
I
S
0.12
S
S
S
S
S
Use for PM33E panel.
Based on CLSI interpretive guidelines for viridans streptococci, all MICs of >0.25 will report as R, since
Penicillin (P)
NOTE: 1.
2.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
N/R
0.25
R
S
I
S
0.12
S
S
S
S
S
0.03
S
S
S
S
S
Use for PC37 and PC42E panels.
Based on CLSI interpretive guidelines for enterococci, all MICs of >0.25 will report as R, since these
9020-7493B
Page 100 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
5.
6.
7.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
16
R
1
R
0.5
R
0.25
N/R
Use for PC30 panel.
Do not report drug, therapy or MIC for all streptococci.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 and/or Cefoxitin Screen >4, report Penicillin as
other than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Penicillin as resistant
guide.
Based on EUCAST interpretive guidelines for staphylococci, all MICs of 0.25 will report as N/R, since
these dilutions do not differentiate between S and R (S0.12, R>0.25).
Penicillin (P)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
2
R
0.25
R
0.12
S
0.06
S
0.03
S
Do not report drug, therapy or MIC for all streptococci.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2 and/or Cefoxitin Screen >4, report Penicillin as
guide.
9020-7493B
Page 101 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
S
R
4
R
S
R
2
R
S
I
S
1
R
S
I
S
0.5
R
S
I
S
0.25
R
S
I
S
0.12
S
S
S
S
S
0.06
S
S
S
S
S
0.03
S
S
S
S
S
Staphylococci, Enterococci, beta-hemolytic streptococci, and viridans streptococci therapy based on
CLSI M100-S22. L. monocytogenes therapies based on CLSI M45-A2
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Penicillin as resistant regardless of MIC.
therapy guide.
If beta-lactamase positive, report Penicillin as Blac regardless of MIC.
For enterococci, if beta-lactamase positive, report Penicillin as Blac regardless of MIC.
Because intermediate and resistant interpretations have not been defined for beta-hemolytic streptococci,
no interpretations will be provided if the result is >0.12.
intermediate and resistant interpretations have not been defined for L. monocytogenes, no interpretations will
9020-7493B
Page 102 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
2.
3.
4.
5.
6.
7.
8.
9.
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
8
R
S
N/R
0.12
S
S
S
S
S
0.06
S
S
S
S
S
0.03
S
S
S
S
S
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Penicillin as resistant regardless of
MIC.
therapy guide.
Penicillin (P)
NOTE: 1.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
R
8
R
S
R
2
R
S
I
S
0.25
R
S
I
S
0.12
S
S
S
S
S
0.06
S
S
S
S
S
0.03
S
S
S
S
S
therapy guide.
9020-7493B
Page 103 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
MIC
4.
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
L. monocytogenes
>
R
R
N/R
0.25
R
S
I
S
0.12
S
S
S
S
S
0.03
S
S
S
S
S
therapy guide.
be provided if the result is >0.25.
Based on CLSI interpretive guidelines for enterococci, all MICs of >0.25 will report as R, since these
(P/T)
NOTE: 1.
2.
3.
STAPHYLOCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
S
4
S
2
S
1
S
Do not report drug, therapy or MIC, for CNS with an MIC 0.5 for oxacillin or CfxS >4.
Do not report drug, therapy or MIC, for S. aureus and S. lugdunensis with an MIC >2 for Oxacillin or
CfxS >4.
For non-beta-lactamase producing enterococci, refer to Penicillin result.
Pristinamycin (Prs)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
2
I
I
I
1
S
S
S
0.5
S
S
S
9020-7493B
Page 104 of 158

Rifampin (Rif)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
16
I
I
8
I
I
4
I
S
1
I
S
0.5
S
S
Rifampin (Rif)
MIC
STAPHYLOCOCCI
>
R
2
I
1
S
0.5
S
Synercid (Syn)
(Quinupristin/Dalfopristin)
NOTE: 1.
2.
3.
4.
5.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
I
S
S
E. faecium
ENTEROCOCCI
(other than E. faecium)
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
R
R
R
R
>
4
R
I
R
R
2
I
I
I
I
1
S
S
S
S
Staphylococci and E. faecium therapies based on EUCAST V3.1.
Enterococci (except E. faecium) and streptococci therapies based on CLSI M100-S22.
It is important to speciate strains of enterococci, since Synercid is not active against E. faecalis.
Synercid (Syn)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
(E. faecium only)
STREPTOCOCCI
R
R
>
4
R
I
2
I
I
1
S
S
0.5
S
S
2. Use for EUCAST panel class, except for PC30 panel.
3. It is important to speciate strains of enterococci, since Synercid is not active against E. faecalis.
9020-7493B
Page 105 of 158

Synercid (Syn)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
(E. faecium only)
STREPTOCOCCI
R
R
>
2
I
I
1
S
S
0.5
S
S
0.25
S
S
Use for PC30 panel.
It is important to speciate strains of enterococci, since Synercid is not active against E. faecalis.
Based on EUCAST interpretive guidelines for E. faecium, all MICs of >2 will report as R, since these
dilutions do not differentiate between I and R (S1, I=2-4, R>4).
Synercid (Syn)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
R
R
R
>
4
R
R
R
2
I
I
I
1
S
S
S
0.5
S
S
S
0.25
S
S
S
2. It is important to speciate strains of enterococci, since Synercid is not active against E. faecalis.
3. Do not report therapy for viridans streptococci (S. bovis group).
Teicoplanin (Tei)
NOTE: 1.
2.
3.
4.
5.
MIC
S. AUREUS
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
R
R
R
>
8
R
S
R
4
R
S
R
2
S
S
S
1
S
S
S
S. aureus and enterococci therapies based on EUCAST V3.1.
Staphylococci (except S. aureus) therapy based on CLSI M100-S22.
Use for EUCAST Blended panel class, except for PC42E and PM33E panels.
Do not report drug, therapy or MIC for S. haemolyticus.
Based on CLSI interpretive guidelines for staphylococci (except S. aureus), all MICs of >8 will report
as R, since these dilutions do not differentiate between I and R (S8, I=16, R32).
Teicoplanin (Tei)
MIC
S. AUREUS
STAPHYLOCOCCI
ENTEROCOCCI
R
R
>
16
R
I
8
R
S
4
R
S
2
S
S
1
S
S
NOTE: 1. S. aureus and enterococci therapies based on EUCAST V3.1.
2. Staphylococci (except S. aureus) therapy based on CLSI M100-S22.
3. Use for PC42E and PM33E panels.
9020-7493B
STREPTOCOCCI
R
R
R
R
S
S
Page 106 of 158

Teicoplanin (Tei)
MIC
S. AUREUS
COAGULASE
NEGATIVE
STAPHYLOCOCCI
ENTEROCOCCI
ENTEROCOCCI
STREPTOCOCCI
STREPTOCOCCI
R
R
>
8
R
R
4
R
R
2
S
S
1
S
S
3. Do not report drug, therapy or MIC for all coagulase negative staphylococci (CNS).
Teicoplanin (Tei)
MIC
STAPHYLOCOCCI
R
>
16
I
8
S
4
S
2
S
1
S
Tetracycline (Te)
NOTE: 1.
2.
3.
4.
5.
6.
MIC
STAPHYLOCOCCI
R
I
S
S
S
S
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
N/R
2
I
S
I
S
1
S
S
S
S
Staphylococci and beta-hemolytic streptococci (S. agalactiae) therapies based on EUCAST V3.1.
Use for EUCAST Blended panel class, except for PC38, PC42E and PM33E panels.
Based on CLSI interpretive guidelines for enterococci all MICs of >2 will report as R, since these
dilutions do not differentiate S, I and R (S4, I=8, R16).
Based on CLSI interpretive guidelines for viridans streptococci all MICs of >2 will report as N/R, since
these dilutions do not differentiate I and R (S2, I=4, R8).
Tetracycline (Te)
NOTE: 1.
2.
3.
4.
9020-7493B
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
R
8
R
I
R
R
4
R
S
R
I
2
I
S
I
S
1
S
S
S
S
Staphylococci and beta-hemolytic streptococci (S. agalactiae) therapies based on EUCAST V3.1.
Use for PC38, PC42E and PM33E panels.
Page 107 of 158

Tetracycline (Te)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
8
R
R
4
N/R
N/R
Use for PC30 panel.
Based on EUCAST interpretive guidelines for staphylococci and beta-hemolytic streptococci, all MICs of
4 will report as N/R, since these dilutions do not differentiate between S, I and R (S1, I=2, R>2).
Tetracycline (Te)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
8
R
R
4
R
R
2
I
I
1
S
S
2. Use for PC36 and PM31 panels.
Tetracycline (Te)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
8
I
I
R
4
S
S
I
2
S
S
S
1
S
S
S
Tetracycline (Te)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
8
I
I
R
4
S
S
N/R
3. Based on CLSI interpretive guidelines for streptococci, all MICs of 4 will report as N/R, since these
9020-7493B
Page 108 of 158

Ticarcillin - K Clavulanate
(Tim)
NOTE: 1.
2.
3.
4.
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
S
Ticarcillin-K Clavulanate as resistant regardless of MIC.
For CNS other than S. lugdunensis, if Oxacillin MIC is 0.5, report Ticarcillin-K Clavulanate as resistant
regardless of MIC.
than S. lugdunensis, if CfxS is >4 and/or Oxacillin MIC is 1, report Ticarcillin-K Clavulanate as resistant
regardless of MIC. For additional information refer to Cefoxitin Screen section in the front of the guide.
Tobramycin (To)
NOTE: 1.
2.
3.
4.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
R
4
R
2
R
1
S
Do not report drug, therapy or MIC for beta-hemolytic streptococci. See notes for species names.
Tobramycin (To)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8
I
4
S
2
S
1
S
2. Do not report drug, therapy or MIC for beta-hemolytic streptococci. See notes for species names.
NOTE: 1.
2.
3.
4.
5.
6.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8/152
R
4/76
I
2/38
S
1/19
S
Use for EUCAST Blended and EUCAST panel classes, except for PC30 and PC36 panels
If TFG negative, report therapy as TFG for all gram-positive organisms.
Do not report therapy for enterococci.
9020-7493B
Page 109 of 158

NOTE: 1.
2.
3.
4.
5.
6.
7.
4.
5.
6.
7.
ENTEROCOCCI
STREPTOCOCCI
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
2/38
S
1/19
S
Use for PC36 panel.
Based on EUCAST interpretive guidelines for staphylococci, all MICs of >2/38 will report as R, since
these dilutions do not differentiate S, I and R (S2/38, I=4/76, R>4/76).
NOTE: 1.
2.
3.
4.
STAPHYLOCOCCI
>
R
8/152
R
2/38
S
Use for PC30 panel.
Based on EUCAST interpretive guidelines for staphylococci, all MICs of >2/38 will report as R, since
these dilutions do not differentiate S, I and R (S2/38, I=4/76, R>4/76).
NOTE: 1.
2.
3.
MIC
MIC
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
8/152
R
4/76
R
2/38
S
1/19
S
0.5/9.5
S
0.06/1.14
S
9020-7493B
Page 110 of 158

Vancomycin (Va)
NOTE: 1.
2.
3.
MIC
STAPHYLOCOCCI
(S. aureus)
COAGULASENEGATIVE
STAPHYLOCOCCI
ENTEROCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
(S. agalactiae)
VIRIDANS
STREPTOCOCCI
(S. bovis group)
>
R
R
R
R
R
16
R
R
R
R
R
8
R
R
R
R
R
4
R
S
S
R
R
2
S
S
S
S
S
1
S
S
S
S
S
0.5
S
S
S
S
S
0.25
S
S
S
S
S
Vancomycin (Va)
MIC
S. AUREUS
COAGULASE- NEGATIVE
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
16
R
I
I
8
I
I
I
4
I
S
S
2
S
S
S
1
S
S
S
S
0.5
S
S
S
S
0.25
S
S
S
S
2. Do not report drug, therapy or MIC for all streptococci except for beta-hemolytic streptococci (S. agalactiae)
3. The CLSI interpretative guideline for Vancomycin with streptococci is 1 for susceptible. Because
intermediate and resistant interpretations have not been defined for streptococci, no interpretations will be
provided if the result is >1.
Vancomycin (Va)
MIC
S. AUREUS
COAGULASE- NEGATIVE
STAPHYLOCOCCI
ENTEROCOCCI
STREPTOCOCCI
>
R
R
R
N/R
16
R
I
I
N/R
8
I
I
I
N/R
4
I
S
S
N/R
2
S
S
S
N/R
2. Use for PBC20, PBC23, PC1A, PC20 and PC21 panels.
3. The CLSI interpretative guideline for Vancomycin with streptococci is 0.5 for susceptible. Because
intermediate and resistant interpretations have not been defined for streptococci, all MICs of 2 will
report as N/R, since these dilutions do not differentiate between S and NS.
9020-7493B
Page 111 of 158
SYNERGIES PLUS GRAM-NEGATIVE PANELS

Amikacin (Ak)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
32
I
I
I
16
S
S
S
8
S
S
S
3. Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Y. pestis.
NOTE: 1.
2.
3.
4.
5.
3.
4.
3.
4.
5.
6.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B PSEUDOMALLEI
>
R
16/8
I
8/4
S
Rapid results (<16 hrs) are not provided for Amoxicillin-K Clavulanate on Synergies plus Gram-Negative
Ampicillin (Am)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
16/8
R
4/2
S
Use for Synergies plus Neg Combo Type 3 panels and Synergies plus Neg/Urine Combo Type 4 panels
Rapid results (<16 hrs) are not provided for Amoxicillin-K Clavulanate on Synergies plus Gram-Negative
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
V. CHOLERAE
>
R
16
I
8
S
4
S
2
S
Do not report drug, therapy or MIC for P. vulgaris or Shigella spp. See back of therapy guide for species
names.
For the following groups, Citrobacter spp., Enterobacter spp., Klebsiella spp. or Providencia spp., do not
report rapid Synergies plus results (<16 hrs) for drug, therapy or MIC. Overnight results (16-20 hrs) can be
reported. See back of therapy guide for species names.
For rapid Synergies plus results (<16 hrs), intermediate and resistant MICs obtained for P. mirabilis must be
confirmed with overnight incubation (16-20 hours) of the Synergies plus panels.
Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, and V. cholerae.
9020-7493B
Page 112 of 158

Amp-Sulbactam (A/S)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
6.
3.
4.
5.
(Acinetobacter spp. only)
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
I
I
I
8
S
S
S
Rapid results (<16 hrs) are not provided for Aztreonam on Synergies plus Gram-Negative panels.
Results are available at 16-20 hours.
Aztreonam cannot be used as a Screening antimicrobial agent for extended-spectrum beta-lactamases
(ESBL) on Synergies plus panels.
On Synergies plus panels, ESBL-a and ESBL-b can be used as Screening antimicrobial agents for
extended-spectrum beta-lactamases (ESBL), see information under ESBL-a and ESBL-b.
Cefazolin (Cfz)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
16/8
I
8/4
S
4/2
S
Use for the Synergies plus Neg BP Combo Type 8 and Synergies plus Neg Combo Type 2 panels panels.
Do not report drug, therapy or MIC for the following groups: Citrobacter spp., Enterobacter spp., M. morganii,
Salmonella spp. or Shigella spp. See back of therapy guide for species names.
Do not report therapy for Acinetobacter spp. because according to the FDA approved pharmaceutical
manufacturers package insert, sufficient strains of Acinetobacter spp. have not been tested to establish
efficacy with Ampicillin-Sulbactam.
Aztreonam (Azt)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
Use for Synergies plus Neg Combo Type 3 panels, Synergies plus Neg/Urine Combo Type 4 panels,
Synergies plus Neg BP Combo Type 8 panels.

Do not report drug, therapy or MIC for K. oxytoca, K. pneumoniae/oxytoca and Klebsiella spp.
Due to expected natural resistance to Cefazolin, drug, MIC and interpretative results from
Enterobacter spp., C. freundii Group, M. morganii, P. vulgaris, P. penneri, Providencia spp., Serratia
spp. or Y. enterocolitica will not be reported in the software or on patient reports. See back of therapy
results can occur.
9020-7493B
Page 113 of 158

Cefazolin (Cfz)
NOTE: 1.
2.
3.
4.
4.
5.
3.
4.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
32
R
R
4
N/R
S
Use for Synergies plus Neg Combo Type 3 panel.
Rapid results (<16 hrs) are not provided for Cefepime on Synergies plus Gram-Negative panels. Results
are available at 16-20 hours.
Based on EUCAST interpretive guidelines for Enterobacteriaceae, all MICs of 4 will report as N/R, since
Cefepime (Cpe)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
16
I
8
S
Use for the Synergies plus Neg BP Combo Type 7 and Synergies plus Neg Combo Type 2 panels.
Rapid results (<16 hrs) are not provided for Cefazolin for the Synergies plus Gram-Negative panels
listed in Note 2. Results are available 16-20 hours.
results can occur.
Cefepime (Cpe)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
16
I
I
I
8
S
S
S
Therapy based CLSI M100-S22.
Rapid results (<16 hrs) are not provided for Cefepime on Synergies plus Gram-Negative panels. Results
are available at 16-20 hours.
9020-7493B
Page 114 of 158

Cefotaxime (Cft)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
8
S
S
4
S
S
2. Use for the Synergies plus Neg/Urine Combo Type 4 and Synergies plus Neg BP Combo Type 8 panel.
3. Cefotaxime cannot be used as a Screening antimicrobial agent for extended-spectrum beta-lactamases
4. On Synergies plus panels, ESBL-a and ESBL-b can be used as Screening antimicrobial agents for
5. Do not report drug, therapy or MIC for Acinetobacter spp., C. freundii Group, E. cloacae, Klebsiella
spp., or Proteus spp. See back of therapy guide for species names.
6. For rapid Synergies plus results (<16 hrs), do not report drug, therapy or MIC for S. marcescens
with MICs of >32 (I, R).
7. For rapid Synergies plus results (<16 hrs), intermediate/resistant MICs obtained for S. marcescens
must be confirmed with overnight incubation (16-20 hrs) of the Synergies plus panels.
10. Do not report therapy for P aeruginosa based on CLSI M100-S22.
Cefotaxime (Cft)
NOTE: 1.
2.
3.
5.
4.
6.
7.
8.
5.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
16
I
I
8
S
S
2
S
S
Use for the Synergies plus Neg BP Combo Type 7, Synergies plus Neg/Urine Combo Type 2 and
Synergies plus Neg/Urine Combo Type 1 panels.
Rapid results (<16 hrs) are not provided for Cefotaxime on the Synergies plus Gram-Negative
panels listed in Note 2. Results are available at 16-20 hours.
Cefotaxime cannot be used as a Screening antimicrobial agent for extended-spectrum beta
lactamases (ESBL) on Synergies plus panels.
On Synergies plus panels, ESBL-a and ESBL-b can be used as Screening antimicrobial agents for
Do not report therapy for P. aeruginosa based on CLSI M100-S22.
Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
MIC
MIC
ENTEROBACTERIACEAE
P AERUGINOSA
>
16
2
For ESBL Confirmation only.
Use for the Synergies plus Neg Combo Type 3.
Rapid results (<16 hours) are not provided for Cefotaxime on Synergies plus Neg Combo Type 3
Cefotaxime is a confirmation antimicrobial agent for extended-spectrum beta-lactamases (ESBL).
For overnight (16-20 hrs) results, see ESBL information in front of therapy guide.
9020-7493B
Page 115 of 158

ESBL Confirm Cefotaxime
(ECft)
MIC
ENTEROBACTERIACEAE
NON-ENTEROBACTERIACEAE P AERUGINOSA
B PSEUDOMALLEI
>
16
2
NOTE: 1. For ESBL Confirmation only.
2. ECft is Cefotaxime. Rapid results (<16 hours) are not provided for ECft on Synergies plus Gramnegative panels. Results are available at 16-20 hours.
3. ECft is a confirmation antimicrobial agent for extended-spectrum beta-lactamases (ESBL). For
Overnight results (16-20 hrs), see ESBL information in front of guide.
Cefotaxime-K
Clavulanate (Cft/CA)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
4/4
0.5/4
NOTE: 1. On Synergies plus panels, Cefotaxime-K Clavulanate is a confirmation antimicrobial for extended
-spectrum beta-lactamases (ESBL). See ESBL information in front of guide.
2. Rapid results (<16 hrs) are not provided for Cefotaxime-K Clavulanate on the Synergies plus
Gram-Negative panels. Results are available at 16-20 hours.
Cefotetan (Ctn)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
32
I
16
S
Rapid results (<16 hrs) are not provided for Cefotetan on Synergies plus Gram-Negative panels.
results can occur.
Cefoxitin (Cfx)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
16
I
8
S
2. Rapid results (<16 hrs) are not provided for Cefoxitin on Synergies plus Gram-Negative
panels. Results are available 16-20 hours.
3. Do not report therapy for Salmonella/Shigella group and Y. pestis because dangerously
Cefoxitin (Cfx)
NOTE: 1.
2.
3.
9020-7493B
MIC
ENTEROBACTERIACEAE
P AERUGINOSA
>
R
32
I
8
S
Use for Synergies plus Neg Combo Type 3 panels and Synergies plus Neg/Urine Combo Type 4
panels
Rapid results (<16 hrs) are not provided for Cefoxitin on Synergies plus Gram-Negative panels.
Page 116 of 158

Ceftazidime (Caz)
NOTE: 1.
2.
3.
4.
5.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
R
R
R
R
16
I
I
I
I
8
S
S
S
S
4
S
S
S
S
2
S
S
S
S
For E. cloacae, do not report rapid Synergies plus results (<16 hrs) for drug, therapy or MIC.
Overnight results (16-20 hrs) can be reported.
Ceftazidime cannot be used as a Screening antimicrobial agent for extended-spectrum beta-lactamases
On Synergies plus panels, ESBL-a and ESBL-b can be used as screening antimicrobial agents for
ESBL Confirm
Ceftazidime (ECaz)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
B. PSEUDOMALLEI
>
8
1
NOTE: 1. For ESBL Confirmation only.
2. ECaz is Ceftazidime. Rapid results (<16 hrs) are not provided for ECaz on Synergies plus GramNegative panels. Results are available at 16-20 hours.
3. ECaz is a confirmation antimicrobial agent for extended-spectrum beta-lactamases (ESBL). For
Dried Overnight results and ESBL Confirmation organisms, see ESBL information in front of guide.
Ceftazidime-K
Clavulanate (Caz/CA)
MIC
Ceftriaxone (Cax)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
2/4
0.25/4
NOTE: 1. Rapid results (<16 hrs) are not provided for Ceftazidime-K Clavulanate on Synergies plus GramNegative panels. Results are available 16-20 hours.
2. On Synergies plus panels, Ceftazidime-K Clavulanate is a confirmation antimicrobial for extendedspectrum beta-lactamases (ESBL). See ESBL information in front of guide.
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
32
I
I
8
S
S
Do not report drug, therapy or MIC for P. vulgaris.
For Citrobacter spp. or E. cloacae, do not report rapid Synergies plus results (<16 hrs) for drug,
therapy or MIC. Overnight results (16-20 hrs) can be reported. See back of therapy guide for
species names.
Ceftriaxone cannot be used as a screening antimicrobial agent for extended-spectrum beta
lactamases (ESBL) on Synergies plus panels.
On Synergies plus panels, ESBL-a and ESBL-b can be used as screening antimicrobial agents for
Do not report therapy for B. cepacia, B. pseudomallei, S. maltophilia and Vibrio spp.
Do not report therapy for P. aeruginosa based on CLSI M100-S22.
9020-7493B
Page 117 of 158

(parenteral)
NOTE: 1.
2.
3.
4.
4.
5.
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
>
R
R
2
I
I
1
S
S
0.5
S
S
3. For Y. pestis therapy based on CLSI M100-S17 interpretive breakpoints.
Colistin (Cl)
3.
4.
P. AERUGINOSA
>
R
16
I
8
S
Report for Urine source only.
Rapid results (<16 hrs) are not provided for Cephalothin on Synergies plus Gram-Negative panels.
Do not report therapy for Salmonella/Shigella group and Y. pestis because dangerously misleading results
can occur.
Plesiomonas shigelloides, S. maltophilia and Vibrio spp.
Ciprofloxacin (Cp)
NOTE: 1.
2.
P. AERUGINOSA
>
R
16
I
8
S
4
S
For Enterobacter spp. or K. pneumoniae, do not report rapid Synergies plus results (<16 hrs) for drug,
therapy or MIC. Overnight results (16-20 hrs) can be reported. See back of therapy guide for species
names.
results can occur.
The CLSI M100-S22 breakpoints for Enterobacteriaceae and Cefuroxime axetil (oral) are S4, R=816, R32.
Cephalothin (Cf)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
P AERUGINOSA
Y. PESTIS
R
I
S
S
R
I
S
S
PSEUDOMONAS SPP.
>
R
R
4
R
S
2
S
S
Rapid results (<16 hrs) are not provided for Colistin on Synergies plus Gram-Negative panels.
9020-7493B
Page 118 of 158

ESBL-a (ESa)
MIC
ENTEROBACTERIACEAE
>
4
NOTE: 1. ESBL-a is Cefpodoxime. Rapid results (<16 hrs) are not provided for ESBL-a on Synergies plus
2. ESBL-a is a screening antimicrobial agent for extended-spectrum beta-lactamases (ESBL). For Dried
Overnight results and E. coli, K. oxytoca, K. pneumoniae and P. mirabilis, see ESBL information in
front of guide.
ESBL-b (ESb)
MIC
ENTEROBACTERIACEAE
>
1
NOTE: 1. ESBL-b is Ceftazidime. Rapid results (<16 hrs) are not provided for ESBL-b on Synergies plus
2. ESBL-b is a screening antimicrobial agent for extended-spectrum beta-lactamases (ESBL). For Dried
Overnight results and E. coli, K. oxytoca, K. pneumoniae and P. mirabilis, see ESBL information in
front of therapy guide.
Fosfomycin (Fos)
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
32
S
S
2. Rapid results (<16 hrs) are not provided for Fosfomycin on Synergies plus Gram-Negative panels.
3. Do not report therapy for Aeromonas spp., Plesiomonas shigelloides, Vibrio spp. and Y. pestis.
Gatifloxacin (Gat)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
A. LWOFFII
P. AERUGINOSA
>
R
R
4
I
I
2
S
S
Use for the Synergies plus Neg BP Combo Type 7, Synergies plus Neg/Urine Combo Type 2,
Synergies plus Neg/Urine Combo Type 1 and Synergies plus Neg Combo Type 2 panels.
Do not report drug, therapy or MIC for P. aeruginosa and Non-Enterobacteriaceae, except A. lwoffii.
Gentamicin (Gm)
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
Y. PESTIS
>
R
R
R
R
8
I
I
I
I
4
S
S
S
S
2
S
S
S
S
1
S
S
S
S
9020-7493B
Page 119 of 158

Imipenem (Imp)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
MIC
ENTEROBACTERIACEAE
>
R
4
I
2
S
2. Do not report therapy for B. pseudomallei and Y. pestis.
Levofloxacin (Lvx)
MIC
ENTEROBACTERIACEAE
R
I
S
ACINETOBACTER SPP.
R
I
S
P. AERUGINOSA
R
I
S
PSEUDOMONAS SPP.
>
R
R
R
4
R
R
R
1
S
S
S
0.5
S
S
S
Use for Synergies plus Neg Combo Type 3 panel.
Rapid results (<16 hrs) are not provided for Levofloxacin on Synergies plus Neg Combo Type 3
Based on EUCAST interpretive guidelines for Enterobacteriaceae, Acinetobacter spp. and
Pseudomonas spp., all MICs of >1 will report as R, since these dilutions do not differentiate between
I and R (S1, I=2, R>2).
NOTE: 1.
2.
3.
4.
5.
Meropenem (Mer)
4.
5.
B. PSEUDOMALLEI
>
R
R
R
8
I
I
I
4
S
S
S
Do not report therapy for B. cepacia and S. maltophilia.
Levofloxacin (Lvx)
NOTE: 1.
2.
3.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
I
I
I
4
S
S
S
Use for the Synergies plus Neg BP Combo Type 7 and Synergies plus Neg Combo Type 2 panels.
For P. aeruginosa, do not report rapid Synergies plus results (<16 hrs) drug, therapy or MIC.
Overnight results (16-20 hrs) can be reported.
9020-7493B
Page 120 of 158

Nalidixic Acid (NA)
NOTE: 1.
2.
3.
4.
5.
3.
4.
5.
3.
4.
5.
P AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
64
I
32
S
Use for the Synergies plus Neg/Urine Combo Type 1 and Synergies plus Neg/Urine Combo Type 2
panels.
Rapid results (<16 hrs) are not provided for Nitrofurantoin on the Synergies plus Gram-Negative
panels listed in Note 2. Results are available at 16-20 hours.
Norfloxacin (Nxn)
NOTE: 1.
2.
3.
4.
>
R
64
I
32
S
16
S
Use for the Synergies plus Neg BP Combo Type 7, Synergies plus Neg BP Combo Type 8
and Synergies plus Neg/Urine Combo Type 4 panels.

Due to expected natural resistance to Nitrofurantoin, drug, MIC and interpretative results from M.
morganii, Proteus spp., Providencia spp. or Serratia spp. will not be reported in the software or on
patient reports. See back of therapy guide for species names.
Nitrofurantoin (Fd)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
16
I
8
S
Rapid results (<16 hrs) are not provided for Nalidixic Acid on Synergies plus Gram-Negative panels.
Do not report drug, therapy or MIC for E. cloacae and K. pneumoniae.
Do not report therapy for Salmonella because the ability of the Synergies plus panels to detect
Nitrofurantoin (Fd)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
8
I
I
I
4
S
S
S
Use for Synergies plus Neg/Urine Combo Type 4 panel.

9020-7493B
Page 121 of 158

Norfloxacin (Nxn)
NOTE: 1.
2.
3.
4.
5.
4.
5.
6.
3.
4.
5.
6.
P. AERUGINOSA
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
64
R
R
16
I
S
8
S
S
Therapy based on EUCAST
Use for the Synergies plus Neg/Urine Combo Type 4.
Rapid results (<16 hrs) are not provided for Piperacillin on Synergies plus Gram-Negative panels.
Piperacillin (Pi)
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
R
8
I
I
I
4
S
S
S
Use for Synergies plus Neg BP Combo Type 8 panels.
Rapid results (<16 hrs) are not provided for Norfloxacin on the Synergies plus Gram-Negative panels
listed in Note 2. Results are available at 16-20 hours.
Piperacillin (Pi)
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
32
I
I
S
16
S
S
S
Use for the Synergies plus Neg BP Combo Type 8 and Synergies plus Neg/Urine Combo Type 1
panels.
Do not report drug, therapy or MIC for S. maltophilia or Citrobacter spp. See back of therapy guide for
species names.
For Acinetobacter spp., K. oxytoca, M. morganii or P. mirabilis, do not report rapid Synergies plus
results (<16 hrs) for drug, therapy or MIC. Overnight results (16-20 hrs) can be reported. See back of
therapy guide for species names.
Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, and Plesiomonas
shigelloides.
9020-7493B
Page 122 of 158

(P/T)
NOTE: 1.
2.
3.
4.
5.
6.
7.
8.
3.
4.
5.
6.
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
32
I
I
S
16
S
S
S
8
S
S
S
Use for the Synergies plus Neg Combo Type 2, Synergies plus Neg BP Combo Type 8,
Synergies plus Neg Combo Type 3 and Synergies plus Neg/Urine Combo Type 4 panels.
Do not report drug, therapy, or MIC for S. maltophilia and Acinetobacter spp. See back of therapy guide for
species names.
For Citrobacter spp. or Enterobacter spp., do not report rapid Synergies plus results (<16 hrs) for drug,
therapy or MIC. Overnight results (16-20 hrs) can be reported. See back of therapy guide for species
names.
For rapid Synergies plus results (<16 hrs), do not report drug, therapy or MIC for Serratia spp. with MICs of
32 (I, R).
For rapid Synergies plus results (<16 hrs), intermediate/resistant MICs obtained for Serratia spp. must be
confirmed with overnight incubation (16-20 hrs) of the Synergies plus panels.
(P/T)
NOTE: 1.
2.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
I
16
S
S
S
Therapy based on CLSI M100-S22
Use for the Synergies plus Neg BP Combo Type 7, Synergies plus Neg/Urine Combo Type 1 and
Synergies plus Neg/Urine Combo Type 2 panels.
Rapid results (<16 hrs) are not provided for Piperacillin-Tazobactam on the Synergies plus GramNegative panels listed in Note 2. Results are available at 16-20 hours.
Do not report drug, therapy or MIC for S. maltophilia and Acinetobacter spp. See back of therapy
Tetracycline (Te)
MIC
ENTEROBACTERIACEAE
>
8
4
2
R
I
S
S
R
I
S
S
MIC
B. PSEUDOMALLEI
Y. PESTIS
P. AERUGINOSA
V. CHOLERAE
>
R
R
8
I
I
4
S
S
2
S
S
pseudomallei) therapies based on CLSI M100-S22. B. pseudomallei and Y. pestis therapies based
on CLSI M45-A2.
2. Use these tables for the Synergies plus Neg BP Combo Type 8 and Synergies plus Neg/Urine
Combo Type 1 panels.
3. Do not report therapy for B. cepacia, S. maltophilia and V. cholerae.
9020-7493B
Page 123 of 158

Ticarcillin (Ti)
4.
5.
6.
7.
4.
5.
6.
3.
4.
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
MIC
ENTEROBACTERIACEAE
ACINETOBACTER SPP.
PSEUDOMONAS SPP.
>
R
R
64
R
R
16
N/R
S
Use for Synergies plus Neg Combo Type 3 panels and Synergies plus Neg/Urine Combo Type 4 panels.
Rapid results (<16 hrs) are not provided for Ticarcillin-K Clavulanate on Synergies plus Gram-Negative
NOTE: 1.
2.
ENTEROBACTERIACEAE
>
R
R
64
R
R
16
N/R
S
Use for Synergies plus Neg Combo Type 3 panels and Synergies plus Neg/Urine Combo Type 4 panels.
Rapid results (<16 hrs) are not provided for Ticarcillin on Synergies plus Gram-Negative panels.
Do not report drug, therapy, or MIC for S. maltophilia.
NOTE: 1.
2.
3.
NOTE: 1.
2.
3.
MIC
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
R
R
64
I
I
S
16
S
S
S
Rapid results (<16 hrs) are not provided for Ticarcillin-K Clavulanate on Synergies plus GramNegative panels. Results are available at 16-20 hours.
Do not report therapy for Aeromonas spp., B. pseudomallei, Plesiomonas shigelloides and Vibrio spp.
Tobramycin (To)
MIC
ENTEROBACTERIACEAE
P AERUGINOSA
>
R
R
R
8
I
I
I
4
S
S
S
2
S
S
S
3. Do not report therapy for Aeromonas spp., B. cepacia, B. pseudomallei, Plesiomonas shigelloides, S.
9020-7493B
Page 124 of 158

Trimethoprim (T)
NOTE: 1.
2.
3.
4.
MIC
ENTEROBACTERIACEAE
P. AERUGINOSA
>
R
8
S
Rapid results (<16 hrs) are not provided for Trimethoprim on Synergies plus Gram-Negative panels.
MIC
ENTEROBACTERIACEAE
2/38
>
R
S
MIC
B PSEUDOMALLEI
P AERUGINOSA
R
S
Y PESTIS
>
R
R
S
S
For rapid Synergies plus panel results (<16 hrs), do not report drug, therapy or MIC for P. aeruginosa.
For overnight results (16-20 hours), do not report therapy for P. aeruginosa.
Do not report therapy for V. cholerae, sufficient strains were not tested to establish efficacy. Interpretive
breakpoints should not be reported.
2/38
NOTE: 1.
2.
3.
4.
9020-7493B
Page 125 of 158
SYNERGIES PLUS GRAM-POSITIVE PANELS

Ampicillin (Am)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
32
R
16
R
8
S
4
S
2
S
1
S
Use for enterococci.
For enterococci, if beta-lactamase positive, report Ampicillin as Blac regardless of MIC.
The predicted interpretation for staphylococci will be based on the Penicillin and/or Oxacillin MICs.
Chloramphenicol (C)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
16
I
8
S
4
S
Clindamycin (Cd)
NOTE: 1.
2.
3.
4.
MIC
STAPHYLOCOCCI
R
I
S
S
ENTEROCOCCI
>
R
2
I
1
I
0.5
S
0.25
S
0.12
S
Do not report drug, therapy or MIC for enterococci.
For staphylococci, if Erythromycin MIC is N/R and Clindamycin MIC is 2, do not report therapy.
Erythromycin (E)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
4
I
2
I
1
I
0.5
S
3. Do not report drug, therapy or MIC for enterococci.
9020-7493B
Page 126 of 158

Gentamicin (Gm)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
8
I
4
S
2
S
1
S
0.5
S
0.25
S
Imipenem (Imp)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
(E. faecalis only)
>
R
8
I
4
S
2
S
1
S
0.5
S
NOTE: 1. Therapy based on FDA approved breakpoints for E. faecalis.
2. Do not report drug, therapy or MIC for enterococci (except for E. faecalis.)
3. The predicted interpretation for staphylococci will be based on the Penicillin and/or Oxacillin MICs.
Levofloxacin (Lvx)
MIC
STAPHYLOCOCCI
>
R
4
R
2
I
1
S
0.5
S
0.25
S
Linezolid (Lzd)
MIC
MIC
ENTEROCOCCI
R
S
S
S
S
R
I
S
S
S
STAPHYLOCOCCI
>
R
64
I
32
S
16
S
9020-7493B
R
I
S
S
S
S
STAPHYLOCOCCI
>
4
2
1
0.5
Nitrofurantoin (Fd)
ENTEROCOCCI
ENTEROCOCCI
R
I
S
S
Page 127 of 158

Oxacillin (Ox)
MIC
S. AUREUS &
S. LUGDUNENSIS
OTHER
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
2
S
R
1
S
R
0.5
S
R
0.25
S
S
0.12
S
S
3. For rapid results (<16 hours), do not report drug, therapy or MIC for S. aureus with Oxacillin MICs <4
and coagulase-negative staphylococci with Oxacillin MICs <0.5. Results are available at 16-20 hours.
Penicillin (P(E))
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
64
R
32
R
16
R
8
S
4
S
2
S
2. Use for enterococci.
3. For enterococci, if beta-lactamase positive, report Penicillin as Blac regardless of MIC.
Penicillin (P(S))
NOTE: 1.
2.
3.
4.
5.
6.
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
0.12
S
0.06
S
0.03
S
Use for staphylococci.
Do not report drug, therapy or MIC for S. saprophyticus.
For S. aureus and S. lugdunensis, if Oxacillin MIC is >2, report Penicillin as resistant regardless of MIC.
Rifampin (Rif)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
2
I
1
S
0.5
S
0.25
S
9020-7493B
Page 128 of 158

Synercid (Syn)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
(E. faecium)
R
R
>
2
I
I
1
S
S
0.5
S
S
0.25
S
S
0.12
S
S
2. It is important to speciate strains of enterococci, since Synercid is only active against E. faecium.
3. Do not report drug, therapy or MIC for all enterococci, except E. faecium.
Teicoplanin (Tei)
MIC
STAPHYLOCOCCI
ENTEROCOCCI
>
R
16
I
8
S
4
S
2
S
1
S
Tetracycline (Te)
MIC
STAPHYLOCOCCI
R
I
S
S
S
S
ENTEROCOCCI
>
R
8
I
4
S
2
S
1
S
0.5
S
MIC
STAPHYLOCOCCI
R
I
S
S
S
S
ENTEROCOCCI
>
R
2/38
S
1/19
S
0.5/9.5
S
Vancomycin (Va)
MIC
S. aureus
COAGULASE- NEGATIVE
STAPHYLOCOCCI
ENTEROCOCCI
>
R
R
R
16
R
I
I
8
I
I
I
4
I
S
S
2
S
S
S
1
S
S
S
0.5
S
S
S
0.25
S
S
S
2. For rapid results (<16 hrs), do not report drug, therapy or MIC for S. aureus with MICs of 8 or 16.
Final results will be reported after overnight incubation (16-20 hrs).
9020-7493B
Page 129 of 158
FASTIDIOUS PANELS - STREPTOCOCCI

Amoxicillin/
K Clavulanate (Aug)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
STREPTOCOCCI
(Group A, B, C and G)
VIRIDANS
STREPTOCOCCI
>
R
4/2
I
2/1
S
1/0.5
S
Streptococci (Group A, B, C and G) and viridans streptococci therapies based on EUCAST V3.1.
S. pneumoniae therapy based on CLSI M100-S22.
Use for MICroSTREP plus 6E panel only.

For all streptococci (except S. pneumoniae) refer to the penicillin result.
Amoxicillin/
K Clavulanate (Aug)
MIC
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
4/2
2/1
1/0.5
0.5/0.25
0.25/0.12
2. Use for MICroSTREP plus 5 panel only.

3. For all streptococci refer to the penicillin result.
S. PNEUMONIAE
>
4/2
2/1
1/0.5
0.5/0.25
0.25/0.12
Ampicillin (Am)
NOTE: 1.
2.
3.
4.
MIC
R
I
S
S
S
S
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
4
R
R
2
I
I
1
I
I
0.5
S
S
0.25
S
S
S
0.12
S
S
S
0.06
S
S
S
S. pneumoniae and viridans streptococci therapies based on EUCAST V3.1.
Beta-hemolytic streptococci therapy based on CLSI M100-S22.

Because intermediate and resistant interpretations have not been defined, no interpretations will be
provided if the result is >0.25.
9020-7493B
Page 130 of 158

Ampicillin (Am)
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
16
R
8
R
4
R
2
I
1
I
0.5
S
0.25
S
0.12
S
0.06
S
0.03
S

3. For streptococci (Group A, B, C and G) refer to the penicillin result.
Ampicillin (Am)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
R
I
I
S
S
S
S
S
VIRIDANS
STREPTOCOCCI
>
R
8
R
4
I
2
I
1
I
0.5
I
0.25
S
S
0.12
S
S
0.06
S
S
0.03
S
S
Azithromycin (Azi)
NOTE: 1.
2.
3.
4.
5.
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
2
R
R
R
1
R
R
I
0.5
I
I
S
0.25
S
S
S
0.12
S
S
S
S. pneumoniae and Streptococci (Group A, B, C and G) therapies based on EUCAST V3.1.

Susceptibility and resistance to Azithromycin can be predicted by testing Erythromycin.
9020-7493B
Page 131 of 158

Azithromycin (Azi)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
4
R
R
R
2
R
R
R
1
I
I
I
0.5
S
S
S
0.25
S
S
S
0.12
S
S
S
3. Susceptibility and resistance to Azithromycin can be predicted by testing Erythromycin.
Cefaclor (Cfr)
MIC
S. PNEUMONIAE
>
16
8
4
2
1
0.5
Cefepime (Cpe)
NOTE: 1.
2.
3.
4.
MIC
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
R
I
S
S
S. PNEUMONIAE
>
R
R
2
I
R
1
S
R
0.5
S
S
S
0.25
S
S
S
Use for MICroSTREP plus 6E panel only

Cefepime (Cpe)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
2
I
I
1
S
S
0.5
S
S
S
0.25
S
S
S
0.12
S
S
S
2. The CLSI interpretative guideline for Cefepime with beta-hemolytic streptococci is 0.5 for susceptible.
9020-7493B
Page 132 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
>
R
R
2
I
R
1
I
R
0.5
S
S
S
0.25
S
S
S
Use for MICroSTREP plus 6E panels only.

The CLSI interpretative guideline for Cefotaxime with beta-hemolytic streptococci is 0.5 for
susceptible. Because intermediate and resistant interpretations have not been defined, no
Cefotaxime (Cft)
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
32
R
16
R
8
R
4
R
2
I
1
I
0.5
S
0.25
S
0.12
S
2. Use for MICroSTREP plus 5 panels only.

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
VIRIDANS
STREPTOCOCCI
MIC
S. PNEUMONIAE
(Meningitis)
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
R
R
R
R
S
S
S
VIRIDANS
STREPTOCOCCI
>
R
R
8
R
R
4
R
R
2
R
I
1
I
S
0.5
S
S
S
0.25
S
S
S
0.12
S
S
S
0.06
S
S
S
0.03
S
S
S
The CLSI interpretative guideline for Cefotaxime with beta-hemolytic streptococci is 0.5 for
susceptible. Because intermediate and resistant interpretations have not been defined, no
For S. pneumoniae, Cefotaxime breakpoints are based on isolates from CSF (meningitis). For all other
S. pneumoniae isolates report both meningitis breakpoints (S0.5, I=1, R2) and non-meningitis
breakpoints (S1, I=2, R4).
Results of testing Cefotaxime should be routinely reported for CSF isolates of S. pneumoniae.
9020-7493B
Page 133 of 158

Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
>
R
R
2
I
R
1
I
R
0.5
S
S
S
0.25
S
S
S
Beta-Hemolytic therapy based on CLSI M100-S22.
Use for MICroSTREP plus 6E panels only.

The CLSI interpretative guideline for Ceftriaxone with beta-hemolytic streptococci is 0.5 for susceptible.
Ceftriaxone (Cax)
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
8
R
4
R
2
I
1
I
0.5
S
0.25
S
0.12
S

Ceftriaxone (Cax)
NOTE: 1.
2.
3.
4.
VIRIDANS
STREPTOCOCCI
MIC
S. PNEUMONIAE
(Meningitis)
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
R
R
S
S
S
VIRIDANS
STREPTOCOCCI
>
R
R
2
R
I
1
I
S
0.5
S
S
S
0.25
S
S
S
The CLSI interpretative guideline for Ceftriaxone with beta-hemolytic streptococci is 0.5 for susceptible.
For S. pneumoniae, Ceftriaxone breakpoints are based on isolates from CSF (meningitis). For all other
S. pneumoniae isolates report both meningitis breakpoints (S0.5, I=1, R2) and non-meningitis
breakpoints (S1, I=2, R4).
Results of testing Ceftriaxone should be routinely reported for CSF isolates of S. pneumoniae.

(parenteral)
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
4
R
2
R
1
I
0.5
S
0.25
S
2. Use for MICroSTREP plus 5 and MICroSTREP plus 6E panels.

R
R
R
R
S
S
9020-7493B
Page 134 of 158

(parenteral)
MIC
Chloramphenicol (C)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
8
R
4
R
2
R
1
I
0.5
S
0.25
S
2. The CLSI breakpoints for Cefuroxime axetil (oral) are S1, I=2, R4.
NOTE: 1.
2.
3.
4.
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
8
S
S
I
4
S
S
S
2
S
S
S
S. pneumoniae and streptococci (Group A, B, C, and G) therapies based on EUCAST V3.1.
Chloramphenicol (C)
MIC
S. PNEUMONIAE
>
R
16
R
8
S
4
S
2
S

Chloramphenicol (C)
MIC
S. PNEUMONIAE
>
R
16
R
8
R
4
S
2
S
1
S
NOTE: 1. Therapy based on CLSI M100-S22
9020-7493B
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
S
S
S
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
I
S
S
S
R
R
I
S
S
S
Page 135 of 158

Ciprofloxacin (Cp)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
4
2
1
0.5
0.25
0.12
0.06
2. Use for MICroSTREP plus 3 and MICroSTREP plus 5 panels.

NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
2
R
R
R
1
R
R
R
0.5
I
I
I
0.25
S
S
S
0.12
S
S
S
S. pneumoniae and streptococci (Group A, B, C and G) therapies based on EUCAST V3.1.

Susceptibility and resistance to Clarithromycin can be predicted by testing Erythromycin.
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
2
R
R
R
1
R
R
R
0.5
I
I
I
0.25
S
S
S
0.12
S
S
S
2. Susceptibility and resistance to Clarithromycin can be predicted by testing Erythromycin.
Clindamycin (Cd)
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
R
4
R
R
2
R
R
1
R
R
0.5
S
S
0.25
S
S
0.12
S
S
0.06
S
S
9020-7493B
VIRIDANS
STREPTOCOCCI
R
R
R
R
S
S
S
S
Page 136 of 158

Clindamycin (Cd)
MIC
S. PNEUMONIAE
>
R
2
R
1
R
0.5
I
0.25
S
0.12
S
0.06
S
Daptomycin (Dap)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
I
S
S
S
R
R
R
I
S
S
S
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
2
R
1
S
S
0.5
S
S
0.25
S
S
Streptococci (Group A, B, C and G) therapy based on EUCAST V3.1.

The CLSI interpretative guideline for viridans streptococci is 1 for susceptible. Because intermediate and
resistant interpretations have not been defined, no interpretations will be provided if the result is >1.
Daptomycin (Dap)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
2
1
S
S
0.5
S
S
0.25
S
S
2. The CLSI interpretative guideline with beta-hemolytic and viridans streptococci is 1 for susceptible.
provided if the result is >1.
Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
0.5
I
I
I
0.25
S
S
S
0.12
S
S
S
0.06
S
S
S

Susceptibility and resistance to Azithromycin and Clarithromycin can be predicted by testing
Erythromycin.
9020-7493B
Page 137 of 158

Erythromycin (E)
NOTE: 1.
2.
3.
4.
5.
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
4
R
R
2
R
R
1
R
R
0.5
N/R
N/R
Use for MICroSTREP plus 5 panel only.

Susceptibility and resistance to Azithromycin and Clarithromycin can be predicted by testing Erythromycin.
Based on EUCAST interpretive guidelines for S. pneumoniae and streptococci (Group A, B, C and G),
all MICs of 0.5 will report as N/R, since these dilutions do not differentiate between S and I (S0.25,
I=0.5, R>0.5).
Erythromycin (E)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
R
4
R
R
R
2
R
R
R
1
R
R
R
0.5
I
I
I
0.25
S
S
S
0.12
S
S
S
0.06
S
S
S
3. Susceptibility and resistance to Azithromycin and Clarithromycin can be predicted by testing Erythromycin.
Gatifloxacin (Gat)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
STREPTOCOCCI
VIRIDANS STREPTOCOCCI
>
2
1
0.5
0.25
0.12
NOTE: 1. Do not report drug, therapy or MIC.
Levofloxacin (Lvx)
MIC
S. PNEUMONIAE
>
R
R
R
4
R
R
I
2
S
I
S
1
S
S
S
0.5
S
S
S
NOTE: 1. S. pneumoniae and streptococci (Group A, B, C and G) therapies based on EUCAST V3.1.
2. Viridans streptococci therapy based on CLSI M100-S22.
3. Use for MICroSTREP plus 6E panel only.
9020-7493B
Page 138 of 158

Levofloxacin (Lvx)
MIC
S. PNEUMONIAE
>
R
8
R
4
R
2
S
1
S
0.5
S
0.25
S

Levofloxacin (Lvx)
MIC
S. PNEUMONIAE
>
4
2
1
0.5
0.25
Linezolid (Lzd)
NOTE: 1.
2.
3.
4.
MIC
R
I
S
S
S
S
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
I
S
S
S
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
STREPTOCOCCI
R
I
S
S
S
S
R
I
S
S
S
S
>
R
R
4
I
I
2
S
S
S
1
S
S
S

The CLSI interpretative guideline for viridans streptococci is 2 for susceptible. Because intermediate and
resistant interpretations have not been defined, no interpretations will be provided if the result is >2.
Linezolid (Lzd)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
>
4
2
S
S
S
1
S
S
S
0.5
S
S
S
2. The CLSI interpretative guideline with S. pneumoniae, beta-hemolytic streptococci and viridans streptococci
is 2 for susceptible. Because intermediate and resistant interpretations have not been defined, no
9020-7493B
Page 139 of 158

Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
6.
6.
4.
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
MIC
S. PNEUMONIAE
(Meningitis)
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
8
R
R
4
R
R
2
R
S
1
I
S
0.5
N/R
S

Report therapy for systemic source only.
For streptococci (Group A, B, C and G) refer to the penicillin result.
Based on EUCAST v2.0 interpretive guidelines for S. pneumoniae, for infections other than meningitis the
breakpoints are S2, R>2.
Based on EUCAST interpretive guidelines for S. pneumoniae (meningitis), all MICs of 0.5 will report as
N/R, since these dilutions do not differentiate between S and I (S0.25, I=0.5-1, R>1).
Meropenem (Mer)
NOTE: 1.
2.
3.
S. PNEUMONIAE
(Meningitis)
>
R
R
2
R
S
1
I
S
0.5
I
S
S
0.25
S
S
S
S. pneumoniae (meningitis) and viridans streptococci therapies based on EUCAST V3.1.

The CLSI interpretative guideline for beta-hemolytic streptococci is 0.5 for susceptible. Because
intermediate and resistant interpretations have not been defined, no interpretations will be provided if the
result is >0.5.
Based on EUCAST interpretive guidelines for S. pneumoniae, for infections other than meningitis
breakpoints are S2, R>2.
Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
MIC
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
4
R
2
R
1
R
0.5
I
S
S
0.25
S
S
S
0.12
S
S
S
0.06
S
S
S
The CLSI interpretative guideline for Meropenem with beta-hemolytic streptococci and viridans
streptococci is 0.5 for susceptible. Because intermediate and resistant interpretations have not been
defined, no interpretations will be provided if the result is >0.5.
Results of testing Meropenem should be routinely reported for CSF isolates of S. pneumoniae.
9020-7493B
Page 140 of 158

Minocycline (Min)
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
2
R
R
1
I
I
0.5
S
S
2. Use for MICroSTREP plus 6C and MICroSTREP plus 6E panels only.

Moxifloxacin (Mxf)
MIC
S. PNEUMONIAE
>
R
2
R
1
R
0.5
S
0.25
S

Moxifloxacin (Mxf)
MIC
S. PNEUMONIAE
>
4
2
1
0.5
0.25
Penicillin (P)
NOTE: 1.
2.
3.
4.
5.
9020-7493B
MIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
I
S
S
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
I
S
S
S
S. PNEUMONIAE
(meningitis)
>
R
R
R
16
R
R
R
8
R
R
R
4
R
R
R
2
R
R
I
1
R
R
I
0.5
R
R
I
0.25
R
S
S
0.12
R
S
S
0.06
S
S
S
0.03
S
S
S
Use for MICroSTREP plus 5 and MICroSTREP plus 6E panels.

For S. pneumoniae, Penicillin breakpoints are based on isolates from CSF (meningitis).
For S. pneumoniae isolates from pneumonia, refer to EUCAST v2.0.
For S. pneumoniae from sources other than pneumonia or meningitis, the breakpoints are S0.06, I=0.122, R>2.
Page 141 of 158

Penicillin (P)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
8
R
R
4
R
R
2
R
I
1
R
I
0.5
R
I
0.25
R
I
0.12
R
S
S
0.06
S
S
S
0.03
S
S
S
The CLSI interpretive guideline for Penicillin with beta-hemolytic streptococci is 0.12 for susceptible.
Because intermediate and resistant interpretations have not been defined no interpretations will be
Results of testing Penicillin should be routinely reported for CSF isolates of S. pneumoniae.
For S. pneumoniae, Penicillin breakpoints are based on isolates from CSF (meningitis). For all other
S. pneumoniae isolates report both meningitis breakpoints (S0.06, R0.12) and non-meningitis breakpoints
(S2, I=4, R8). Breakpoints for oral administration are S0.06, I=0.12-1, R2.
Pristinamycin (Prs)
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
R
2
R
I
1
S
S
2. Use for MICroSTREP plus 6C and MICroSTREP plus 6E panels only.

Pristinamycin (Prs)
NOTE: 1.
2.
3.
4.
MIC
S. PNEUMONIAE
STREPTOCOCCI
>
R
R
4
R
R
2
N/R
N/R

Based on SFM 2012 interpretive guidelines for S. pneumoniae, all MICs 2 will report as N/R, since
Based on SFM 2012 interpretive guidelines for other streptococci, all MICs 2 will report as N/R, since
Rifampin (Rif)
MIC
S. PNEUMONIAE
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
16
8
4
2
1

3. Based on EUCAST interpretive guidelines for all streptococci, these dilutions do not differentiate between S,
I and R (S0.06, I=0.12-0.5, R>0.5).
9020-7493B
Page 142 of 158

Rifampin (Rif)
MIC
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
2
I
1
S
0.5
S
2. Use for MICroSTREP plus 3, MICroSTREP plus 6C and MICroSTREP plus 6E panels.
Tetracycline (Te)
MIC
S. PNEUMONIAE
STREPTOCOCCI
ViIRIDANS
STREPTOCOCCI
>
R
R
R
4
R
R
I
2
I
I
S
1
S
S
S
NOTE: 1. S. pneumoniae and streptococci (Group A, B, C and G) therapies based on EUCAST V3.1.
2. Viridans streptococci therapy based on CLSI M100-S22.

Tetracycline (Te)
MIC
S. PNEUMONIAE
>
R
8
R
4
R
2
I
1
S
0.5
S

Tetracycline (Te)
MIC
S. PNEUMONIAE
MIC
VIRIDANS
STREPTOCOCCI
R
R
R
I
S
S
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
I
S
S
S
R
I
S
S
S
R
I
S
S
S
S. PNEUMONIAE
STREPTOCOCCI
>
4
2
1
0.5
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
>
R
R
8/152
R
R
4/76
R
R
2/38
I
I
1/19
S
S
0.5/9.5
S
S
0.25/4.75
S
S
9020-7493B
Page 143 of 158

MIC
Vancomycin (Va)
MIC
S. PNEUMONIAE
>
2/38
1/19
0.5/9.5
0.25/4.75
BETA-HEMOLYTIC
STREPTOCOCCI
R
I
I
S
S
S. PNEUMONIAE
STREPTOCOCCI
>
R
R
8
R
R
4
R
R
2
S
S
1
S
S
0.5
S
S
0.25
S
S

Vancomycin (Va)
MIC
VIRIDANS
STREPTOCOCCI
S. PNEUMONIAE
BETA-HEMOLYTIC
STREPTOCOCCI
VIRIDANS
STREPTOCOCCI
R
R
R
S
S
S
S
VIRIDANS
STREPTOCOCCI
>
8
4
2
1
S
S
S
0.5
S
S
S
0.25
S
S
S
0.12
S
S
S
2. The CLSI interpretative guideline for Vancomycin with streptococci is 1 for susceptible. Because
intermediate and resistant interpretations have not been defined for streptococci, no interpretations will
3. Results of testing Vancomycin should be routinely reported for CSF isolates of S. pneumoniae.
9020-7493B
Page 144 of 158
FASTIDIOUS PANELS - HAEMOPHILUS

Ampicillin (Am)
MIC
>
16
8
4
2
1
0.5
0.25
0.12
0.06
0.03

Ampicillin (Am)
NOTE: 1.
2.
3.
4.
MIC
HAEMOPHILUS
R
R
R
R
R
S
S
S
S
S
S
HAEMOPHILUS
>
R
8
R
4
R
2
I
1
S
0.5
S
0.25
S
0.12
S
0.06
S
0.03
S

If beta-lactamase positive, report Ampicillin BLac regardless of MIC.
Results of testing Ampicillin should be routinely reported for CSF isolates of H. influenzae.
Amoxicillin-K Clavulanate (Aug)
MIC
>
4/2
2/1
1/0.5
0.5/0.25
0.25/0.12
2. Use for MICroSTREP plus 3 and 5 panels.
9020-7493B
HAEMOPHILUS
R
S
S
S
S
S
Page 145 of 158

Azithromycin (Azi)
NOTE: 1.
2.
3.
4.
MIC
HAEMOPHILUS
>
4
S
2
S
1
S
0.5
S
0.25
S

The CLSI interpretative guideline for Azithromycin with Haemophilus spp. is 4 for susceptible.
Because intermediate and resistant interpretations have not been defined for Haemophilus
spp., no interpretations will be provided if the result is >4.
Cefaclor (Cfr)
MIC
>
16
8
2
1

Cefepime (Cpe)
MIC
HAEMOPHILUS
R
I
S
S
S
HAEMOPHILUS
>
2
S
1
S
0.5
S
0.25
S
0.12
S

3. The CLSI interpretative guideline for Cefepime with Haemophilus spp. is 2 for susceptible.
Because intermediate and resistant interpretations have not been defined for Haemophilus
spp., no interpretations will be provided if the result is >2.
9020-7493B
Page 146 of 158

Cefotaxime (Cft)
NOTE: 1.
2.
3.
4.
4.
HAEMOPHILUS
>
32
16
8
4
2
S
1
S
0.5
S
0.25
S
0.12
S
0.06
S
0.03
S
Use for MICroSTREP plus 3 and 5 panels.

The CLSI interpretative guidelines for Cefotaxime with Haemophilus spp. is 2 for susceptible.
Because intermediate and resistant interpretations have not been defined for Haemophilus spp.,
no interpretations will be provided if the result is >2.
Results of testing Cefotaxime should be routinely reported for CSF isolates of H. influenzae.
Ceftriaxone (Cax)
NOTE: 1.
2.
3.
MIC
MIC
HAEMOPHILUS
>
8
4
2
S
1
S
0.5
S
0.25
S
0.12
S

The CLSI interpretative guidelines for Ceftriaxone with Haemophilus spp. is 2 for susceptible.
Because intermediate and resistant interpretations have not been defined for Haemophilus spp.,
no interpretations will be provided if the result is >2.
Results of testing Ceftriaxone should be routinely reported for CSF isolates of H. influenzae.
Cefuroxime (Crm)
MIC
>
4
2
1
0.5
9020-7493B
HAEMOPHILUS
R
S
S
S
S
Page 147 of 158

Cefuroxime (Crm)
MIC
>
8
4
2
1
0.5
0.25

Chloramphenicol (C)
MIC
>
16
8
4
2

3. Report for systemic source only.
Chloramphenicol (C)
NOTE: 1.
2.
3.
4.
MIC
HAEMOPHILUS
R
I
S
S
S
S
S
HAEMOPHILUS
R
R
R
R
S
HAEMOPHILUS
>
R
8
R
4
I
2
S
1
S

Results of testing Chloramphenicol should be routinely reported for CSF isolates of H. influenzae.
Ciprofloxacin (Cp)
MIC
>
4
2
1
0.5
0.25
9020-7493B
HAEMOPHILUS
R
R
R
R
S
S
Page 148 of 158

Ciprofloxacin (Cp)
MIC
HAEMOPHILUS
>
2
1
S
0.5
S
0.25
S
0.12
S
0.06
S

3. The CLSI interpretative guidelines for Ciprofloxacin with Haemophilus spp. is 1 for
susceptible. Because intermediate and resistant interpretations have not been defined for
Haemophilus spp., no interpretations will be provided if the result is >1.
Clindamycin (Cd)
MIC
HAEMOPHILUS
>
4
2
1
0.5
NOTE: 1. Use for MICroSTREP plus 5 panel only.

Clindamycin (Cd)
NOTE:
MIC
HAEMOPHILUS
>
2
1
0.5
0.25

Erythromycin (E)
MIC
HAEMOPHILUS
>
4
2
1
0.5

3. Do not report therapy for H. influenzae.
9020-7493B
Page 149 of 158

Erythromycin (E)
NOTE:
MIC
HAEMOPHILUS
>
4
2
1
0.5
0.25

Levofloxacin (Lvx)
MIC
>
8
4
2
1
0.5
0.25

Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
MIC
HAEMOPHILUS
R
R
R
R
S
S
S
HAEMOPHILUS
>
R
8
R
4
R
2
R
1
I
0.5
N/R

For H. influenzae, Meropenem breakpoints for non meningitis are S2, R>2.
Based on EUCAST interpretive guidelines for meningitis, all MICs of 0.5 will report as N/R since these
dilutions do not differentiate between S and I (S0.25, I=0.5-1, R>1).
Meropenem (Mer)
NOTE: 1.
2.
3.
4.
5.
9020-7493B
MIC
HAEMOPHILUS
>
4
2
1
0.5
S
0.25
S
0.12
S
0.06
S

The CLSI interpretative guidelines for Meropenem with Haemophilus spp. is 0.5 for susceptible. Because
intermediate and resistant interpretations have not been defined for Haemophilus spp, no interpretations will
be provided if the result is >0.5.
Results of testing Meropenem should be routinely reported for CSF isolates of H. influenzae.
Page 150 of 158

Penicillin (P)
MIC
HAEMOPHILUS
>
16
8
4
2
1
0.5
0.25
0.12
0.06
0.03
NOTE: 1. Use for MICroSTREP plus 5 and MICroSTREP plus 3 panels only.
Pristinamycin (Prs)
MIC
HAEMOPHILUS
>
4
2

Rifampin (Rif)
MIC
>
16
8
4
2
1
0.5
2. Use for MICroSTREP plus 3 and 5 panels.

Tetracycline (Te)
MIC
>
8
4
2
1
0.5

Tetracycline (Te)
MIC
>
4
2
1

9020-7493B
HAEMOPHILUS
R
R
R
R
I
S
S
HAEMOPHILUS
R
R
R
I
S
S
HAEMOPHILUS
R
I
S
S
Page 151 of 158

Trimethoprim/Sulfamethoxazole
(T/S)
MIC
>
8/152
4/76
2/38
1/19
0.5/9.5

Trimethoprim-Sulfamethoxazole
(T/S)
MIC
Vancomycin (Va)
MIC
>
2/38
1/19
0.5/9.5
0.25/4.75
HAEMOPHILUS
R
R
R
R
I
S
HAEMOPHILUS
R
I
I
S
S
HAEMOPHILUS
>
8
4
2
1

Vancomycin (Va)
MIC
HAEMOPHILUS
>
8
4
2
1
0.5
9020-7493B
Page 152 of 158
Species Classifications for Organism Groups

ACINETOBACTER GROUP
Acinetobacter anitratus/haemolyticus
Acinetobacter baumannii
Acinetobacter baumannii/haemolyticus
Acinetobacter haemolyticus
Acinetobacter lwoffii
Acinetobacter species
CITROBACTER GROUP
Citrobacter amalonaticus
Citrobacter amalonaticus/diversus
Citrobacter amalonaticus/koseri
Citrobacter braakii
Citrobacter diversus
Citrobacter farmeri
Citrobacter koseri
Citrobacter species
Citrobacter youngae
CITROBACTER FREUNDII GROUP
Citrobacter braakii
Citrobacter youngae
Citrobacter species
CITROBACTER AMALONATICUS/KOSERI GROUP
Citrobacter amalonaticus/koseri
Citrobacter amalonaticus/diversus
Citrobacter farmeri
Citrobacter species
KLEBSIELLA GROUP
Raoultella (K.) ornithinolytica
Klebsiella oxytoca
Klebsiella ozaenae
Klebsiella planticola
Klebsiella pneumoniae
Klebsiella pneumoniae/oxytoca
Klebsiella rhinoscleromatis
Klebsiella species
Klebsiella terrigena
9020-7493B
ENTEROBACTER GROUP
Pantoea agglomerans
Enterobacter amnigenus 1
Enterobacter amnigenus 2
Enterobacter asburiae
Enterobacter cancerogenous
Enterobacter gergoviae
Enterobacter hormaechei
Enterobacter intermedius
Enterobacter sakazakii
Enterobacter species
Enterobacter taylorae
ESBL GROUP- SCREENING
Escherichia coli
Escherichia coli LYS-/ORNEscherichia coli O157:H7
Klebsiella oxytoca
Proteus mirabilis
ESBL GROUP- CONFIRMATION
Citrobacter koseri
Citrobacter farmeri
Citrobacter koseri
Citrobacter species
Escherichia coli
Escherichia coli LYS-/ORNKlebsiella oxytoca
Morganella morganii
Proteus mirabilis
Proteus vulgaris
Salmonella species
Serratia marcescens
PROTEUS/PROVIDENCIA GROUP
Proteus penneri
Proteus species
Proteus vulgaris
Proteus vulgaris/penneri
Providencia alcalifaciens 1-2
Providencia species
Providencia stuartii
Page 153 of 158

PROVIDENCIA GROUP
Providencia alcalifaciens 1-2
Providencia species
Providencia stuartii (urea +/-)
SALMONELLA/SHIGELLA GROUP
Salmonella choleraesuis
Salmonella species
Salmonella typhi
Salmonella/Arizona
Shigella boydii
Shigella boydii/dysenteriae/flexneri
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Shigella species
SERRATIA GROUP
Serratia ficaria
Serratia fonticola
Serratia liquefaciens
Serratia marcescens
Serratia odorifera 1
Serratia odorifera 2
Serratia plymuthica
Serratia rubidaea
Serratia species
SHIGELLA GROUP
Shigella boydii
Shigella boydii/dysenteriae/flexneri
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Shigella species
VIBRIO SPP other than V. cholerae
Vibrio alginolyticus
Vibrio hollisae
Vibrio damsela
Vibrio fluvialis
Vibrio fluvialis/furnissii
Vibrio furnissii
Vibrio metschnikovii
Vibrio mimicus
Vibrio parahaemolyticus
Vibrio species
Vibrio vulnificus
9020-7493B
MISCELLANEOUS FASTIDIOUS GROUP-NEG

Actinobacillus actinomycetemcomitans
Bordetella parapertussis
Bordetella pertussis
CDC Group EO-2
CDC Group EF-4A
CDC Group EF-4B
CDC group EF-4B/Neisseria weaveri/N. elongata
C. violaceum
Eikenella corrodens
Neisseria elongata subspecies nitroreducens
Neisseria weaveri (CDC grp M5)
Pasteurella-Actinobacillus species
Pasteurella-Actinobacillus species SF
Pasteurella aerogenes
Pasteurella multocida
Pasteurella multocida SF
P. pneumoniae/A. urea/M. haemolytica
Pasteurella pneumotropica
Pasteurella species
MISCELLANEOUS FASTIDIOUS GROUP-POS
Abiotrophia/Granulicatella species
Aerococcus urinae
Aerococcus viridans
Erysipelothrix species
Gemella haemolysans
Gemella morbillorum
Gemella species
Kytococcus sedentarius
Leuconostoc spp.
Listeria innocua/seeligeri
Pediococcus species
Rhodococcus equi
Rothia dentocariosa
Rothia mucilaginosa
Rothia species
PROTEUS GROUP
Proteus mirabilis
Proteus vulgaris
Proteus penneri
Proteus vulgaris/penneri
Proteus species
AEROMONAS SPP-GROUP
Aeromonas caviae
Aeromonas jandaei
Aeromonas sobria
Aeromonas trota
Aeromonas veronii
Aeromonas species
Page 154 of 158

OTHER SPECIES GROUP
Acinetobacter lwoffii
Actinobacillus actinomycetemcomitans
Aeromonas caviae
Aeromonas jandaei
Aeromonas sobria
Aeromonas trota
Aeromonas veronii
Aeromonas species
Rhizobium (A.) radiobacter
Alcaligenes species
Alcaligenes spp/Achrom xylosox/Ralstonia paucula
Achromobacter xylosoxidans subsp xylosoxidans
Bordetella parapertussis
Bordetella pertussis
Brevundimonas (P.) diminuta
Brevundimonas (P.) vesicularis
Brevundimonas species
Burkholderia (P.) cepacia
Burkholderia gladioli
Burkholderia pseudomallei
Burkholderia species
Cedecea species
Cedecea davisae
Cedecea lapagei
Cedecea neteri
Cedecea spp 3
Cedecea spp 5
CDC group EF-4A
CDC group EF-4B
CDC group EF-4B/Neisseria weaveri/N. elongata
Chryseobacterium (F.) meningosepticum
Chryseobacterium species
Delftia (C.) acidovorans
Delftia (C.) acidovorans/Comamonas testosteroni
Comamonas testosteroni
Edwardsiella tarda
Empedobacter (F.) brevis
Enterobacter asburiae
Enterobacter hormaechei
Escherichia albertii
Escherichia fergusonii
Escherichia hermanii
Escherichia species
Escherichia vulneris
Ewingella americana
Flavobacterium species
Hafnia alvei
Kingella species
Klebsiella rhinoscleromatis
Kluyvera ascorbata
Kluyvera cryocrescens
Kluyvera species
Moraxella atlantae
Moraxella lacunata
9020-7493B
Moraxella non-liquefaciens
Moraxella osloensis
Psychrobacter (M.) phenypyruvicus
Moraxella species/Psychrobacter longate
Neisseria elongata subsp. nitroducans
Ochrobactrum anthropi
Oligella species
Oligella urethralis
Pasteurella aerogenes
Mannheimia (P.) haemolytica
P. pneumoniae/A. urea/M. haemolytica
Pasteurella multocida
Pasteurella pneumotropica
Pasteurella species
Actinobacillus (P.) ureae
Photorhabdus luminescens
Plesiomonas shigelloides
Pseudomonas alcaligenes
Pseudomonas alcaligenes/pseudoalcaligenes
Pseudomonas fluorescens
Pseudomonas fluorescens/putida
Pseudomonas (C.) luteola
Pseudomonas mendocina
Pseudomonas (F.) oryzihabitans
Pseudomonas pseudoalcaligenes
Pseudomonas putida
Pseudomonas species
Pseudomonas stutzeri
Pseudomonas stutzeri/mendocina
Ralstonia (B.) pickettii
Roseomonas species
Shewanella putrefaciens
Sphingomonas (P.) paucimobilis
Stenotrophomonas (X.) maltophilia
Tatumella ptyseos
Vibrio alginolyticus
Vibrio hollisae
Vibrio cholerae
Vibrio damsela
Vibrio fluvialis
Vibrio fluvialis/furnissii
Vibrio furnissii
Vibrio metschnikovii
Vibrio mimicus
Vibrio parahaemolyticus
Vibrio species
Vibrio vulnificus
Yersinia enterocolitica group
Yersinia frederiksenii
Yersinia intermedia
Yersinia kristensenii
Yersinia pestis
Yersinia pseudotuberculosis
Yersinia ruckeri
Yersinia species
Yokenella regensburgei
Page 155 of 158

VIRIDANS STREPTOCOCCI GROUP
Gamma-hemolytic streptococcus
Group F Streptococcus
Streptococcus acidominimus
Streptococcus anginosus/constellatus
Streptococcus anginosus/milleri
Streptococcus constellatus/milleri
Streptococcus equi
Streptococcus equinis
Streptococcus iniae
Streptococcus intermedius/milleri
Streptococcus milleri group
Streptococcus mitis group
Streptococcus mitis
Streptococcus mitis/oralis
Streptococcus mutans
Streptococcus parasanguis
Streptococcus salivarius
Streptococcus sanguis
Streptococcus sanguis II
Streptococcus uberis
Streptococcus species
Viridans streptococcus
Viridans streptococcus group
BETA-HEMOLYTIC STREPTOCOCCI GROUP
Beta-hemolytic Streptococcus non-Group A, non-B
Beta-hemolytic Streptococcus non-Group A
Group A Streptococcus
Group C Streptococcus
Group G Streptococcus
Group C/G Streptococcus
Streptococcus agalactiae (Group B)
Streptococcus agalactiae, hemolytic
Streptococcus agalactiae, non-hemolytic
Streptococcus equisimilis
Streptococcus pyogenes (Group A)
Streptococcus zooepidemicus
9020-7493B
MISCELLANEOUS STREPTOCOCCI GROUP

Beta-hemolytic Streptococcus non-group A, non-B
Beta-hemolytic Streptococcus non-group A
Group C Streptococcus
Group D Streptococcus
Group G Streptococcus
Streptococcus agalactiae (Group B)
Streptococcus agalactiae, hemolytic
Streptococcus agalactiae, non-hemolytic
Streptococcus bovis group
Streptococcus equi/equisimilis
Streptococcus zooepidemicus
Viridans streptococcus
GROUP A STREPTOCOCCUS GROUP
Streptococcus pyogenes
Group A Streptococcus
ENTEROCOCCUS GROUP (for Dried-Overnight grampositive panels)
Enterococcus avium
Enterococcus casseliflavus
Enterococcus durans
Enterococcus durans/hirae
Enterococcus faecalis
Enterococcus faecium
Enterococcus faecium group
Enterococcus gallinarum
Enterococcus hirae
Enterococcus mundtii
Enterococcus raffinosus
Enterococcus species
ENTEROCOCCUS GROUP (for SYNERGIES PLUS
gram-positive panels)
Enterococcus avium
Enterococcus casseliflavus
Enterococcus durans
Enterococcus durans/hirae
Enterococcus faecalis
Enterococcus faecium
Enterococcus faecium group
Enterococcus gallinarum
Enterococcus hirae
Enterococcus mundtii
Enterococcus raffinosus
Enterococcus species
Page 156 of 158

COAGULASE NEGATIVE STAPHYLOCOCCI GROUP
Macrococcus caseolyticus
Staphylococcus arlettae
Staphylococcus auricularis
Staphylococcus capitis
Staphylococcus capitis-capit
Staphylococcus capitis-ureo
Staphylococcus caprae
Staphylococcus carnosus
Staphylococcus chromogenes
Staphylococcus cohnii
Staphylococcus cohnii-cohnii
Staphylococcus cohnii-urea
Staphylococcus epidermidis
Staphylococcus equorum
Staphylococcus gallinarum
Staphylococcus haemolyticus
Staphylococcus hominis
Staphylococcus hominis-hominis
Staphylococcus hominis-novo
Staphylococcus hyicus
Staphylococcus hyicus/chromo
Staphylococcus intermedius
Staphylococcus kloosii
Staphylococcus lentus
Staphylococcus lugdunensis
Staphylococcus saprophyticus
Staphylococcus schleiferi
Staphylococcus schleiferi coagulans
Staphylococcus schleiferi schleiferi
Staphylococcus sciuri
Staphylococcus simulans
Staphylococcus species
Staphylococcus warneri
Staphylococcus xylosus
Coagulase Negative Staphylococci
9020-7493B
Page 157 of 158
Specific Classification for Panel Groups

EUCAST Panel Class- French panels
Dried Overnight Gram Negative
Neg Combo 48 (NC48)
Neg MIC 39 (NM39)
Neg Urine Combo 57 (NUC57)
EUCAST Panel Class French panels

Dried Overnight Gram Positive
Pos Combo 30 (PC30)
Pos Strep Combo 36 (PC36)
Pos MIC 31 (PM31)
EUCAST Blended Panel ClassDried Overnight Gram Negative

Neg Breakpoint Combo 45 (NBC45)
Neg Breakpoint Combo 46 (NBC46)
Neg Breakpoint Combo 49E (NBC49E)
Neg Combo 53 (NC53)
Neg Combo 58 (NC58)
Neg Entero Combo 70 (NC70)
Neg Non Entero Combo 71 (NC71)
Neg MIC 40 (NM40)
Neg MIC 44 (NM44)
Neg Urine Combo 56 (NUC56)
Neg Urine Combo 59 (NBC59)
Neg Urine Combo 69 (NBC69)
EUCAST Blended Panel Class

Dried Overnight Gram Positive
Pos Breakpoint Combo 32 (PBC32)
Pos Breakpoint Combo 33 (PBC33)
Pos Combo 35 (PC35)
Pos Combo 37 (PC37)
Pos Combo 38 (PC38)
Pos Combo 42 (PC42)
Pos MIC 32 (PM32)
Pos MIC 33 (PM33)
EUCAST Blended Panel ClassDried MICroSTREP

MICroSTREP plus 6 (MSP6)
ANVISA Panel Class

Dried Overnight Gram Negative*
Neg Combo 66
* NC66 uses primarily ANVISA for cephalosporins and
CLSI for everything else.
9020-7493B
Page 158 of 158

Panel Update 5 PDF

Загружено:

Сведения о документе

Исходное описание:

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Panel Update 5 PDF

Загружено:

Авторское право:

Доступные форматы

Adult Therapy

Adult Therapy Guide Legend

Siemens Healthcare Diagnostics Inc.

SYNERGIES PLUS GRAM NEGATIVE PANELS: .............................................................................................................. 6

SYNERGIES PLUS GRAM POSITIVE PANELS: ............................................................................................................... 6

SYNERGIES PLUS GRAM-NEGATIVE PANELS .............................................................................................. 112

SYNERGIES PLUS GRAM-POSITIVE PANELS ................................................................................................ 126

SHIGELLA GROUP.............................................................................................................................................. 154

ENTEROCOCCUS GROUP (for SYNERGIES PLUS GRAM-POSITIVE PANELS)........................................... 156

General Notes for Reporting Results:

CLSI M45-A2; Methods for Antimicrobial

January 1999, 2004, 2007, 2009,

Synergies plus Gram Negative panels:

H. segnis and Actinobacillus actinomycetemcomitans), Cardiobacterium spp., Eikenella corrodens, and

Blac = Beta-lactamase positive

MIC values are reported in g/ml or mg/l.

Urine/Systemic Therapy Interpretation Rules:

Extreme Caution from the CLSI M45-A2:

Streptococci Reporting (Viridans, Beta-hemolytic and S. pneumoniae):

contraindicated on MicroScan Dried Overnight Gram positive panels.

3. All streptococci are contraindicated on Synergies plus Positive panels.

Predicted Susceptibility Rules for Synergies plus Pos Panels

Extended Spectrum Beta-Lactamase (ESBL) Interpretations:

Panel Dilution Ranges

Interpretations Reported as R* for the following Antimicrobial Agents:

Interpretations Reported as S, I or R for the following Antimicrobial Agents:

ANTIMICROBIAL AGENT THERAPY GUIDE TABLES

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

NON-ENTEROBACTERIACEAE PSEUDOMONAS SPP.

NON-ENTEROBACTERIACEAE PSEUDOMONAS SPP.

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

Cefuroxime sodium (Crm)

Cefuroxime sodium (Crm)

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS

DRIED OVERNIGHT AND RAPID (FLUOROGENIC) GRAM-NEGATIVE PANELS